Details of Disease

General Information of Disease (ID: DISD51WR)

• Disease Name: Lung adenocarcinoma
• Synonyms: non-small cell lung adenocarcinoma; adenocarcinoma of the lung; bronchogenic lung adenocarcinoma; adenocarcinoma of lung; nonsmall cell adenocarcinoma; lung adenocarcinoma
• Definition: A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells. There is a male predilection with a male to female ratio of 2:1. Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding. If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever. Tobacco smoke is a known risk factor.
• Disease Hierarchy:
  DIS5Y6R9: Non-small-cell lung cancer
  DIS3IHTY: Adenocarcinoma
  DISD51WR: Lung adenocarcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005061
  MESH ID: D000077192
  UMLS CUI: C0152013
  MedGen ID: 57744
  HPO ID: HP:0030078
  Orphanet ID: 415268
  SNOMED CT ID: 254626006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Carboplatin	DMG281S	Approved	Small molecular drug	[2]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 506 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALOX12B	TTQ4QQH	Limited	Biomarker	[4]
ALOX5	TTSJ6Q4	Limited	Biomarker	[4]
ANXA5	TT2Z83I	Limited	Biomarker	[5]
ASPH	TT2KHP7	Limited	Biomarker	[6]
ATR	TT8ZYBQ	Limited	Altered Expression	[7]
CDC25A	TTLZS4Q	Limited	Biomarker	[8]
CDK4	TT0PG8F	Limited	Biomarker	[9]
CYP2A6	TTAQ6ZW	Limited	Genetic Variation	[10]
DEPDC1	TT8S9CM	Limited	Altered Expression	[11]
EPOR	TTAUX24	Limited	Altered Expression	[12]
FGF7	TTFY134	Limited	Genetic Variation	[10]
FGFR4	TT1KX2S	Limited	Biomarker	[13]
GABRA3	TT37EDJ	Limited	Altered Expression	[14]
GAPDH	TTUGSWA	Limited	Altered Expression	[15]
GDF15	TT4MXVG	Limited	Altered Expression	[16]
GDF2	TTAP4T1	Limited	Biomarker	[17]
GIP	TT40HS5	Limited	Biomarker	[18]
KCNK3	TTGR91N	Limited	Altered Expression	[19]
LCK	TT860QF	Limited	Biomarker	[20]
LDHA	TTW76JE	Limited	Biomarker	[21]
MTAP	TTDBX7N	Limited	Genetic Variation	[10]
MYLK2	TTHLGB2	Limited	Genetic Variation	[22]
NCL	TTK1V5Q	Limited	Biomarker	[23]
P2RY12	TTZ1DT0	Limited	Biomarker	[24]
P2RY6	TTNVSKA	Limited	Biomarker	[24]
PCSK9	TTNIZ2B	Limited	Biomarker	[25]
PDK1	TTCZOF2	Limited	Posttranslational Modification	[26]
PGR	TTUV8G9	Limited	Biomarker	[27]
RAF1	TTAN5W2	Limited	Genetic Variation	[28]
RASA1	TTPNZ1F	Limited	Biomarker	[29]
SLC38A1	TT1YE9Z	Limited	Altered Expression	[19]
TACSTD2	TTP2HE5	Limited	Altered Expression	[30]
TNK2	TTIET93	Limited	Altered Expression	[31]
WEE1	TTJFOAL	Limited	Biomarker	[32]
WNK1	TTJ9UMX	Limited	Biomarker	[33]
ARRB2	TT8SO2I	Disputed	Altered Expression	[34]
CYP1A2	TTS1DTU	Disputed	Genetic Variation	[35]
DDR2	TTU98HG	Disputed	Genetic Variation	[36]
DSG3	TTEO4P8	Disputed	Biomarker	[37]
EPHA5	TTV9KOD	Disputed	Genetic Variation	[38]
FLT1	TT1VAUK	Disputed	Altered Expression	[39]
KEAP1	TT3Z6Y9	Disputed	Genetic Variation	[40]
KRT6A	TT2FX8W	Disputed	Biomarker	[37]
NTRK2	TTKN7QR	Disputed	Biomarker	[41]
NTRK3	TTXABCW	Disputed	Genetic Variation	[42]
PRKDC	TTK3PY9	Disputed	Biomarker	[43]
RRM2	TT1S4LJ	Disputed	Biomarker	[23]
ABCC3	TTVLG21	moderate	Biomarker	[44]
ADRB1	TTR6W5O	moderate	Biomarker	[45]
AIMP2	TTXWHGF	moderate	Altered Expression	[46]
ALCAM	TT2AFT6	moderate	Altered Expression	[47]
ANG	TTURHFP	moderate	Altered Expression	[48]
ARAF	TT5TURO	moderate	Genetic Variation	[28]
AXL	TTZPY6J	moderate	Altered Expression	[49]
BMI1	TTIPNSR	moderate	Biomarker	[50]
BRAF	TT0EOB8	moderate	Biomarker	[51]
CD24	TTCTYNP	moderate	Biomarker	[52]
CD80	TT89Z17	moderate	Altered Expression	[53]
CDK1	TTH6V3D	moderate	Altered Expression	[54]
CEACAM3	TTPX7I5	moderate	Biomarker	[55]
CEBPB	TTUI35N	moderate	Altered Expression	[56]
CHRNA4	TT4H1MQ	moderate	Altered Expression	[57]
CLCN3	TT8XNZ7	moderate	Altered Expression	[58]
COL1A2	TTUABC1	moderate	Biomarker	[59]
CPS1	TT42M75	moderate	Altered Expression	[60]
CTAG1A	TTE5ITK	moderate	Biomarker	[61]
CTSD	TTPT2QI	moderate	Biomarker	[62]
CYP1B1	TTI84H7	moderate	Genetic Variation	[63]
DDR1	TTI1FPZ	moderate	Biomarker	[64]
DKK3	TTY2ZV6	moderate	Biomarker	[65]
DLK1	TTF4AVB	moderate	Altered Expression	[66]
EPAS1	TTWPA54	moderate	Biomarker	[9]
ESRRB	TTKF0XS	moderate	Altered Expression	[67]
EYA2	TTUY9C6	moderate	Altered Expression	[68]
F11R	TT3C8EG	moderate	Altered Expression	[69]
FLT4	TTDCBX5	moderate	Biomarker	[70]
FOLR1	TTVC37M	moderate	Altered Expression	[71]
FUT4	TTNV1KZ	moderate	Altered Expression	[72]
GAS6	TT69QD2	moderate	Altered Expression	[73]
GPC3	TTJTSX4	moderate	Altered Expression	[74]
GRB2	TTEYRJ9	moderate	Biomarker	[75]
GSN	TTUH7OM	moderate	Altered Expression	[76]
GZMB	TTKEPHX	moderate	Biomarker	[77]
IKBKB	TTJ3E9X	moderate	Genetic Variation	[78]
IL12RB2	TT4SWR8	moderate	Genetic Variation	[79]
IMP3	TTEJA2R	moderate	Biomarker	[80]
INHBA	TTVB30D	moderate	Genetic Variation	[81]
IRS1	TTAJSQ0	moderate	Biomarker	[82]
MAP3K3	TTJZNIG	moderate	Altered Expression	[83]
MAP4K4	TT6NI13	moderate	Biomarker	[84]
MBTPS1	TTNSM2I	moderate	Altered Expression	[85]
MIA	TT5HNVS	moderate	Biomarker	[86]
MMP10	TTXLEG7	moderate	Biomarker	[87]
MMP15	TTNSTO3	moderate	Altered Expression	[88]
MSLN	TT4RXME	moderate	Altered Expression	[89]
MTTP	TTUS1RD	moderate	Biomarker	[90]
NCOA3	TT124R0	moderate	Altered Expression	[91]
NECTIN4	TTPO9EG	moderate	Biomarker	[92]
NEDD4	TT1QU6G	moderate	Altered Expression	[93]
NEK2	TT3VZ24	moderate	Altered Expression	[94]
NRAS	TTW2R9X	moderate	Genetic Variation	[28]
PAK1	TTFN95D	moderate	Biomarker	[95]
PBK	TTMY6BZ	moderate	Altered Expression	[96]
PDCD2	TTYOVWN	moderate	Altered Expression	[97]
PLA2G2A	TTO8QRU	moderate	Biomarker	[98]
PRKCI	TTWJTHX	moderate	Biomarker	[99]
RAC3	TT9BQ50	moderate	Altered Expression	[100]
ROCK1	TTZN7RP	moderate	Biomarker	[101]
ROS1	TTSZ6Y3	moderate	Biomarker	[102]
S1PR1	TT9JZCK	moderate	Biomarker	[103]
SCGB1A1	TTONPVW	moderate	Genetic Variation	[104]
SCT	TTOBVIN	moderate	Biomarker	[105]
SELP	TTE5VG0	moderate	Altered Expression	[106]
SETD2	TTPC3H4	moderate	Altered Expression	[107]
SLC7A11	TTBZMIO	moderate	Biomarker	[108]
SLIT2	TTDWK85	moderate	Biomarker	[109]
STRAP	TT165DP	moderate	Biomarker	[110]
TACC3	TTQ4UFD	moderate	Genetic Variation	[111]
TAGLN	TTDRZ9H	moderate	Altered Expression	[112]
TFAP2A	TTDY4BS	moderate	Biomarker	[113]
TRAF6	TTCDR6M	moderate	Altered Expression	[114]
USP14	TTVSYP9	moderate	Biomarker	[115]
VIPR1	TTCL30I	moderate	Altered Expression	[116]
ABCC1	TTOI92F	Strong	Biomarker	[117]
ABCG1	TTMWDGU	Strong	Biomarker	[118]
ABL2	TT1A6HL	Strong	Biomarker	[119]
ACVR1B	TTPKHTZ	Strong	Genetic Variation	[120]
ADAM17	TT6AZXG	Strong	Biomarker	[121]
ADORA2A	TTM2AOE	Strong	Altered Expression	[122]
AGR2	TT9K86S	Strong	Altered Expression	[123]
AHCY	TTE2KUJ	Strong	Biomarker	[23]
AHR	TT037IE	Strong	Altered Expression	[124]
AKT1	TTWTSCV	Strong	Altered Expression	[125]
AKT2	TTH24WI	Strong	Biomarker	[126]
ALB	TTFNGC9	Strong	Biomarker	[127]
ALKBH5	TTOHB1M	Strong	Biomarker	[128]
ALOX5AP	TTDMBF5	Strong	Altered Expression	[129]
AMOT	TTI48OS	Strong	Biomarker	[130]
ANTXR2	TTOD34I	Strong	Genetic Variation	[131]
ANXA1	TTUCK4B	Strong	Biomarker	[132]
APC2	TTSMK36	Strong	Biomarker	[133]
APOA1	TT5S8DR	Strong	Biomarker	[127]
AQP3	TTLDNMQ	Strong	Altered Expression	[134]
ARRB1	TTMVD4A	Strong	Altered Expression	[135]
ASAP3	TTB4ZEN	Strong	Biomarker	[136]
ATF4	TTQCKWT	Strong	Biomarker	[137]
ATXN2	TTPQJ7P	Strong	Genetic Variation	[138]
AURKA	TTPS3C0	Strong	Altered Expression	[139]
AURKB	TT9RTBL	Strong	Altered Expression	[140]
AZGP1	TTUPYLV	Strong	Altered Expression	[141]
B2M	TTY7FKA	Strong	Genetic Variation	[28]
BCL11A	TTR61MW	Strong	Biomarker	[142]
BGN	TT0JPVF	Strong	Biomarker	[143]
BPI	TTXCSDR	Strong	Biomarker	[144]
BRCA2	TTUARD6	Strong	Genetic Variation	[145]
BRD7	TT07ZS1	Strong	Altered Expression	[146]
CA12	TTSYM0R	Strong	Biomarker	[147]
CACNA1C	TTZIFHC	Strong	Altered Expression	[148]
CCNA2	TTAMQ62	Strong	Biomarker	[149]
CCR3	TTD3XFU	Strong	Altered Expression	[150]
CD200	TT0BE68	Strong	Biomarker	[151]
CD44	TTWFBT7	Strong	Genetic Variation	[152]
CD69	TTPQE9F	Strong	Altered Expression	[153]
CDC25C	TTESBNC	Strong	Altered Expression	[154]
CDC7	TTSMTDI	Strong	Biomarker	[155]
CDH1	TTLAWO6	Strong	Altered Expression	[156]
CDH2	TT1WS0T	Strong	Biomarker	[157]
CDH3	TTARMD9	Strong	Altered Expression	[94]
CDK5R1	TTBYM6V	Strong	Altered Expression	[158]
CEACAM6	TTIGH2W	Strong	Biomarker	[159]
CENPE	TTZD5QR	Strong	Biomarker	[160]
CFB	TTA0P7K	Strong	Genetic Variation	[161]
CFI	TT6ATLX	Strong	Biomarker	[162]
CHEK1	TTTU902	Strong	Altered Expression	[163]
CHPF	TTAZB7S	Strong	Altered Expression	[164]
CHRNA5	TTH2QRX	Strong	Genetic Variation	[10]
CHRNA7	TTLA931	Strong	Biomarker	[165]
CHRNB4	TTTVAFQ	Strong	Genetic Variation	[10]
CHUK	TT1F8OQ	Strong	Biomarker	[78]
CLCF1	TTI6V13	Strong	Biomarker	[166]
CLDN4	TTMTS9H	Strong	Altered Expression	[167]
CMA1	TT8VUE0	Strong	Biomarker	[168]
CNTFR	TTT2F9E	Strong	Biomarker	[166]
COPS5	TTSTNJR	Strong	Biomarker	[169]
CPM	TTVOH2M	Strong	Biomarker	[170]
CREBBP	TTFRCTK	Strong	Biomarker	[171]
CTNNB1	TTRPKQG	Strong	Genetic Variation	[172]
CTSA	TT5NILS	Strong	Altered Expression	[173]
CTSE	TTLXC4Q	Strong	Altered Expression	[174]
CUL3	TTPCU0Q	Strong	Altered Expression	[175]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[161]
CYP24A1	TT82UI1	Strong	Biomarker	[176]
CYP3A5	TTHS0OK	Strong	Biomarker	[177]
DDIT4	TTVEOY6	Strong	Biomarker	[178]
DEPTOR	TTLYP6D	Strong	Biomarker	[179]
DKK1	TTE3RAC	Strong	Biomarker	[180]
DLL3	TT1C9K6	Strong	Altered Expression	[181]
DNMT3A	TTJUALD	Strong	Genetic Variation	[28]
DOT1L	TTSZ8T1	Strong	Biomarker	[29]
DTL	TT8396I	Strong	Altered Expression	[182]
E2F3	TTWIJYH	Strong	Altered Expression	[183]
EED	TTFNJ4R	Strong	Biomarker	[184]
EEF2K	TT1QFLA	Strong	Biomarker	[185]
EGF	TTED8JB	Strong	Altered Expression	[186]
EGFL6	TTXJGAR	Strong	Altered Expression	[187]
EGLN1	TT9ISBX	Strong	Biomarker	[188]
EGLN2	TTMHFRY	Strong	Posttranslational Modification	[189]
EIF4E	TTZGCP6	Strong	Biomarker	[171]
EIF5A	TTIVCNR	Strong	Biomarker	[190]
EPCAM	TTZ8WH4	Strong	Altered Expression	[47]
EPHA1	TTLFZVU	Strong	Altered Expression	[191]
EPHA3	TTHS2LR	Strong	Genetic Variation	[192]
EPHA4	TTG84D3	Strong	Altered Expression	[191]
EPHA8	TTHZ2LW	Strong	Biomarker	[13]
EPHB1	TT8MDAC	Strong	Genetic Variation	[193]
EPHB2	TTKPV6O	Strong	Biomarker	[194]
EPHB6	TTZEMUY	Strong	Altered Expression	[195]
EPX	TTCIO0M	Strong	Altered Expression	[196]
ERBB3	TTSINU2	Strong	Altered Expression	[197]
ESRRA	TTPNQAC	Strong	Altered Expression	[198]
ETS2	TT9AH0M	Strong	Altered Expression	[199]
EZH2	TT9MZCQ	Strong	Altered Expression	[200]
EZR	TTE47YC	Strong	Genetic Variation	[201]
F2RL3	TTD0652	Strong	Altered Expression	[202]
FAM83B	TT1Q347	Strong	Biomarker	[203]
FBXW7	TT29KY7	Strong	Biomarker	[204]
FER	TTRA9G0	Strong	Biomarker	[13]
FGF4	TTCEKVZ	Strong	Biomarker	[205]
FGFR3	TTST7KB	Strong	Biomarker	[206]
FHL1	TTI7ENL	Strong	Posttranslational Modification	[207]
FOLR2	TTT54CI	Strong	Genetic Variation	[71]
FOSL1	TTY8LZG	Strong	Biomarker	[208]
FOXM1	TTD3KOX	Strong	Biomarker	[160]
FOXP1	TT0MUCI	Strong	Biomarker	[209]
FUT3	TTUPAD7	Strong	Biomarker	[210]
GADD45B	TTMDW9L	Strong	Biomarker	[211]
GART	TTEXB9Z	Strong	Biomarker	[23]
GATA3	TT45KOB	Strong	Biomarker	[27]
GHR	TTHJWYD	Strong	Biomarker	[211]
GJB1	TTSJIRP	Strong	Altered Expression	[212]
GJB2	TTRGZX3	Strong	Biomarker	[213]
GJB6	TTAU8SJ	Strong	Biomarker	[214]
GLIPR1	TTEQF1O	Strong	Altered Expression	[215]
GLRX	TTRJCNG	Strong	Altered Expression	[216]
GOT1	TTU507L	Strong	Altered Expression	[217]
GPI	TT19JIZ	Strong	Biomarker	[23]
GUSB	TTHS7CM	Strong	Altered Expression	[218]
HDAC1	TT6R7JZ	Strong	Altered Expression	[219]
HDGF	TTKGV26	Strong	Biomarker	[220]
HK2	TTK02H8	Strong	Biomarker	[23]
HLA-A	TTHONFT	Strong	Biomarker	[221]
HLA-DQA1	TTU2I3J	Strong	Genetic Variation	[161]
HMGB2	TTA78JQ	Strong	Biomarker	[23]
HOXA11	TTEX4ZA	Strong	Biomarker	[222]
HOXA13	TTN26OM	Strong	Altered Expression	[223]
HOXA5	TTXSVQP	Strong	Altered Expression	[224]
HOXB13	TTZ6I58	Strong	Altered Expression	[118]
HS6ST2	TTS6LBM	Strong	Biomarker	[225]
HSP90AA1	TT78R5H	Strong	Biomarker	[226]
HSPA8	TTMQL3K	Strong	Altered Expression	[227]
HSPB1	TT9AZWY	Strong	Altered Expression	[228]
HTATIP2	TTC6IX5	Strong	Altered Expression	[229]
HTRA1	TT8POQR	Strong	Biomarker	[230]
IDO1	TTZJYKH	Strong	Altered Expression	[231]
IFNAR1	TTSYFMA	Strong	Altered Expression	[232]
IGF2R	TTPNE41	Strong	Biomarker	[233]
IGFBP7	TTUQ01B	Strong	Biomarker	[234]
IL11	TTGUYTR	Strong	Biomarker	[235]
IL17F	TT2B6PS	Strong	Altered Expression	[236]
IL1R2	TT51DEV	Strong	Biomarker	[237]
IL25	TTVMO5W	Strong	Biomarker	[236]
IL37	TTQTX98	Strong	Altered Expression	[238]
IL7R	TTAWI51	Strong	Biomarker	[239]
IL9	TT0JTFD	Strong	Biomarker	[240]
IMPDH2	TTTB4UP	Strong	Biomarker	[23]
IRF8	TTHUBNK	Strong	Biomarker	[241]
ITGA11	TTANXZ7	Strong	Altered Expression	[242]
ITGA6	TT165T3	Strong	Altered Expression	[243]
ITGA8	TT1FW8B	Strong	Altered Expression	[244]
JAG2	TTOJY1B	Strong	Biomarker	[245]
JAK1	TT6DM01	Strong	Biomarker	[246]
KAT2B	TTVK7SB	Strong	Biomarker	[247]
KCNH1	TT9XKUC	Strong	Genetic Variation	[138]
KCNJ4	TTXF0ZW	Strong	Biomarker	[248]
KCNMA1	TTE87WJ	Strong	Altered Expression	[249]
KDM3A	TTKXS4A	Strong	Biomarker	[250]
KDR	TTUTJGQ	Strong	Biomarker	[251]
KLK5	TTULSEW	Strong	Altered Expression	[252]
KPNB1	TTHOJ5F	Strong	Biomarker	[253]
KRT17	TTKV0EC	Strong	Biomarker	[254]
KRT19	TT3JF9E	Strong	Biomarker	[255]
LANCL1	TTZW8NS	Strong	Biomarker	[256]
LAPTM4B	TTEJQT0	Strong	Biomarker	[257]
LATS2	TTML7FG	Strong	Altered Expression	[258]
LIFR	TTID542	Strong	Biomarker	[259]
LOXL2	TTFSUHX	Strong	Altered Expression	[260]
LYN	TT1RWNJ	Strong	Altered Expression	[261]
MAGEA2	TTOZT28	Strong	Biomarker	[262]
MALT1	TTCI81G	Strong	Altered Expression	[263]
MAP2K7	TT6QY3J	Strong	Biomarker	[264]
MAP3K2	TTIX0ZU	Strong	Genetic Variation	[265]
MAP4	TT0VFPN	Strong	Altered Expression	[266]
MAPK14	TTQBR95	Strong	Altered Expression	[46]
MAPK9	TT3IVG2	Strong	Biomarker	[267]
MDM2	TT9TE0O	Strong	Altered Expression	[268]
MELTF	TT8OBT3	Strong	Genetic Variation	[269]
MGLL	TTZ963I	Strong	Biomarker	[270]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[271]
MLH1	TTISG27	Strong	Genetic Variation	[272]
MMP11	TTZW4MV	Strong	Biomarker	[273]
MRM2	TTUQ7WN	Strong	Altered Expression	[274]
MS4A1	TTUE541	Strong	Biomarker	[275]
MSI2	TTTXQF6	Strong	Biomarker	[276]
MSR1	TT2TDH9	Strong	Altered Expression	[277]
MTA1	TTO4HUS	Strong	Biomarker	[278]
MUC1	TTBHFYQ	Strong	Biomarker	[279]
MUC16	TTC1PS3	Strong	Biomarker	[280]
MUTYH	TTNB0ZK	Strong	Biomarker	[281]
MYC	TTNQ5ZP	Strong	Altered Expression	[282]
MYCBP	TTVW4XU	Strong	Altered Expression	[283]
NAPRT	TTVR1FW	Strong	Altered Expression	[284]
NDUFA13	TTRU1NG	Strong	Altered Expression	[285]
NEDD8	TTNDC4K	Strong	Altered Expression	[286]
NFE2L2	TTA6ZN2	Strong	Genetic Variation	[287]
NOTCH3	TTVX7IA	Strong	Altered Expression	[288]
NPM1	TTHBS98	Strong	Biomarker	[23]
NR1H3	TTECBXN	Strong	Biomarker	[289]
NR3C2	TT26PHO	Strong	Biomarker	[290]
NRP2	TTRXUVC	Strong	Biomarker	[291]
NSD1	TTTSJ3H	Strong	Genetic Variation	[292]
NTSR1	TTTUMEP	Strong	Altered Expression	[293]
OGG1	TTRU01G	Strong	Biomarker	[281]
OLFM4	TTK1CX7	Strong	Biomarker	[294]
OLR1	TTKSND3	Strong	Biomarker	[295]
P2RY14	TT72OKI	Strong	Biomarker	[211]
PAM	TTF4ZPC	Strong	Genetic Variation	[296]
PAWR	TT3I4WV	Strong	Biomarker	[202]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[297]
PDE4D	TTSKMI8	Strong	Biomarker	[298]
PDK2	TTJGCKM	Strong	Biomarker	[299]
PECAM1	TT4EZB2	Strong	Biomarker	[300]
PFKFB3	TTTHMQJ	Strong	Altered Expression	[301]
PGRMC1	TTY3LAZ	Strong	Altered Expression	[302]
PHGDH	TT8DRCK	Strong	Altered Expression	[303]
PIK3CB	TT9H4P3	Strong	Biomarker	[143]
PKM	TT4LOT8	Strong	Altered Expression	[304]
PLK4	TTGPNZQ	Strong	Altered Expression	[305]
PLOD2	TT8MEUD	Strong	Biomarker	[306]
PPM1D	TTENJAB	Strong	Biomarker	[211]
PPP2CA	TTHTKNY	Strong	Biomarker	[307]
PPP3CA	TTA4LDE	Strong	Biomarker	[29]
PRAME	TTPH7T0	Strong	Altered Expression	[308]
PRDX4	TTPBL9I	Strong	Altered Expression	[309]
PRKCA	TTFJ8Q1	Strong	Biomarker	[310]
PRKD1	TTSLUMT	Strong	Genetic Variation	[311]
PROM1	TTXMZ81	Strong	Altered Expression	[312]
PRTN3	TT5MLC4	Strong	Biomarker	[313]
PTK7	TTXH2ZN	Strong	Altered Expression	[314]
PTN	TTA9EJK	Strong	Altered Expression	[315]
PTPN13	TT405FP	Strong	Biomarker	[316]
PTPRB	TT64I9Q	Strong	Altered Expression	[317]
RAC1	TT2M9CG	Strong	Biomarker	[318]
RCVRN	TTDQTEY	Strong	Biomarker	[319]
REG4	TTVZEHU	Strong	Altered Expression	[320]
RHOA	TTP2U16	Strong	Genetic Variation	[28]
RHOB	TT6LPFO	Strong	Biomarker	[321]
RICTOR	TT143WL	Strong	Genetic Variation	[322]
RIPK4	TTB4S01	Strong	Altered Expression	[323]
RNF43	TTD91BL	Strong	Biomarker	[324]
ROBO1	TTND1YP	Strong	Biomarker	[325]
ROR1	TTDEJAU	Strong	Altered Expression	[326]
RPS6KA1	TTIXKA4	Strong	Altered Expression	[327]
RPSA	TTLUW5B	Strong	Altered Expression	[328]
RRM1	TTWP0NS	Strong	Biomarker	[23]
RSPO1	TTI9HL4	Strong	Altered Expression	[329]
RSPO3	TT7HJTF	Strong	Biomarker	[329]
RTN4R	TTVRZUO	Strong	Biomarker	[330]
RUNX3	TTKCVO7	Strong	Biomarker	[331]
S1PR3	TTDYP7I	Strong	Altered Expression	[332]
SATB1	TTLFRIC	Strong	Biomarker	[23]
SDC2	TT5H2F0	Strong	Altered Expression	[333]
SERPINB3	TT6QLPX	Strong	Altered Expression	[334]
SFTPD	TTGLMU7	Strong	Genetic Variation	[335]
SH2B3	TT36N7Z	Strong	Genetic Variation	[138]
SIK1	TT1H6LC	Strong	Genetic Variation	[336]
SLC12A1	TTS087L	Strong	Altered Expression	[337]
SLC12A3	TTP362L	Strong	Genetic Variation	[338]
SLC12A5	TTH6UZY	Strong	Altered Expression	[339]
SLC15A2	TT27Q3A	Strong	Biomarker	[23]
SLC16A3	TTG6VD5	Strong	Altered Expression	[340]
SLC19A1	TT09I7D	Strong	Biomarker	[23]
SLC1A5	TTF7WRM	Strong	Biomarker	[341]
SLC3A2	TT5CZSM	Strong	Biomarker	[342]
SLC5A2	TTF8JAT	Strong	Biomarker	[343]
SLC5A7	TTRV7W3	Strong	Biomarker	[174]
SMAD6	TTON5JB	Strong	Biomarker	[344]
SMARCA4	TTVQEZS	Strong	Biomarker	[345]
SMYD3	TTKLJYX	Strong	Altered Expression	[265]
SOAT2	TTAK0IN	Strong	Biomarker	[346]
SOD2	TT9O4C5	Strong	Biomarker	[347]
SOX2	TTCNOT6	Strong	Biomarker	[348]
SOX5	TTXHSZK	Strong	Biomarker	[349]
SP1	TTZEP6S	Strong	Biomarker	[350]
SPDEF	TT2ZUPY	Strong	Altered Expression	[94]
SPOCK1	TTF23RE	Strong	Altered Expression	[81]
SPTBN1	TTS9BDA	Strong	Biomarker	[351]
SRC	TT6PKBN	Strong	Biomarker	[352]
SRGN	TTCHB06	Strong	Altered Expression	[353]
SRPK1	TTU3WV6	Strong	Altered Expression	[354]
SRPK2	TTCZEJ9	Strong	Biomarker	[354]
SRR	TTZFUY6	Strong	Biomarker	[23]
STAT6	TTWOE1T	Strong	Altered Expression	[355]
STC1	TTDLUER	Strong	Altered Expression	[356]
STK33	TTP34DQ	Strong	Biomarker	[357]
STK39	TTYQTIU	Strong	Biomarker	[23]
STMN1	TT7W5OT	Strong	Altered Expression	[358]
SULF2	TTLQTHB	Strong	Posttranslational Modification	[359]
SYK	TT2HUPM	Strong	Altered Expression	[360]
TAOK1	TTQY9DH	Strong	Altered Expression	[361]
TBX21	TTNF9PH	Strong	Biomarker	[362]
TF	TT8WXAV	Strong	Biomarker	[127]
TFF1	TTNOJIZ	Strong	Altered Expression	[363]
TIAM1	TTNU6I5	Strong	Altered Expression	[364]
TNFRSF17	TTZ3P4W	Strong	Altered Expression	[365]
TNFSF10	TTA5MS9	Strong	Therapeutic	[366]
TNFSF13	TTOI1RM	Strong	Altered Expression	[365]
TNKS	TTVUSO7	Strong	Altered Expression	[282]
TNS4	TT1K65C	Strong	Altered Expression	[367]
TOP2A	TTCGY2K	Strong	Biomarker	[368]
TOP2B	TT4NVEM	Strong	Altered Expression	[368]
TPT1	TT3PTB6	Strong	Altered Expression	[369]
TRIM28	TTQ2BKV	Strong	Biomarker	[370]
TRIM59	TT613U4	Strong	Altered Expression	[371]
TRIP10	TTKHTGE	Strong	Biomarker	[372]
TRPA1	TTELV3W	Strong	Biomarker	[373]
TRPC3	TTNVC34	Strong	Altered Expression	[374]
TSG101	TTHU7JA	Strong	Altered Expression	[375]
TWIST1	TTX1MY7	Strong	Altered Expression	[376]
UCHL5	TTSX29Z	Strong	Biomarker	[115]
USP10	TT5IH09	Strong	Altered Expression	[377]
USP8	TT1J07C	Strong	Altered Expression	[378]
UTS2	TTERU0T	Strong	Biomarker	[379]
VDAC1	TTAMKGB	Strong	Biomarker	[380]
VEGFC	TT0QUFV	Strong	Biomarker	[381]
VEGFD	TTOM5H4	Strong	Altered Expression	[382]
VSIR	TT51SK8	Strong	Genetic Variation	[383]
WNT7A	TT8NARC	Strong	Biomarker	[384]
WRN	TT2H5WQ	Strong	Biomarker	[292]
WWP2	TT6TU05	Strong	Altered Expression	[385]
XRCC5	TTCB9KW	Strong	Biomarker	[386]
YAP1	TT8UN2D	Strong	Altered Expression	[387]
ZEB2	TTT2WK4	Strong	Biomarker	[388]
ACLY	TT0Z6Y2	Definitive	Altered Expression	[389]
ADAM9	TTTYQNS	Definitive	Biomarker	[390]
AGER	TTMO9HF	Definitive	Biomarker	[391]
APEX1	TTHGL48	Definitive	Altered Expression	[392]
ARG1	TT7ZQEV	Definitive	Altered Expression	[393]
ATAD2	TT9A0HI	Definitive	Biomarker	[394]
BCL2L2	TTQ79W8	Definitive	Altered Expression	[395]
BSG	TT5UJWD	Definitive	Altered Expression	[396]
CD74	TTCMYP9	Definitive	Genetic Variation	[397]
CD9	TTZEIBV	Definitive	Biomarker	[398]
CDC20	TTBKFDV	Definitive	Altered Expression	[54]
CLDN18	TT6PKBX	Definitive	Biomarker	[399]
CLDN6	TTKSV48	Definitive	Altered Expression	[400]
CNTN1	TTPR8FK	Definitive	Biomarker	[401]
CRK	TTFEUYR	Definitive	Altered Expression	[46]
DCK	TTJOCE4	Definitive	Biomarker	[402]
DGKA	TTGL8F0	Definitive	Altered Expression	[403]
DPYD	TTZPS91	Definitive	Biomarker	[404]
DYRK2	TT84OS6	Definitive	Altered Expression	[405]
E2F1	TTASI04	Definitive	Altered Expression	[406]
EP300	TTGH73N	Definitive	Altered Expression	[407]
EREG	TTYSB89	Definitive	Altered Expression	[408]
ERN1	TTKIAT3	Definitive	Altered Expression	[409]
FASN	TT7AOUD	Definitive	Biomarker	[410]
HNF4A	TT2F3CD	Definitive	Biomarker	[411]
HNRNPA1	TTPJ9XK	Definitive	Biomarker	[412]
ID1	TTBXVDE	Definitive	Genetic Variation	[413]
IDH1	TTV2A1R	Definitive	Altered Expression	[414]
IL24	TT1EPXZ	Definitive	Altered Expression	[415]
IRF3	TTYR7OH	Definitive	Altered Expression	[416]
LGALS1	TTO3NYT	Definitive	Altered Expression	[417]
MAP3K8	TTGECUM	Definitive	Biomarker	[418]
MMP12	TTXZ0KQ	Definitive	Biomarker	[419]
MUC5AC	TTEL90S	Definitive	Altered Expression	[420]
NEDD9	TT1UREA	Definitive	Biomarker	[421]
NLRP1	TTQX29T	Definitive	Altered Expression	[422]
OSM	TTIVXSE	Definitive	Altered Expression	[423]
OSMR	TTAH0KM	Definitive	Altered Expression	[424]
PARG	TT39J16	Definitive	Altered Expression	[425]
PLK1	TTH4IP0	Definitive	Biomarker	[426]
PRKCZ	TTBSN0L	Definitive	Biomarker	[99]
PRMT5	TTR1D7X	Definitive	Altered Expression	[427]
PTPN11	TT7WUAV	Definitive	Altered Expression	[428]
RECK	TTRZBW7	Definitive	Altered Expression	[429]
S100A9	TT0TMQG	Definitive	Biomarker	[430]
SCGB2A2	TT1W3RE	Definitive	Altered Expression	[431]
SLC34A2	TTQPZTM	Definitive	Altered Expression	[432]
TAGLN2	TTP6BIJ	Definitive	Biomarker	[433]
TK1	TTP3QRF	Definitive	Biomarker	[434]
TP53BP1	TTX4UE9	Definitive	Altered Expression	[435]
TPX2	TT0PHL4	Definitive	Altered Expression	[436]
TTK	TTP7EGM	Definitive	Altered Expression	[437]
ULK1	TT4D7MJ	Definitive	Altered Expression	[438]
XPA	TTGT87E	Definitive	Genetic Variation	[439]

This Disease Is Related to 15 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A3	DTCRIWV	moderate	Altered Expression	[440]
ABCC11	DTWN7FC	Strong	Genetic Variation	[441]
SLC11A1	DT650XW	Strong	Biomarker	[442]
SLC12A2	DTHKL3Q	Strong	Altered Expression	[337]
SLC25A16	DTNU9EW	Strong	Genetic Variation	[443]
SLC2A10	DT3BI6S	Strong	Biomarker	[444]
SLC2A3	DT9SQ3L	Strong	Biomarker	[445]
SLC2A5	DTOR02F	Strong	Altered Expression	[446]
SLC4A4	DTWDEIL	Strong	Biomarker	[23]
SLC4A7	DT03V27	Strong	Biomarker	[23]
SLC5A8	DTE3TAW	Strong	Posttranslational Modification	[447]
ABCA3	DT2T6VQ	Definitive	Biomarker	[448]
SLC35A4	DT2OPRB	Definitive	Biomarker	[449]
SLC44A1	DT3I2SU	Definitive	Biomarker	[450]
SLC52A1	DT7NOKR	Definitive	Biomarker	[451]

This Disease Is Related to 29 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
DIO3	DET89OV	moderate	Biomarker	[66]
UGT2B17	DEAZDL8	moderate	Genetic Variation	[452]
ACOT13	DEMK5U6	Strong	Altered Expression	[453]
ACP5	DESITDW	Strong	Biomarker	[454]
ADH1C	DEM1HNL	Strong	Biomarker	[455]
AGMAT	DEG5L6E	Strong	Biomarker	[456]
AK2	DEY1FJO	Strong	Altered Expression	[457]
AKR1C2	DEOY5ZM	Strong	Biomarker	[458]
ALDH1A1	DE2JP1Y	Strong	Altered Expression	[376]
CYP2A13	DEXZA9U	Strong	Altered Expression	[459]
DDAH1	DEY0TQC	Strong	Biomarker	[460]
FAAH	DEUM1EX	Strong	Altered Expression	[461]
FPGS	DECWT2V	Strong	Altered Expression	[462]
GMDS	DE8K7F3	Strong	Altered Expression	[463]
HIF1AN	DEY1CBW	Strong	Altered Expression	[464]
HK1	DEDMAGE	Strong	Biomarker	[23]
HPRT1	DEVXTP5	Strong	Biomarker	[465]
HSD17B10	DEGSPC9	Strong	Biomarker	[127]
MGST1	DEAPJSO	Strong	Altered Expression	[466]
NAT2	DER7TA0	Strong	Genetic Variation	[467]
PAPSS1	DEDG68B	Strong	Altered Expression	[468]
PARK7	DEPOVCH	Strong	Biomarker	[469]
PMM2	DEBRX3L	Strong	Biomarker	[210]
UBASH3B	DE10BJ5	Strong	Biomarker	[470]
UCK2	DETN1O0	Strong	Biomarker	[23]
UGT1A3	DEF2WXN	Strong	Biomarker	[471]
GSTM4	DERQ52Z	Definitive	Altered Expression	[472]
LDHC	DEQG7F9	Definitive	Biomarker	[473]
PSAT1	DEBS17P	Definitive	Biomarker	[474]

This Disease Is Related to 936 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAM12	OTZKOTDB	Limited	Biomarker	[475]
ADAMTS7	OTVKZ1DV	Limited	Genetic Variation	[10]
AK5	OTTGXLOT	Limited	Genetic Variation	[10]
AKT1S1	OT4JHN4Y	Limited	Altered Expression	[476]
ALKBH3	OTS1CD9Z	Limited	Biomarker	[477]
APOBEC3B	OTHLNI51	Limited	Biomarker	[478]
C1D	OTI9PMN1	Limited	Genetic Variation	[193]
CABLES1	OTMN4XSX	Limited	Genetic Variation	[10]
CISD2	OTVS7S2H	Limited	Altered Expression	[479]
CLDN15	OT9K0KI7	Limited	Altered Expression	[480]
CLDN5	OTUX60YO	Limited	Altered Expression	[481]
CLPTM1L	OTDJWQXI	Limited	Genetic Variation	[482]
COPS6	OTG9AAG0	Limited	Biomarker	[169]
DCTN4	OTM7C943	Limited	Genetic Variation	[10]
DOK2	OTIJ38UF	Limited	Altered Expression	[483]
EMX2	OT0V8OYK	Limited	Altered Expression	[484]
ERICH6B	OTTQNLM7	Limited	Genetic Variation	[193]
ERP44	OT7ZI7AG	Limited	Biomarker	[485]
ESRP1	OTNCS4SL	Limited	Biomarker	[486]
ETV5	OTE2OBM4	Limited	Altered Expression	[487]
FAM227B	OTDZYIIY	Limited	Genetic Variation	[10]
FAM83A	OTBI16V7	Limited	Altered Expression	[488]
FRZB	OTTO3DPY	Limited	Biomarker	[489]
FUT1	OTODG57A	Limited	Genetic Variation	[490]
GABBR2	OT67RIFY	Limited	Biomarker	[491]
GALK2	OTHR35JF	Limited	Genetic Variation	[10]
GASK1B	OT2HPHEI	Limited	Biomarker	[492]
GGPS1	OTVEHG28	Limited	Altered Expression	[493]
GIPC2	OT68YFO1	Limited	Genetic Variation	[10]
GPC1	OTQKRSSV	Limited	Altered Expression	[494]
GPR180	OT2P0XNK	Limited	Biomarker	[495]
HAVCR2	OTOL603T	Limited	Biomarker	[496]
HEATR6	OTD3MYS0	Limited	Altered Expression	[91]
HHLA2	OTYBTVQS	Limited	Altered Expression	[497]
HOXB9	OTMVHQOU	Limited	Altered Expression	[498]
HOXC10	OT5WF17M	Limited	Biomarker	[499]
IGFBP4	OT2HZRBD	Limited	Posttranslational Modification	[500]
KDM4B	OT5P1UPY	Limited	Biomarker	[501]
KIF14	OTXHT4JM	Limited	Altered Expression	[502]
KIF23	OTY850JC	Limited	Biomarker	[503]
KIF5B	OTT34MT8	Limited	Biomarker	[504]
KLF17	OT5NWVP7	Limited	Biomarker	[505]
LAT	OTZC1XZ1	Limited	Altered Expression	[506]
MB	OTYWYL2D	Limited	Altered Expression	[507]
MIGA1	OT6BFR2U	Limited	Genetic Variation	[10]
MORF4L1	OTEA6FYJ	Limited	Genetic Variation	[10]
MPZL2	OTKFNDUI	Limited	Genetic Variation	[10]
MUC6	OTPVL723	Limited	Altered Expression	[508]
NAF1	OTMJKJAK	Limited	Genetic Variation	[10]
NOX1	OTZPJQCC	Limited	Altered Expression	[509]
OLA1	OTAPOTTG	Limited	Biomarker	[510]
PDPN	OTBUV19I	Limited	Biomarker	[511]
PKP3	OTPL1HRB	Limited	Altered Expression	[512]
PODXL	OTPNQXF3	Limited	Altered Expression	[513]
PVR	OT3N91T7	Limited	Biomarker	[514]
RAB31	OTMLXQZ0	Limited	Genetic Variation	[10]
RAB5A	OTFR2KM4	Limited	Altered Expression	[515]
RASSF3	OT4V9SRK	Limited	Genetic Variation	[10]
RBM10	OTES2MES	Limited	Altered Expression	[516]
RGS11	OTIAZ36F	Limited	Altered Expression	[517]
RNLS	OTVP2WJM	Limited	Genetic Variation	[193]
RTKN	OTSS8XR6	Limited	Biomarker	[518]
S100A2	OTTGHJ1H	Limited	Altered Expression	[30]
SOS1	OTTCWXC3	Limited	Genetic Variation	[519]
SPANXA1	OTMK3QIS	Limited	Biomarker	[520]
STXBP6	OTUEKTIP	Limited	Posttranslational Modification	[521]
TEKT5	OTZ5OUHY	Limited	Genetic Variation	[10]
TNKS1BP1	OTBIZECQ	Limited	Altered Expression	[522]
AHNAK	OT6KH1WG	Disputed	Altered Expression	[523]
CMTR2	OT82FBWS	Disputed	Biomarker	[29]
EPB41L3	OTS6CHG2	Disputed	Altered Expression	[524]
FASTK	OTTHFZMP	Disputed	Biomarker	[525]
HELLS	OTVVV668	Disputed	Biomarker	[23]
JUNB	OTG2JXV5	Disputed	Biomarker	[526]
KPNA2	OTU7FOE6	Disputed	Biomarker	[23]
KRT6B	OTBXJYHY	Disputed	Biomarker	[37]
NAA10	OTYB9R6I	Disputed	Biomarker	[23]
OPN3	OTON6BFU	Disputed	Altered Expression	[527]
SELENOP	OT02B8IR	Disputed	Biomarker	[528]
SIX3	OTP5E3VU	Disputed	Altered Expression	[529]
TMC5	OTO5D86M	Disputed	Altered Expression	[37]
TPI1	OT14KP4B	Disputed	Biomarker	[23]
ACIN1	OTK81F92	moderate	Posttranslational Modification	[530]
ACTN4	OTCNZAJ5	moderate	Altered Expression	[531]
ACTR10	OTRF3E58	moderate	Altered Expression	[532]
ACTR3B	OTNEC9UT	moderate	Altered Expression	[532]
ACTR3C	OTLAWZPC	moderate	Altered Expression	[532]
AHSA1	OTC7AFHT	moderate	Altered Expression	[46]
ALDH3A1	OTAYZZE6	moderate	Biomarker	[533]
ARMC8	OTNAXGM7	moderate	Biomarker	[534]
ASPM	OTKXQMNA	moderate	Biomarker	[249]
ATP2C1	OTQN51T3	moderate	Biomarker	[535]
BCL2L11	OTNQQWFJ	moderate	Biomarker	[536]
BEX4	OT3LXD15	moderate	Biomarker	[537]
BHLHE41	OTY9GJ1Y	moderate	Altered Expression	[538]
BRMS1	OTV5A6LL	moderate	Altered Expression	[539]
CA11	OT8RX3AJ	moderate	Altered Expression	[97]
CA8	OT9Y8GA8	moderate	Altered Expression	[97]
CALB2	OTSNMCG9	moderate	Biomarker	[540]
CBX3	OTOP9RLD	moderate	Altered Expression	[541]
CCL19	OTQ2UJMH	moderate	Altered Expression	[542]
CCL28	OTY6XNQ7	moderate	Altered Expression	[150]
CDCA2	OTX8UF9J	moderate	Altered Expression	[543]
CDK2AP2	OTR99SJ8	moderate	Altered Expression	[525]
CENPU	OTQ4TZRS	moderate	Altered Expression	[544]
CKAP4	OTDUC9ME	moderate	Altered Expression	[545]
CLDN10	OT2CVAKY	moderate	Biomarker	[546]
CLIC4	OT6KTPKD	moderate	Genetic Variation	[547]
CRABP2	OTY01V9G	moderate	Biomarker	[225]
CTAG1B	OTIQGW6U	moderate	Biomarker	[61]
CXCL5	OTZOUPCA	moderate	Biomarker	[548]
DDB1	OTTR2L3Z	moderate	Biomarker	[549]
EEF1A2	OT9Z23K5	moderate	Altered Expression	[550]
ERVW-1	OTWV8DXJ	moderate	Altered Expression	[551]
FEN1	OT6QGG7O	moderate	Biomarker	[552]
FLOT1	OT0JPPJZ	moderate	Biomarker	[553]
FLOT2	OTZ0QR5L	moderate	Altered Expression	[554]
FMR1NB	OT5IC2M2	moderate	Biomarker	[221]
GATA6	OTO2BC0F	moderate	Biomarker	[555]
GINS2	OT974IYI	moderate	Altered Expression	[556]
GPX2	OTXI2NTI	moderate	Biomarker	[557]
GPX4	OTRAFFX2	moderate	Altered Expression	[558]
GRAP2	OTS5NIZ3	moderate	Altered Expression	[46]
GRK6	OT4LZTP9	moderate	Biomarker	[559]
GRP	OT8JDFNI	moderate	Biomarker	[560]
HOXA9	OTKNK5H0	moderate	Posttranslational Modification	[561]
HOXB3	OT9UC5PE	moderate	Biomarker	[562]
ID3	OTUULW5Z	moderate	Biomarker	[563]
KIF18B	OTOBUDOE	moderate	Altered Expression	[564]
KLF15	OTGMQMVR	moderate	Biomarker	[565]
KLF6	OTQY9S7F	moderate	Biomarker	[566]
KLF8	OTUC5CDB	moderate	Biomarker	[567]
LAMTOR2	OTHEDISB	moderate	Altered Expression	[525]
LDHB	OT9B1CT3	moderate	Altered Expression	[568]
LMO3	OTR7AJHN	moderate	Biomarker	[569]
LRP1B	OT4YZG2N	moderate	Genetic Variation	[570]
MARCKSL1	OT13J2FM	moderate	Altered Expression	[571]
MCM4	OT19PNNG	moderate	Biomarker	[572]
MED1	OTOO24C4	moderate	Biomarker	[573]
MFN2	OTPYN8A3	moderate	Biomarker	[574]
MFSD2A	OTVG1VG0	moderate	Altered Expression	[575]
MRPL28	OT4LUTZU	moderate	Biomarker	[576]
MSN	OTZJ4J6G	moderate	Altered Expression	[577]
MUC5B	OTPW6K5C	moderate	Altered Expression	[578]
MYBPH	OTQJBPUR	moderate	Altered Expression	[579]
MYCL	OT1MFQ5U	moderate	Genetic Variation	[580]
MYOD1	OTV2S79X	moderate	Biomarker	[581]
NANOG	OTUEY1FM	moderate	Biomarker	[582]
NDUFC2	OT9M119L	moderate	Biomarker	[203]
NNAT	OTNRLO7G	moderate	Altered Expression	[583]
NXT1	OT0VO6AY	moderate	Biomarker	[576]
OPCML	OT93PQ6Y	moderate	Biomarker	[584]
OPN1LW	OTFNUZ7O	moderate	Biomarker	[171]
PAG1	OTFOJUIQ	moderate	Biomarker	[171]
PAQR7	OTIWX5AM	moderate	Biomarker	[352]
PCBP4	OTDLL4NB	moderate	Biomarker	[171]
PCNT	OTW4Z65J	moderate	Biomarker	[585]
PIP	OTH719AH	moderate	Biomarker	[27]
PLA2G10	OTRZ2L5A	moderate	Biomarker	[98]
PLAGL2	OT6AP4V2	moderate	Altered Expression	[586]
POLDIP2	OT8SZSJ6	moderate	Altered Expression	[46]
PRC1	OTHD0XS0	moderate	Biomarker	[587]
PRPF31	OTSJ0Z1Y	moderate	Genetic Variation	[588]
PSMD2	OT6HZHN7	moderate	Biomarker	[589]
PTPRG	OT9N2WOF	moderate	Biomarker	[590]
PTPRU	OTHDO0QG	moderate	Altered Expression	[440]
QKI	OTTAUGLB	moderate	Biomarker	[591]
RAD54B	OTMWB2P2	moderate	Biomarker	[552]
RBM47	OT6W67VM	moderate	Altered Expression	[592]
RDX	OTNSYUN6	moderate	Altered Expression	[577]
RELB	OTU3QYEF	moderate	Biomarker	[593]
RGMB	OT2DROYU	moderate	Altered Expression	[53]
RGN	OTD04KB1	moderate	Altered Expression	[594]
RIT1	OTVNOGOH	moderate	Genetic Variation	[595]
RNF19A	OTKWCV80	moderate	Altered Expression	[46]
RPP14	OT4OYFSK	moderate	Altered Expression	[525]
RPS15A	OT0BUA12	moderate	Biomarker	[596]
SELENBP1	OT3NZNTR	moderate	Biomarker	[597]
SESN2	OT889IXY	moderate	Altered Expression	[328]
SF3B6	OTPRKS6S	moderate	Altered Expression	[525]
SFTPA2	OT6SFOMU	moderate	Genetic Variation	[598]
SIAH2	OTKED2XN	moderate	Altered Expression	[599]
SLIT3	OTU8MKEU	moderate	Altered Expression	[600]
SMARCA1	OT0Y6PTU	moderate	Altered Expression	[601]
SMARCA2	OTSGJ8SV	moderate	Altered Expression	[602]
SNTG1	OT6GBQHI	moderate	Biomarker	[603]
SPAG5	OTCLJ56M	moderate	Altered Expression	[604]
SPINK1	OTSUVAL2	moderate	Biomarker	[419]
SRF	OTW18FQN	moderate	Biomarker	[605]
SRSF1	OTF61HOV	moderate	Altered Expression	[606]
STK11	OT1YZSP3	moderate	Biomarker	[607]
TAS2R13	OTSTOX5G	moderate	Altered Expression	[608]
TCHP	OTVDMHSY	moderate	Biomarker	[609]
TET1	OTZDHT1D	moderate	Biomarker	[610]
TIMM8A	OTDX9687	moderate	Biomarker	[611]
TRIB2	OTHSX3MX	moderate	Biomarker	[612]
TRIB3	OTG5OS7X	moderate	Altered Expression	[608]
TRIM23	OTVIGJ4T	moderate	Biomarker	[613]
ABCE1	OTH19LOA	Strong	Biomarker	[614]
ABCF1	OT6Q079J	Strong	Genetic Variation	[161]
ABHD11	OTJE9UZY	Strong	Biomarker	[615]
ACOT11	OTGPB0SM	Strong	Biomarker	[453]
ACSL4	OTI71MUJ	Strong	Biomarker	[23]
ACTR2	OT3C8U5T	Strong	Genetic Variation	[616]
ADAM28	OT3GBVHL	Strong	Altered Expression	[617]
ADAR	OTQNOHR8	Strong	Biomarker	[618]
ADARB1	OTGKSZEV	Strong	Altered Expression	[619]
ADGRA2	OTBT4W36	Strong	Biomarker	[620]
ADGRG1	OTQBB8NT	Strong	Biomarker	[621]
ADGRG6	OTY2UBXO	Strong	Genetic Variation	[622]
ADSS1	OTF6FE38	Strong	Altered Expression	[623]
AFF4	OTTL5Y8R	Strong	Altered Expression	[624]
AGO2	OT4JY32Q	Strong	Altered Expression	[625]
AGRN	OTWJENAZ	Strong	Biomarker	[178]
AK1	OT614AR3	Strong	Genetic Variation	[626]
AK4	OTA0T02Q	Strong	Biomarker	[627]
ALDH18A1	OT6W40XU	Strong	Biomarker	[23]
ALDH1A3	OT1C9NKQ	Strong	Biomarker	[628]
ALDOA	OTWRFTIB	Strong	Biomarker	[127]
ALOX15B	OTWQQ08W	Strong	Altered Expression	[629]
AMY1A	OT6G4B8O	Strong	Altered Expression	[283]
ANLN	OTXJY54C	Strong	Biomarker	[630]
ANP32A	OTRHPFO2	Strong	Biomarker	[23]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[470]
APC	OTKV0TIK	Strong	Altered Expression	[162]
APOM	OTI3FQQC	Strong	Genetic Variation	[161]
APPBP2	OTLNFV4J	Strong	Biomarker	[631]
AQP4	OTA9MYD5	Strong	Biomarker	[632]
AQP5	OT77GBY8	Strong	Altered Expression	[633]
ARHGDIA	OTEXWJDO	Strong	Altered Expression	[634]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[635]
ARHGEF7	OT9BPJCL	Strong	Biomarker	[636]
ARID1B	OTILK3Q7	Strong	Biomarker	[637]
ARIH1	OTO3XDR2	Strong	Altered Expression	[638]
ARL14	OTE4MKOZ	Strong	Biomarker	[639]
ARMH1	OTTJC0D6	Strong	Biomarker	[256]
ASCL1	OTI4X44G	Strong	Biomarker	[640]
ASF1A	OT4S44GP	Strong	Biomarker	[641]
ASXL3	OTNDJWEZ	Strong	Genetic Variation	[103]
ATAD3A	OTWF6HBP	Strong	Biomarker	[642]
ATAD3B	OTL508AF	Strong	Biomarker	[643]
ATF6	OTAFHAVI	Strong	Biomarker	[409]
ATG16L2	OTJYU0W8	Strong	Genetic Variation	[644]
ATG3	OT28VBVK	Strong	Biomarker	[645]
ATMIN	OTEADE76	Strong	Biomarker	[646]
ATOH8	OT7SY3BN	Strong	Altered Expression	[344]
ATP5PD	OTAJDLE2	Strong	Biomarker	[127]
ATXN1	OTQF0HNR	Strong	Biomarker	[647]
B4GALT1	OTBCXEK7	Strong	Biomarker	[648]
BABAM1	OTCFPER6	Strong	Genetic Variation	[138]
BAG1	OTRQNIA4	Strong	Altered Expression	[649]
BATF2	OT4XBZC9	Strong	Biomarker	[650]
BAZ1A	OTWHOVZS	Strong	Genetic Variation	[616]
BEX1	OTBQIF0H	Strong	Altered Expression	[537]
BEX5	OTZ2RB6L	Strong	Biomarker	[537]
BIK	OTTH1T3D	Strong	Biomarker	[210]
BOK	OTDQPDIX	Strong	Altered Expression	[651]
BPIFB1	OTOZYJMO	Strong	Genetic Variation	[269]
BPY2	OT2WQPNQ	Strong	Biomarker	[652]
BRMS1L	OTJIW47U	Strong	Altered Expression	[539]
BZW1	OT4GUFIG	Strong	Altered Expression	[653]
BZW2	OTBT0A1B	Strong	Biomarker	[23]
C2	OTHMF4YM	Strong	Genetic Variation	[161]
C5orf34	OTT2ESR4	Strong	Altered Expression	[654]
CAMK1D	OTU24HAU	Strong	Biomarker	[655]
CANX	OTYP1F6J	Strong	Biomarker	[327]
CAPG	OTJ86KI6	Strong	Biomarker	[127]
CAPS	OTC9GZ2M	Strong	Altered Expression	[656]
CAST	OTBXZZGF	Strong	Genetic Variation	[657]
CASTOR1	OTYIH7WK	Strong	Biomarker	[658]
CAVIN2	OTFHHDRU	Strong	Biomarker	[659]
CAVIN3	OTOLBK79	Strong	Biomarker	[660]
CBLC	OT3RKZI9	Strong	Biomarker	[661]
CCDC6	OTXRQDYG	Strong	Biomarker	[662]
CCDC66	OTE8VSSO	Strong	Altered Expression	[663]
CCDC8	OTO295IH	Strong	Biomarker	[327]
CCL1	OT23NON8	Strong	Biomarker	[235]
CCL4L2	OTDBSXOU	Strong	Biomarker	[664]
CCRL2	OT5PX0RX	Strong	Altered Expression	[665]
CCT4	OT5D452X	Strong	Biomarker	[666]
CCT5	OTPZ38BT	Strong	Biomarker	[23]
CD151	OTF3UZS7	Strong	Altered Expression	[667]
CD247	OT45FGUX	Strong	Altered Expression	[668]
CD82	OTH8MC64	Strong	Altered Expression	[669]
CDCA7	OT12HDZY	Strong	Biomarker	[670]
CDCP1	OTD7RRWK	Strong	Biomarker	[671]
CDH23	OTOJGQ7S	Strong	Altered Expression	[672]
CDK10	OTKP7TTR	Strong	Altered Expression	[673]
CDKN2B	OTAG24N1	Strong	Genetic Variation	[674]
CDKN3	OTBE3H07	Strong	Altered Expression	[675]
CDX2	OTCG4TSY	Strong	Genetic Variation	[676]
CEACAM21	OTHVCMIP	Strong	Biomarker	[677]
CENPA	OT0NEJ4X	Strong	Altered Expression	[54]
CEP55	OTGSG2PA	Strong	Altered Expression	[678]
CEP72	OTVYNPNL	Strong	Genetic Variation	[679]
CFDP1	OTXY7J96	Strong	Biomarker	[589]
CFHR1	OT72R16T	Strong	Biomarker	[680]
CHD1L	OT7CZK7C	Strong	Altered Expression	[681]
CHD4	OTBDEHDP	Strong	Genetic Variation	[269]
CHL1	OT6E6E8P	Strong	Altered Expression	[682]
CHPT1	OT4FJ0K3	Strong	Biomarker	[218]
CHRNA3	OTCZQY1U	Strong	Altered Expression	[683]
CIDEC	OTMDZ56K	Strong	Biomarker	[639]
CKAP2L	OT4T73GG	Strong	Altered Expression	[684]
CLDN1	OT27KV99	Strong	Genetic Variation	[685]
CLDN2	OTRF3D6Y	Strong	Altered Expression	[686]
CLEC10A	OTD8HQT6	Strong	Biomarker	[687]
CLEC14A	OT0UJQ4O	Strong	Posttranslational Modification	[688]
CLSTN1	OTQN35G2	Strong	Biomarker	[689]
COL10A1	OTC4G2YC	Strong	Altered Expression	[94]
COL3A1	OTT1EMLM	Strong	Biomarker	[94]
COL4A5	OTHG60RE	Strong	Biomarker	[444]
COL5A1	OT24078H	Strong	Biomarker	[690]
COPB2	OT82JIGC	Strong	Altered Expression	[691]
COX5A	OTP0961M	Strong	Altered Expression	[692]
COX7A1	OTHV25GG	Strong	Biomarker	[692]
CPA3	OTOK8M0V	Strong	Genetic Variation	[693]
CPEB1	OTLCXC6H	Strong	Biomarker	[694]
CPSF3	OTS3KSNG	Strong	Altered Expression	[695]
CRIM1	OTTZNV6Y	Strong	Altered Expression	[259]
CRLS1	OT7XNL0K	Strong	Altered Expression	[696]
CSRP3	OTECBJMV	Strong	Biomarker	[23]
CST1	OTE4I83Q	Strong	Biomarker	[225]
CST6	OTZVHJTF	Strong	Biomarker	[694]
CTBP1	OTVYH2DH	Strong	Biomarker	[348]
CTC1	OTRJY7QD	Strong	Genetic Variation	[697]
CTHRC1	OTV88X2G	Strong	Altered Expression	[698]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[699]
CTNND1	OTUMPSHR	Strong	Genetic Variation	[700]
CTNND2	OTYKE30Y	Strong	Biomarker	[701]
CTTN	OTJRG4ES	Strong	Altered Expression	[702]
CUEDC2	OTWMOLAJ	Strong	Altered Expression	[703]
CUL4B	OT2QX4DO	Strong	Altered Expression	[704]
CXCL17	OTRCEVIZ	Strong	Altered Expression	[705]
CYGB	OTX153DQ	Strong	Posttranslational Modification	[706]
CYLD	OT37FKH0	Strong	Biomarker	[707]
DAB2	OTRMQTMZ	Strong	Biomarker	[708]
DACH1	OTMKNAGG	Strong	Altered Expression	[344]
DAP	OT5YLL7E	Strong	Posttranslational Modification	[709]
DCAF4	OTQU0EUO	Strong	Altered Expression	[182]
DCBLD1	OTA702JK	Strong	Genetic Variation	[616]
DDX53	OTHK3EGZ	Strong	Biomarker	[710]
DDX59	OTHJANS0	Strong	Altered Expression	[711]
DEDD	OTIL349E	Strong	Biomarker	[712]
DGUOK	OT78HUZB	Strong	Biomarker	[713]
DHDDS	OTVLYBUS	Strong	Biomarker	[218]
DHX15	OT4F98TK	Strong	Genetic Variation	[676]
DHX9	OT5AAOQI	Strong	Genetic Variation	[714]
DIAPH3	OTPOT23F	Strong	Altered Expression	[715]
DIP2A	OTXPTR8R	Strong	Biomarker	[652]
DKK4	OTWCCVF6	Strong	Biomarker	[716]
DLC1	OTP8LMCR	Strong	Altered Expression	[717]
DLD	OT378CU9	Strong	Biomarker	[415]
DMBX1	OT43YF6N	Strong	Biomarker	[718]
DNM1L	OTXK1Q1G	Strong	Biomarker	[719]
DOCK4	OTH3XY8B	Strong	Biomarker	[720]
DRG1	OTIFYMI3	Strong	Biomarker	[721]
DROSHA	OTCE68KZ	Strong	Altered Expression	[722]
DUSP4	OT6WAO12	Strong	Altered Expression	[483]
E2F4	OTB3JFH4	Strong	Altered Expression	[723]
E2F7	OTWW358N	Strong	Altered Expression	[724]
EAF2	OTSOET5L	Strong	Biomarker	[725]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[256]
ECRG4	OTHZYUXX	Strong	Altered Expression	[726]
EDAR	OT3W2UQS	Strong	Genetic Variation	[441]
EDIL3	OTDVVNS0	Strong	Biomarker	[727]
EDN3	OTN7Q9BE	Strong	Biomarker	[214]
EFNA1	OTU2NUA2	Strong	Altered Expression	[191]
EFNB2	OT0DCUOM	Strong	Altered Expression	[244]
EIF2B1	OT4NCVY1	Strong	Biomarker	[23]
EIF2B4	OTTM5SX1	Strong	Biomarker	[526]
EIF2B5	OTV3R4RB	Strong	Biomarker	[526]
EIF3E	OTI0WG98	Strong	Biomarker	[23]
EIF3F	OTU20K6L	Strong	Biomarker	[728]
EIF4G2	OTEO98CR	Strong	Biomarker	[589]
EIF4H	OTGZI072	Strong	Biomarker	[729]
EIF5	OT79PQUN	Strong	Biomarker	[190]
EIF5AL1	OTLA4ONW	Strong	Biomarker	[190]
ELF3	OTUTLEQO	Strong	Biomarker	[730]
ELK1	OTH9MXD6	Strong	Altered Expression	[731]
EMD	OTR8ZANE	Strong	Biomarker	[732]
EMILIN2	OTOYK5A8	Strong	Biomarker	[694]
ENKUR	OTXXBBQT	Strong	Biomarker	[733]
EPB41L4B	OT2K30P7	Strong	Altered Expression	[734]
ERCC1	OTNPYQHI	Strong	Biomarker	[735]
ERCC2	OT1C8HQ4	Strong	Genetic Variation	[736]
ERGIC3	OT8RWHN3	Strong	Biomarker	[737]
ESPL1	OTMGEVOK	Strong	Biomarker	[738]
ESYT2	OTWCXTX3	Strong	Altered Expression	[739]
ETV4	OT8C98UZ	Strong	Altered Expression	[276]
EYA4	OTINGR3Z	Strong	Posttranslational Modification	[740]
FA2H	OT8HA13U	Strong	Altered Expression	[741]
FAIM2	OT6QINVO	Strong	Biomarker	[742]
FAM111B	OT9IQ9NV	Strong	Biomarker	[743]
FAM13A	OTZ6GN0Q	Strong	Genetic Variation	[744]
FANCC	OTTIDM3P	Strong	Genetic Variation	[145]
FBL	OTRODIE5	Strong	Biomarker	[23]
FBLN2	OTEHR7N7	Strong	Biomarker	[745]
FBXL7	OTNUK1DJ	Strong	Biomarker	[746]
FBXO22	OTEJ5MO0	Strong	Altered Expression	[747]
FBXW11	OT2A6RLR	Strong	Genetic Variation	[748]
FERMT1	OT626PBA	Strong	Altered Expression	[749]
FERMT2	OTZNPWWX	Strong	Biomarker	[750]
FGA	OTMIHY80	Strong	Biomarker	[751]
FGF22	OTVIX6J0	Strong	Biomarker	[752]
FGF9	OT2SKDGM	Strong	Altered Expression	[753]
FGL1	OTT0QHQ1	Strong	Genetic Variation	[754]
FKBP11	OTY2GC67	Strong	Biomarker	[23]
FNDC3B	OTBILGDR	Strong	Biomarker	[755]
FOXA2	OTJOCVOY	Strong	Altered Expression	[756]
FOXD3	OTXYV6GO	Strong	Altered Expression	[757]
FOXP4	OTHCGIEZ	Strong	Genetic Variation	[758]
FRY	OT74IAG2	Strong	Genetic Variation	[138]
FSTL1	OT6KEZUD	Strong	Altered Expression	[759]
FUT2	OTLXM6WI	Strong	Biomarker	[760]
GABBR1	OTU5A52J	Strong	Genetic Variation	[161]
GABPA	OT9YB2SA	Strong	Genetic Variation	[761]
GALNT14	OT9BSDDQ	Strong	Altered Expression	[762]
GALNT6	OTOQQVH1	Strong	Biomarker	[763]
GAR1	OTA580RX	Strong	Biomarker	[23]
GBE1	OTK2N05B	Strong	Biomarker	[764]
GBP1	OTUM7RPJ	Strong	Biomarker	[15]
GBX2	OTW0ZI4D	Strong	Altered Expression	[765]
GCC2	OTT5I9FM	Strong	Biomarker	[766]
GEMIN4	OTX7402E	Strong	Biomarker	[589]
GGA2	OT43HO27	Strong	Biomarker	[767]
GINS4	OTCVOO3S	Strong	Altered Expression	[768]
GK5	OT65U8L1	Strong	Altered Expression	[769]
GKN1	OT7ZYFQ9	Strong	Biomarker	[770]
GKN2	OTR9DOYG	Strong	Biomarker	[103]
GNG11	OTHIXBGW	Strong	Biomarker	[526]
GNPNAT1	OTOYH4L9	Strong	Biomarker	[23]
GOPC	OTRBGH71	Strong	Biomarker	[771]
GORASP2	OTL3PLD2	Strong	Biomarker	[772]
GPC5	OT8NR7GC	Strong	Altered Expression	[773]
GPHN	OTAKK1SV	Strong	Biomarker	[774]
GPR158	OTYOC1RQ	Strong	Biomarker	[775]
GPRC5A	OTPOCWR7	Strong	Biomarker	[776]
GRWD1	OT6M13ZV	Strong	Biomarker	[23]
GUK1	OTLI0HRU	Strong	Biomarker	[777]
H1-10	OTBWDA4E	Strong	Biomarker	[23]
HBE1	OTJPKMX4	Strong	Biomarker	[778]
HCP5	OTV0YRI8	Strong	Altered Expression	[779]
HES7	OT6F9R7P	Strong	Altered Expression	[763]
HIP1	OT7AKCFQ	Strong	Altered Expression	[780]
HLA-DQA2	OT1DH0N9	Strong	Genetic Variation	[161]
HMGB3	OTCJ2EZY	Strong	Biomarker	[94]
HMMR	OT4M0JTZ	Strong	Biomarker	[178]
HNF1B	OTSYIC3T	Strong	Genetic Variation	[138]
HNRNPD	OT5UO1FA	Strong	Biomarker	[781]
HNRNPK	OTNPRM8U	Strong	Biomarker	[782]
HOPX	OTBSR6C9	Strong	Biomarker	[783]
HORMAD1	OT7DR5T2	Strong	Altered Expression	[784]
HOXA10	OTB6GQ09	Strong	Biomarker	[785]
HOXA3	OTIX5XFB	Strong	Altered Expression	[786]
HOXB2	OTTD6HMV	Strong	Biomarker	[787]
HOXB4	OTH1HRW5	Strong	Biomarker	[562]
HOXB7	OTC7WYU8	Strong	Altered Expression	[788]
HOXC13	OT52AVNA	Strong	Altered Expression	[789]
HUWE1	OTFH6BJS	Strong	Altered Expression	[790]
HYKK	OTBK1QPN	Strong	Biomarker	[791]
ID4	OTPMJ39I	Strong	Altered Expression	[792]
IDH3A	OT5QQB5L	Strong	Biomarker	[793]
IFIT2	OTI4EOAR	Strong	Altered Expression	[794]
IFITM1	OTECO1G8	Strong	Altered Expression	[795]
IFITM3	OT2QP8D3	Strong	Biomarker	[796]
IGBP1	OTTHH4YE	Strong	Altered Expression	[307]
IGF2BP1	OT9G360P	Strong	Biomarker	[797]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[798]
IL17B	OTS86H50	Strong	Altered Expression	[236]
IL17C	OTKXIVNQ	Strong	Altered Expression	[236]
IL1F10	OTJAASGC	Strong	Biomarker	[799]
IMMT	OTBDSLE7	Strong	Altered Expression	[800]
INF2	OT8ZM13C	Strong	Genetic Variation	[623]
INSL4	OTK9F0LX	Strong	Altered Expression	[801]
INSYN2B	OTJGTKK4	Strong	Altered Expression	[802]
IPO4	OT2N5020	Strong	Biomarker	[23]
IPO5	OTAK40ED	Strong	Biomarker	[23]
IQSEC1	OTK1PBFD	Strong	Altered Expression	[803]
IREB2	OT747D24	Strong	Altered Expression	[791]
IRF4	OT1DHQ1P	Strong	Altered Expression	[804]
IRX5	OT05J514	Strong	Altered Expression	[805]
ISYNA1	OT49ONSE	Strong	Biomarker	[806]
ITIH5	OTP46PZM	Strong	Altered Expression	[807]
ITPKA	OTX5ERUD	Strong	Altered Expression	[808]
ITPRIPL1	OTJ5H965	Strong	Biomarker	[103]
JMJD6	OTILR7E4	Strong	Biomarker	[809]
KCNK15	OT8ELIFL	Strong	Biomarker	[775]
KHDRBS2	OTEKL45T	Strong	Genetic Variation	[292]
KIAA1217	OTRMK3PU	Strong	Biomarker	[810]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[811]
KIF13A	OTSSZGBQ	Strong	Biomarker	[812]
KIF16B	OTDWIFQ2	Strong	Biomarker	[813]
KIF18A	OTSMBJ24	Strong	Altered Expression	[814]
KIF20A	OTXOQHE0	Strong	Biomarker	[815]
KIF2A	OT2WQ6QD	Strong	Biomarker	[816]
KIF2C	OTJ8G3NP	Strong	Altered Expression	[817]
KLF10	OT4F4UGS	Strong	Altered Expression	[818]
KRT16	OTGA0EQN	Strong	Altered Expression	[113]
KRT5	OTVGI9HT	Strong	Biomarker	[37]
KRT8	OTTM4X11	Strong	Altered Expression	[819]
KRTAP8-1	OTKXKZ40	Strong	Biomarker	[820]
LAD1	OT6YGTVX	Strong	Biomarker	[415]
LAMA3	OTFME7HT	Strong	Biomarker	[821]
LAYN	OT9A9Q1X	Strong	Biomarker	[694]
LDB2	OT6Y8IEK	Strong	Genetic Variation	[161]
LDOC1	OTWZH4O9	Strong	Biomarker	[822]
LGALS4	OTKQCG0H	Strong	Altered Expression	[823]
LGR6	OTPZ1PWR	Strong	Biomarker	[824]
LHX3	OTQ5BAJ9	Strong	Biomarker	[825]
LIN28B	OTVWP0FN	Strong	Biomarker	[826]
LMNB1	OT100T3P	Strong	Biomarker	[23]
LMNB2	OTXRDUOS	Strong	Altered Expression	[827]
LOXL1	OTA0NEJU	Strong	Altered Expression	[242]
LPCAT1	OTCV7AGV	Strong	Biomarker	[828]
LPIN1	OTQ75KF2	Strong	Biomarker	[829]
LPP	OT6TU8SE	Strong	Genetic Variation	[830]
LRP12	OTRT1UJ7	Strong	Posttranslational Modification	[831]
LRPPRC	OTXSK5LP	Strong	Biomarker	[832]
LXN	OTZQ2M6Y	Strong	Altered Expression	[833]
LYNX1	OTK4103B	Strong	Biomarker	[834]
LYPD5	OTGP7UKA	Strong	Biomarker	[278]
MAD2L1	OTXNGZCG	Strong	Biomarker	[835]
MAFG	OTBQFUZH	Strong	Biomarker	[836]
MAP1LC3A	OTPMGIU4	Strong	Biomarker	[837]
MAP2K4	OTZPZX11	Strong	Biomarker	[838]
MAPK4	OTVWWUYS	Strong	Altered Expression	[839]
MARCHF9	OTWF84QT	Strong	Biomarker	[840]
MARVELD3	OTFTPOJ4	Strong	Biomarker	[694]
MBD2	OTUQPP0R	Strong	Altered Expression	[610]
MCAT	OTH07FIW	Strong	Biomarker	[168]
MCM10	OTV0O3JN	Strong	Biomarker	[572]
MCM2	OTGGORIQ	Strong	Biomarker	[572]
MCM5	OTAHLB62	Strong	Biomarker	[605]
MCM8	OTC93H3S	Strong	Biomarker	[605]
MCTS1	OT7SAOJP	Strong	Biomarker	[168]
MED19	OTT9RT5N	Strong	Biomarker	[841]
MEST	OT8Q4U8Y	Strong	Biomarker	[842]
METTL3	OTSXP1M3	Strong	Altered Expression	[843]
MFF	OTEVIXOM	Strong	Genetic Variation	[844]
MID1	OTWN1PGU	Strong	Altered Expression	[845]
MIIP	OT79EXZ7	Strong	Altered Expression	[846]
MINDY4	OTBZ2SZB	Strong	Altered Expression	[633]
MIP	OTEBLU3E	Strong	Biomarker	[847]
MOCS2	OTSPV7AX	Strong	Genetic Variation	[292]
MORF4L2	OT8OI3EC	Strong	Altered Expression	[249]
MPC1	OT6DYFUO	Strong	Biomarker	[848]
MPZL3	OTC4LRBU	Strong	Genetic Variation	[616]
MRE11	OTGU8TZM	Strong	Biomarker	[23]
MRPL12	OTU41AM0	Strong	Biomarker	[23]
MRPL41	OTG5URO4	Strong	Biomarker	[849]
MRPS5	OTZZR208	Strong	Biomarker	[23]
MRTFB	OT9OXGS9	Strong	Biomarker	[850]
MSH3	OTD3YPVL	Strong	Biomarker	[851]
MSH5	OTDARQT3	Strong	Genetic Variation	[161]
MSH6	OT46FP09	Strong	Biomarker	[851]
MT1G	OTAV1OCR	Strong	Biomarker	[621]
MTBP	OTWLCW9C	Strong	Biomarker	[852]
MTERF1	OT3EIK39	Strong	Altered Expression	[853]
MTO1	OT7HCZ1D	Strong	Biomarker	[591]
MTSS1	OT5DTDO2	Strong	Altered Expression	[854]
MTX1	OTLSDNZO	Strong	Genetic Variation	[138]
MUC21	OTQ8GP5L	Strong	Altered Expression	[855]
MUC4	OTLT11V1	Strong	Altered Expression	[167]
MUCL3	OTGAD3I0	Strong	Genetic Variation	[161]
MVP	OTJGHJRB	Strong	Altered Expression	[856]
MYBL2	OTZ3JX8Q	Strong	Biomarker	[857]
MYH14	OT1TZEJK	Strong	Genetic Variation	[739]
NAPSA	OT6F8IAL	Strong	Biomarker	[858]
NCAPG	OT1AI9EO	Strong	Biomarker	[859]
NCAPG2	OTZYENKO	Strong	Biomarker	[860]
NCBP1	OTYBR927	Strong	Biomarker	[704]
NCOR1	OT04XNOU	Strong	Genetic Variation	[861]
NCOR2	OTY917X0	Strong	Altered Expression	[541]
ND5	OT45LW1K	Strong	Altered Expression	[862]
ND6	OTG47B7B	Strong	Biomarker	[863]
NECTIN3	OTS8N7MK	Strong	Biomarker	[864]
NEK10	OTN0JAYL	Strong	Genetic Variation	[138]
NELL2	OTS4MJZ7	Strong	Biomarker	[291]
NEUROD1	OTZQ7QJ2	Strong	Genetic Variation	[865]
NFATC2	OTK5T6HZ	Strong	Biomarker	[866]
NFIL3	OTQH9HM3	Strong	Altered Expression	[867]
NFIX	OT1DPZAE	Strong	Altered Expression	[868]
NFS1	OT0HUS40	Strong	Biomarker	[869]
NMU	OTW9X7BQ	Strong	Altered Expression	[94]
NOLC1	OTKDZU0D	Strong	Biomarker	[130]
NOP56	OTT67SRZ	Strong	Biomarker	[23]
NOP58	OTP536HD	Strong	Biomarker	[23]
NPM3	OTIAM1A3	Strong	Biomarker	[23]
NR2F6	OTNVO2B6	Strong	Biomarker	[870]
NSUN3	OTLBKU22	Strong	Genetic Variation	[292]
NUDT1	OTZSES3W	Strong	Genetic Variation	[269]
NUDT21	OTZHKWAR	Strong	Biomarker	[23]
NUP210	OT3BLQ9M	Strong	Altered Expression	[871]
NUP58	OTMLLWJW	Strong	Biomarker	[872]
OCA2	OTDWIGBF	Strong	Altered Expression	[873]
OCIAD2	OTSWB4SZ	Strong	Altered Expression	[874]
OCLN	OTSUTVWL	Strong	Biomarker	[875]
OIP5	OTI5C2DE	Strong	Biomarker	[859]
ORAI3	OTUP3OH3	Strong	Biomarker	[876]
ORM1	OTZKSBRE	Strong	Biomarker	[877]
OSR1	OTB19LEQ	Strong	Biomarker	[562]
OTUD3	OTHUWQHP	Strong	Genetic Variation	[878]
OTUD7B	OTMVM8R7	Strong	Biomarker	[879]
OTX2	OTTV05B1	Strong	Altered Expression	[718]
OVOL2	OTFM1GKF	Strong	Altered Expression	[880]
PABPC4	OTICKKBQ	Strong	Biomarker	[23]
PACC1	OTKBS8CC	Strong	Genetic Variation	[881]
PAFAH1B1	OT9T2TCJ	Strong	Altered Expression	[882]
PAIP1	OTL2F5T5	Strong	Altered Expression	[883]
PCBD1	OTDSRUD5	Strong	Biomarker	[23]
PCDH7	OTP091X8	Strong	Altered Expression	[884]
PCDHGB6	OT1Y20JS	Strong	Biomarker	[885]
PCNP	OTJUQ122	Strong	Biomarker	[886]
PDCD5	OT6T2DDL	Strong	Altered Expression	[887]
PDK4	OTCMHMBZ	Strong	Biomarker	[888]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[889]
PEBP4	OTKDCVC6	Strong	Altered Expression	[890]
PELI1	OTMLBCLC	Strong	Altered Expression	[891]
PERP	OTP0YL53	Strong	Biomarker	[892]
PFN1	OTHTGA1H	Strong	Altered Expression	[893]
PHF5A	OTS94JFM	Strong	Biomarker	[894]
PHLDA2	OTMV9DPP	Strong	Biomarker	[895]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[896]
PHLPP2	OTXB1OUI	Strong	Altered Expression	[896]
PIAS1	OTZVAHZI	Strong	Biomarker	[897]
PIGN	OTHHTJKX	Strong	Biomarker	[23]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[898]
PINK1	OT50NR57	Strong	Biomarker	[899]
PITX1	OTA0UN4C	Strong	Altered Expression	[900]
PITX2	OTWMXAOY	Strong	Altered Expression	[901]
PIWIL1	OT7CRGZ3	Strong	Biomarker	[902]
PKD2	OTIXBU8H	Strong	Biomarker	[903]
PKNOX1	OTUDMNHX	Strong	Altered Expression	[904]
PLEC	OTU4XDEG	Strong	Biomarker	[905]
PLEK2	OTUBWUUK	Strong	Altered Expression	[906]
PLIN2	OTRXJ9UN	Strong	Genetic Variation	[907]
PLPP4	OTH5EXZC	Strong	Biomarker	[908]
PMEPA1	OTY8Z9UF	Strong	Altered Expression	[909]
POLE2	OTAC9V6L	Strong	Altered Expression	[910]
POLQ	OTBHK0E6	Strong	Altered Expression	[305]
POLR1D	OTOCZQNA	Strong	Biomarker	[23]
POU2AF1	OTOO6WHL	Strong	Biomarker	[346]
POU2F2	OTPV0J0C	Strong	Biomarker	[370]
POU3F2	OT30NFOC	Strong	Altered Expression	[911]
PPAN	OT0UFQBZ	Strong	Biomarker	[23]
PPP1R17	OT19635T	Strong	Biomarker	[214]
PPP1R18	OT0JVGOZ	Strong	Genetic Variation	[161]
PPP1R8	OTH5KB2P	Strong	Altered Expression	[464]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[28]
PRDM1	OTQLSVBS	Strong	Altered Expression	[912]
PRDM16	OT0BGA27	Strong	Altered Expression	[913]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[914]
PRDX1	OTZ3BEC4	Strong	Altered Expression	[915]
PRDX3	OTLB2WEU	Strong	Altered Expression	[916]
PRPF19	OTQ1STV3	Strong	Altered Expression	[917]
PRSS3	OTN3S5YB	Strong	Biomarker	[252]
PSD	OTUZIXUZ	Strong	Biomarker	[918]
PSMA7	OTPHI6ST	Strong	Biomarker	[919]
PSMD7	OT7PZZ4K	Strong	Biomarker	[256]
PTGES3	OTPPQWI0	Strong	Altered Expression	[158]
PTPA	OTRGFOI7	Strong	Biomarker	[920]
PTPRH	OTDUHQGF	Strong	Posttranslational Modification	[921]
PTPRT	OTV5TXNN	Strong	Genetic Variation	[922]
PTRH2	OTBU39Q1	Strong	Biomarker	[923]
PXN	OTVMMUOF	Strong	Altered Expression	[924]
PYCR1	OTQHB52T	Strong	Altered Expression	[750]
RAB27B	OTPF9D0K	Strong	Biomarker	[925]
RAB3GAP1	OT4DQ8F2	Strong	Biomarker	[130]
RABEPK	OTCZSREH	Strong	Biomarker	[256]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[926]
RAD51B	OTCJVRMY	Strong	Genetic Variation	[138]
RAD52	OT0OTDHI	Strong	Genetic Variation	[269]
RALY	OT78NNWY	Strong	Genetic Variation	[138]
RANGRF	OTKQC813	Strong	Biomarker	[23]
RAP1A	OT5RH6TI	Strong	Biomarker	[926]
RASGRF1	OTNWJ7EN	Strong	Genetic Variation	[519]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[271]
RBBP8	OTRHJ3GI	Strong	Altered Expression	[663]
RBL2	OTBQSOE6	Strong	Biomarker	[130]
RBM3	OTAJ7R31	Strong	Altered Expression	[927]
RBMY1A1	OTM2F25H	Strong	Genetic Variation	[928]
RCC2	OTUJVTLS	Strong	Biomarker	[929]
RCCD1	OT60N06L	Strong	Altered Expression	[930]
RCL1	OT7O00YX	Strong	Biomarker	[23]
RDM1	OTBSJEAG	Strong	Biomarker	[931]
REG1B	OTSC2133	Strong	Biomarker	[932]
RETN	OTW5Z1NH	Strong	Biomarker	[933]
REXO2	OTLKKURG	Strong	Biomarker	[210]
RFC3	OT1MS7AO	Strong	Biomarker	[934]
RFC4	OTWALD2R	Strong	Altered Expression	[935]
RGS17	OT5RVUDS	Strong	Altered Expression	[936]
RHOJ	OTWI65OA	Strong	Biomarker	[937]
RMC1	OT7K8MTJ	Strong	Biomarker	[938]
RMDN1	OTE1NB6U	Strong	Genetic Variation	[939]
RMDN2	OTK5WSFI	Strong	Genetic Variation	[939]
RMDN3	OTKO7AUM	Strong	Genetic Variation	[939]
RNF39	OTUQA9JT	Strong	Genetic Variation	[161]
RPL10A	OTDLCJ53	Strong	Biomarker	[23]
RPL13A	OTME3VXN	Strong	Biomarker	[23]
RPL17	OTTYMPS6	Strong	Biomarker	[940]
RPL27A	OTQQHPL0	Strong	Biomarker	[23]
RPL36A	OT1LYV85	Strong	Biomarker	[941]
RPS6	OTT4D1LN	Strong	Altered Expression	[942]
RRAD	OTW2O4GD	Strong	Posttranslational Modification	[943]
RRAS	OTBBF28C	Strong	Altered Expression	[158]
RREB1	OT62460U	Strong	Biomarker	[792]
RRS1	OTTNCZN6	Strong	Biomarker	[23]
RSPO2	OT3HHXU0	Strong	Altered Expression	[329]
RUFY3	OTMA4YA4	Strong	Altered Expression	[944]
RUVBL1	OTWV19L7	Strong	Altered Expression	[945]
S100A11	OTI57KDN	Strong	Altered Expression	[946]
S100A7	OTJFVJRF	Strong	Biomarker	[947]
S100A7A	OTNM8DCP	Strong	Biomarker	[948]
S100P	OTJCXNJG	Strong	Genetic Variation	[949]
SAMHD1	OTBCIBC7	Strong	Posttranslational Modification	[950]
SASS6	OT1V8H40	Strong	Altered Expression	[951]
SCGB3A2	OTB63PHR	Strong	Altered Expression	[952]
SDCBP	OTS3NCC5	Strong	Altered Expression	[953]
SEC31A	OT2U42AC	Strong	Biomarker	[954]
SEMA4B	OT1Y3YZD	Strong	Biomarker	[62]
SEMA5A	OTUOIOJV	Strong	Altered Expression	[955]
SEMA7A	OT0ZJK64	Strong	Biomarker	[956]
SERPINB2	OT72QLZB	Strong	Altered Expression	[957]
SET	OTGYYQJO	Strong	Biomarker	[958]
SETX	OTG3JNOQ	Strong	Biomarker	[959]
SFN	OTLJCZ1U	Strong	Biomarker	[960]
SFRP1	OT0U9G41	Strong	Biomarker	[961]
SFTA2	OTVRIUIV	Strong	Biomarker	[37]
SFTPA1	OT87XL1U	Strong	Altered Expression	[962]
SFTPB	OTOHS07E	Strong	Biomarker	[963]
SFXN1	OTL66767	Strong	Biomarker	[23]
SGTA	OTKOJ3JB	Strong	Biomarker	[964]
SH2B1	OTJZO2CI	Strong	Altered Expression	[82]
SH3BGRL3	OTKMW34I	Strong	Altered Expression	[76]
SH3BP4	OTVIRKW7	Strong	Biomarker	[965]
SH3PXD2A	OTYRQJIH	Strong	Biomarker	[966]
SH3RF1	OT7MYGYO	Strong	Genetic Variation	[967]
SHISA3	OTE8TPCP	Strong	Altered Expression	[968]
SHMT1	OTIINA3J	Strong	Biomarker	[969]
SIM1	OTYKFPKZ	Strong	Biomarker	[562]
SIPA1L3	OTNYFUM3	Strong	Posttranslational Modification	[970]
SIVA1	OTDT0XZK	Strong	Genetic Variation	[623]
SIX2	OTYOVGSC	Strong	Biomarker	[971]
SIX4	OTG2HFH0	Strong	Biomarker	[971]
SIX6	OTD1RD9D	Strong	Biomarker	[971]
SKI	OT4KJ8F6	Strong	Biomarker	[972]
SKP1	OT5BPAZ4	Strong	Biomarker	[960]
SLC16A4	OT1YXBKC	Strong	Altered Expression	[340]
SLN	OTERIU75	Strong	Biomarker	[973]
SLURP1	OT89YD2E	Strong	Genetic Variation	[974]
SMAD2	OTC6VB4K	Strong	Altered Expression	[268]
SMAD4	OTWQWCKG	Strong	Genetic Variation	[975]
SMAD5	OTQNSVCQ	Strong	Genetic Variation	[976]
SMARCC1	OTUOMBE7	Strong	Biomarker	[23]
SMARCD1	OTHFFT6G	Strong	Altered Expression	[977]
SMUG1	OT2YIOCQ	Strong	Biomarker	[978]
SND1	OTT734JN	Strong	Biomarker	[979]
SNRPG	OTWX4XK1	Strong	Biomarker	[23]
SOCS2	OTBPNKJQ	Strong	Biomarker	[980]
SOX18	OTPUMHWA	Strong	Altered Expression	[981]
SOX21	OTNT50CC	Strong	Biomarker	[982]
SOX30	OTGT38E3	Strong	Biomarker	[983]
SOX6	OTT0W0LE	Strong	Biomarker	[984]
SOX7	OTOZOFAG	Strong	Altered Expression	[985]
SPANXC	OT1033B9	Strong	Altered Expression	[101]
SPATA2	OTOA45GL	Strong	Biomarker	[940]
SPC25	OTCAS0OH	Strong	Altered Expression	[986]
SPOP	OTP0107S	Strong	Biomarker	[987]
SPRR1B	OTXNW3P6	Strong	Altered Expression	[988]
SPRY4	OT2VK9N0	Strong	Biomarker	[775]
SRCIN1	OTQZNQQ5	Strong	Biomarker	[989]
SRM	OT4N5MDP	Strong	Biomarker	[23]
SRSF2	OTVDHO6U	Strong	Altered Expression	[354]
ST18	OTPRIMTA	Strong	Genetic Variation	[292]
STAT2	OTO9G2RZ	Strong	Altered Expression	[355]
STIP1	OT7TXLOX	Strong	Biomarker	[990]
STK19	OTYM6437	Strong	Genetic Variation	[161]
STK24	OTGUHOIL	Strong	Altered Expression	[991]
STPG4	OT5K4UFL	Strong	Biomarker	[217]
STRBP	OTU7XLZL	Strong	Biomarker	[23]
SUCLG2	OT0KHLY2	Strong	Biomarker	[23]
SUMO1	OTJFD4P5	Strong	Altered Expression	[992]
SUN1	OTIU8V4U	Strong	Biomarker	[993]
SUPT7L	OTZJCPN1	Strong	Altered Expression	[994]
SUV39H2	OTU0F4LL	Strong	Biomarker	[995]
SYBU	OT3FQV7N	Strong	Genetic Variation	[939]
SYNGR2	OTJX84RI	Strong	Genetic Variation	[120]
SYT13	OTG94RJ4	Strong	Biomarker	[996]
TAF8	OTWWGCHV	Strong	Biomarker	[958]
TAOK2	OTNUMOZ1	Strong	Biomarker	[361]
TBX5	OT70PISV	Strong	Genetic Variation	[748]
TCF19	OT7NKLF9	Strong	Altered Expression	[997]
TCF21	OT393IMA	Strong	Altered Expression	[998]
TDRD9	OTS4UBI8	Strong	Altered Expression	[999]
TEAD4	OTJS0T2B	Strong	Biomarker	[1000]
TENM1	OTSKSU4V	Strong	Genetic Variation	[1001]
TERF2IP	OT3M5P3G	Strong	Biomarker	[926]
TESC	OTI8C76M	Strong	Genetic Variation	[338]
TFAM	OTXXV5V7	Strong	Altered Expression	[1002]
TFAP2B	OTR1T8E9	Strong	Altered Expression	[1003]
TFAP2C	OTUDIW05	Strong	Biomarker	[1004]
TFDP1	OT6RZ7VT	Strong	Altered Expression	[781]
TFDP2	OTKQFX5H	Strong	Biomarker	[1005]
TFF3	OTJJDRTU	Strong	Biomarker	[1006]
THAP7	OTZDVYC8	Strong	Altered Expression	[1007]
THBS2	OTXET551	Strong	Altered Expression	[1008]
TIGAR	OTR7NMRJ	Strong	Biomarker	[1009]
TIMM10	OT99QR7R	Strong	Biomarker	[23]
TJP1	OTBDCUPK	Strong	Genetic Variation	[976]
TLE1	OT50MRZ1	Strong	Biomarker	[1010]
TM4SF4	OTRI8EHN	Strong	Biomarker	[1011]
TMED10	OTUXSHH7	Strong	Altered Expression	[158]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[1012]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[1013]
TNMD	OTHLVA9G	Strong	Biomarker	[707]
TNXB	OTVBWAV5	Strong	Genetic Variation	[161]
TOMM40	OTZDQ29F	Strong	Biomarker	[23]
TOP3A	OT3CKUI9	Strong	Biomarker	[368]
TOX3	OTC9NR4W	Strong	Biomarker	[496]
TP53I3	OTSCM68G	Strong	Biomarker	[849]
TRAF3IP3	OTNG0L8X	Strong	Genetic Variation	[1014]
TRAF4	OTJLRVMC	Strong	Altered Expression	[1015]
TRAT1	OTMPUNPD	Strong	Biomarker	[1016]
TRIM11	OTMD6IM2	Strong	Biomarker	[1017]
TRIM15	OTNYAKP6	Strong	Altered Expression	[1018]
TRIM25	OT35SG1R	Strong	Altered Expression	[1019]
TRIM31	OT7VW6RP	Strong	Genetic Variation	[161]
TRIM58	OT7OIIRH	Strong	Posttranslational Modification	[1020]
TRIP13	OTFM3TI9	Strong	Biomarker	[1021]
TROAP	OTC8CE0R	Strong	Biomarker	[1022]
TSBP1	OT5GE8IO	Strong	Genetic Variation	[161]
TSPY1	OTPY57X4	Strong	Biomarker	[194]
TTC21A	OTBJ9JKF	Strong	Biomarker	[1023]
TTF1	OT4K90WD	Strong	Altered Expression	[858]
TTN	OT0LZ058	Strong	Biomarker	[1024]
ACAT2	OTZ092ZJ	Definitive	Biomarker	[1025]
ANAPC11	OTK2SJXR	Definitive	Altered Expression	[1026]
ARHGAP35	OTJ8POG0	Definitive	Biomarker	[1027]
ATP5F1D	OTXTAG2V	Definitive	Altered Expression	[472]
BCL7B	OT8DQQRD	Definitive	Biomarker	[1028]
BHLHE40	OTITX14U	Definitive	Biomarker	[1029]
BPTF	OTD1RZAD	Definitive	Biomarker	[1030]
BTG3	OT9ANHVT	Definitive	Altered Expression	[1031]
BTNL2	OTTTEMZA	Definitive	Genetic Variation	[1032]
C18orf54	OT4WJKTF	Definitive	Genetic Variation	[1033]
CALU	OTSYQN71	Definitive	Biomarker	[1034]
CAPN8	OTXTW2I4	Definitive	Biomarker	[1035]
CASP14	OTKY93H9	Definitive	Altered Expression	[1036]
CCAR2	OTLUDG5T	Definitive	Genetic Variation	[1037]
CCNL2	OT0NIKYM	Definitive	Biomarker	[1038]
CEACAM7	OTKFDTZY	Definitive	Biomarker	[55]
CIB1	OT4BVCRU	Definitive	Biomarker	[477]
CIP2A	OTVS2GXA	Definitive	Biomarker	[1039]
CLCA2	OTF191LZ	Definitive	Biomarker	[1040]
CLDN3	OT71MN9S	Definitive	Genetic Variation	[949]
CLDN7	OTNE0XHQ	Definitive	Biomarker	[685]
CPSF4	OT53UK5L	Definitive	Altered Expression	[1041]
CRISP2	OT8HLTV5	Definitive	Altered Expression	[1042]
CRKL	OTOYSD1R	Definitive	Biomarker	[1043]
CRYGD	OTW29JC4	Definitive	Altered Expression	[1044]
CXCL14	OTM189TA	Definitive	Altered Expression	[1045]
DNAJB4	OTUD01BK	Definitive	Genetic Variation	[10]
DUSP6	OT4H6RKW	Definitive	Posttranslational Modification	[1046]
ECT2	OTQDUCT6	Definitive	Altered Expression	[1047]
EIF3A	OTFABY9G	Definitive	Biomarker	[1034]
ENO1	OTB1KWJS	Definitive	Biomarker	[1048]
ENO2	OTRODL0T	Definitive	Altered Expression	[1048]
ERP29	OTNKANMH	Definitive	Biomarker	[1049]
ERRFI1	OT7VZ2IZ	Definitive	Biomarker	[941]
FOXA1	OTEBY0TD	Definitive	Altered Expression	[1050]
FOXO3	OTHXQG4P	Definitive	Altered Expression	[1051]
GALNT3	OT7M67WT	Definitive	Altered Expression	[1052]
GATA1	OTX1R7O1	Definitive	Altered Expression	[416]
GNAS	OTMH8BKJ	Definitive	Genetic Variation	[1053]
GOLM1	OTOZSV6O	Definitive	Biomarker	[1054]
GORASP1	OTQS91S7	Definitive	Biomarker	[1055]
HIC1	OTI9TWY4	Definitive	Genetic Variation	[1037]
HOXA4	OTNVTQDT	Definitive	Altered Expression	[888]
HSPA14	OTZCA5LK	Definitive	Altered Expression	[1056]
ING4	OT0VVG4V	Definitive	Biomarker	[1057]
IQGAP1	OTZRWTGA	Definitive	Biomarker	[1058]
KIF15	OTJRJEXL	Definitive	Biomarker	[1059]
KIF4A	OT3UWL7D	Definitive	Biomarker	[1060]
KLF5	OT1ABI9N	Definitive	Biomarker	[1061]
LAMA1	OTQZMP86	Definitive	Altered Expression	[1062]
LAMA2	OTFROQWE	Definitive	Altered Expression	[1062]
LAMP3	OTN0XL3W	Definitive	Posttranslational Modification	[1063]
LIMD1	OTN1CG6R	Definitive	Genetic Variation	[1064]
LIPH	OTRGYLKL	Definitive	Altered Expression	[1065]
LMNA	OT3SG7ZR	Definitive	Altered Expression	[1066]
LORICRIN	OTFRPVEO	Definitive	Genetic Variation	[1067]
LSAMP	OTYXVQX2	Definitive	Posttranslational Modification	[1063]
LUM	OTSRC874	Definitive	Altered Expression	[1068]
MACC1	OTV3DLX0	Definitive	Biomarker	[1069]
MAP2K3	OTI2OREX	Definitive	Biomarker	[1070]
MEGF8	OT5G38CH	Definitive	Altered Expression	[1071]
MOK	OTQK7M9V	Definitive	Biomarker	[1072]
MX2	OT05NF37	Definitive	Biomarker	[1073]
NEO1	OTGJ1997	Definitive	Altered Expression	[403]
PDC	OT1UUVYY	Definitive	Biomarker	[1074]
PDCD6	OT2YA5M8	Definitive	Biomarker	[1075]
PLAC8	OT3SYRUJ	Definitive	Biomarker	[1076]
PLS1	OTWURB8U	Definitive	Biomarker	[1077]
PPA1	OTHZK1QB	Definitive	Altered Expression	[472]
PRKD2	OTIFSVI8	Definitive	Altered Expression	[903]
PRR13	OTXPP37T	Definitive	Biomarker	[1042]
PRSS55	OTXXWI5Y	Definitive	Altered Expression	[1042]
PSG2	OT2EIXAI	Definitive	Biomarker	[55]
PTOV1	OT94WT5X	Definitive	Biomarker	[1078]
RAD9A	OTJ3AJQU	Definitive	Genetic Variation	[1079]
RBM5	OTCBWHHV	Definitive	Biomarker	[1080]
REG1A	OTMHUH1D	Definitive	Altered Expression	[440]
RIN1	OTPBROUD	Definitive	Altered Expression	[1081]
RPL19	OT33LM66	Definitive	Biomarker	[1082]
S100A14	OTVFJJ91	Definitive	Altered Expression	[1083]
S100A16	OT3ERKQI	Definitive	Altered Expression	[1084]
SEPHS2	OTTFXROR	Definitive	Biomarker	[1085]
SERINC2	OTZ039U0	Definitive	Altered Expression	[1086]
SERPINB4	OT88LHZ8	Definitive	Biomarker	[1087]
SH3GLB1	OTAZ5OP8	Definitive	Altered Expression	[1028]
SLC12A9	OTR7VRAK	Definitive	Altered Expression	[1088]
SNAI1	OTDPYAMC	Definitive	Altered Expression	[1089]
SOX9	OTVDJFGN	Definitive	Altered Expression	[1090]
SPAG4	OTVXS2SM	Definitive	Altered Expression	[1091]
SPZ1	OTQH8HJ5	Definitive	Altered Expression	[1042]
SUB1	OTK71JYU	Definitive	Altered Expression	[525]
SULF1	OTJCNCO0	Definitive	Altered Expression	[1092]
SUPT20H	OTTMC0LH	Definitive	Biomarker	[449]
SYT1	OTVTPOI6	Definitive	Biomarker	[1055]
TBX2	OTTOT7A9	Definitive	Altered Expression	[1093]
TLE5	OTEH0BFG	Definitive	Altered Expression	[1094]
TMPRSS4	OTCCGY2K	Definitive	Altered Expression	[1095]
TRAF2	OT1MEZZN	Definitive	Altered Expression	[1096]
TRIT1	OTCU9FS5	Definitive	Genetic Variation	[1097]
TSHZ1	OTYQ9ECW	Definitive	Genetic Variation	[1098]

References

• [1] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85.
• [2] Carboplatin FDA Label
• [3] Paclitaxel FDA Label
• [4] Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
• [5] Coordination-driven self-assembly of ruthenium(ii) architectures: synthesis, characterization and cytotoxicity studies.Dalton Trans. 2018 Jun 25;47(25):8466-8475. doi: 10.1039/c8dt00962g.
• [6] Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression.J Pathol. 2008 Sep;216(1):75-82. doi: 10.1002/path.2383.
• [7] Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.J Thorac Oncol. 2019 Nov;14(11):1924-1934. doi: 10.1016/j.jtho.2019.07.003. Epub 2019 Jul 16.
• [8] YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.Oncotarget. 2016 Dec 13;7(50):82139-82157. doi: 10.18632/oncotarget.10080.
• [9] Cross-disease analysis identified novel common genes for both lung adenocarcinoma and lung squamous cell carcinoma.Oncol Lett. 2019 Oct;18(4):3463-3470. doi: 10.3892/ol.2019.10678. Epub 2019 Jul 29.
• [10] Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12.
• [11] Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-B signaling pathway.Onco Targets Ther. 2017 Sep 11;10:4443-4454. doi: 10.2147/OTT.S142244. eCollection 2017.
• [12] Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.PLoS One. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.
• [13] Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.Mol Cancer Res. 2013 Aug;11(8):952-63. doi: 10.1158/1541-7786.MCR-13-0003-T. Epub 2013 May 22.
• [14] GABRA3 promotes lymphatic metastasis in lung adenocarcinoma by mediating upregulation of matrix metalloproteinases.Oncotarget. 2016 May 31;7(22):32341-50. doi: 10.18632/oncotarget.8700.
• [15] Guanylate binding protein 1 (GBP-1) promotes cell motility and invasiveness of lung adenocarcinoma.Biochem Biophys Res Commun. 2019 Oct 15;518(2):266-272. doi: 10.1016/j.bbrc.2019.08.045. Epub 2019 Aug 14.
• [16] The role of GDF15 in bone metastasis of lung adenocarcinoma cells.Oncol Rep. 2019 Apr;41(4):2379-2388. doi: 10.3892/or.2019.7024. Epub 2019 Feb 21.
• [17] BMP9 inhibits the growth and migration of lung adenocarcinoma A549 cells in a bone marrow stromal cellderived microenvironment through the MAPK/ERK and NF-B pathways.Oncol Rep. 2016 Jul;36(1):410-8. doi: 10.3892/or.2016.4796. Epub 2016 May 9.
• [18] Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.J Clin Endocrinol Metab. 2012 Feb;97(2):482-8. doi: 10.1210/jc.2011-2454. Epub 2011 Nov 23.
• [19] TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers.PLoS One. 2016 Jun 13;11(6):e0157453. doi: 10.1371/journal.pone.0157453. eCollection 2016.
• [20] Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.J Natl Cancer Inst. 2016 Jun 22;108(11):djw144. doi: 10.1093/jnci/djw144. Print 2016 Nov.
• [21] LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma.Biosci Rep. 2019 Jan 15;39(1):BSR20181476. doi: 10.1042/BSR20181476. Print 2019 Jan 31.
• [22] Mutational analysis of the kinase domain of MYLK2 gene in common human cancers.Pathol Res Pract. 2006;202(3):137-40. doi: 10.1016/j.prp.2005.12.003. Epub 2006 Jan 31.
• [23] c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.Oncotarget. 2016 Oct 4;7(40):65514-65539. doi: 10.18632/oncotarget.11804.
• [24] Radiosensitizing Effect of P2X7 Receptor Antagonist on Melanoma in Vitro and in Vivo.Biol Pharm Bull. 2017 Jun 1;40(6):878-887. doi: 10.1248/bpb.b17-00083. Epub 2017 Mar 24.
• [25] PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.Exp Ther Med. 2017 May;13(5):1993-1999. doi: 10.3892/etm.2017.4218. Epub 2017 Mar 10.
• [26] Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells.Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1170-8. doi: 10.1016/j.bbamcr.2016.02.015. Epub 2016 Feb 24.
• [27] SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.Am J Surg Pathol. 2019 Mar;43(3):293-302. doi: 10.1097/PAS.0000000000001216.
• [28] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [29] Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9.
• [30] Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development.Cancer Sci. 2005 Oct;96(10):668-75. doi: 10.1111/j.1349-7006.2005.00100.x.
• [31] HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3.Cell Signal. 2017 Nov;39:9-17. doi: 10.1016/j.cellsig.2017.07.014. Epub 2017 Jul 21.
• [32] Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.Clin Cancer Res. 2017 Nov 15;23(22):6993-7005. doi: 10.1158/1078-0432.CCR-17-1098. Epub 2017 Aug 18.
• [33] Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.Lung Cancer. 2019 Mar;129:92-94. doi: 10.1016/j.lungcan.2018.12.011. Epub 2018 Dec 19.
• [34] Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.Br J Cancer. 2018 Aug;119(5):580-590. doi: 10.1038/s41416-018-0200-0. Epub 2018 Aug 6.
• [35] CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.Life Sci. 2009 May 22;84(21-22):779-84. doi: 10.1016/j.lfs.2009.03.008. Epub 2009 Mar 28.
• [36] NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.Mol Cancer Ther. 2015 Oct;14(10):2382-2389. doi: 10.1158/1535-7163.MCT-15-0077. Epub 2015 Jul 23.
• [37] Eight potential biomarkers for distinguishing between lung adenocarcinoma and squamous cell carcinoma.Oncotarget. 2017 May 3;8(42):71759-71771. doi: 10.18632/oncotarget.17606. eCollection 2017 Sep 22.
• [38] Somatic mutations of the protein kinase gene family in human lung cancer.Cancer Res. 2005 Sep 1;65(17):7591-5. doi: 10.1158/0008-5472.CAN-05-1855.
• [39] miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.Mol Cancer Res. 2011 Jan;9(1):25-35. doi: 10.1158/1541-7786.MCR-10-0497. Epub 2010 Nov 29.
• [40] Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids.Cell Metab. 2020 Feb 4;31(2):339-350.e4. doi: 10.1016/j.cmet.2019.11.012. Epub 2019 Dec 5.
• [41] A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma.PeerJ. 2019 Jun 17;7:e7125. doi: 10.7717/peerj.7125. eCollection 2019.
• [42] Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.
• [43] DNA-dependent protein kinase catalytic subunit inhibitor reverses acquired radioresistance in lung adenocarcinoma by suppressing DNA repair.Mol Med Rep. 2015 Jul;12(1):1328-34. doi: 10.3892/mmr.2015.3505. Epub 2015 Mar 18.
• [44] Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma.Int J Mol Med. 2011 Dec;28(6):953-60. doi: 10.3892/ijmm.2011.779. Epub 2011 Aug 19.
• [45] NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer. 2006 Oct 1;119(7):1547-52. doi: 10.1002/ijc.21987.
• [46] Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38 siRNA in Lung Adenocarcinoma Cancer Cells.Anticancer Agents Med Chem. 2019;19(5):638-644. doi: 10.2174/1871520619666190301125203.
• [47] Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.BMC Cancer. 2015 Feb 25;15:84. doi: 10.1186/s12885-015-1086-3.
• [48] Branched -(1,4) glucans from Lentinula edodes (L10) in combination with radiation enhance cytotoxic effect on human lung adenocarcinoma through the Toll-like receptor 4 mediated induction of THP-1 differentiation/activation.J Agric Food Chem. 2011 Nov 23;59(22):11997-2005. doi: 10.1021/jf202457r. Epub 2011 Nov 1.
• [49] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.Mol Cancer. 2019 Feb 11;18(1):24. doi: 10.1186/s12943-019-0953-y.
• [50] MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1.Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7978-7988. doi: 10.26355/eurrev_201909_19014.
• [51] Acute encephalopathy secondary to dabrafenib and trametinib in BRAF-positive metastatic adenocarcinoma of the lung.J Oncol Pharm Pract. 2019 Sep;25(6):1497-1499. doi: 10.1177/1078155218790331. Epub 2018 Jul 31.
• [52] Nicotine inhibits CD24 expression in Lewis lung carcinoma cells by upregulation of RAS expression.Int J Oncol. 2018 Aug;53(2):815-822. doi: 10.3892/ijo.2018.4415. Epub 2018 May 22.
• [53] PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.Cancer Commun (Lond). 2019 Jun 3;39(1):30. doi: 10.1186/s40880-019-0376-6.
• [54] A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.Cancer Lett. 2018 Jul 1;425:43-53. doi: 10.1016/j.canlet.2018.03.043. Epub 2018 Mar 31.
• [55] Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis.Oncol Lett. 2019 May;17(5):4550-4556. doi: 10.3892/ol.2019.10115. Epub 2019 Mar 5.
• [56] CCAAT/enhancer binding protein is dispensable for development of lung adenocarcinoma.PLoS One. 2015 Mar 13;10(3):e0120647. doi: 10.1371/journal.pone.0120647. eCollection 2015.
• [57] Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro.Virol J. 2017 Oct 3;14(1):190. doi: 10.1186/s12985-017-0852-z.
• [58] Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.J Cell Physiol. 2019 May;234(5):6611-6623. doi: 10.1002/jcp.27402. Epub 2018 Sep 19.
• [59] Gene Expression Classification of Lung Adenocarcinoma into Molecular Subtypes.IEEE/ACM Trans Comput Biol Bioinform. 2020 Jul-Aug;17(4):1187-1197. doi: 10.1109/TCBB.2019.2905553. Epub 2019 Mar 18.
• [60] Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.Mol Cancer Res. 2019 Jun;17(6):1351-1364. doi: 10.1158/1541-7786.MCR-18-1068. Epub 2019 Feb 26.
• [61] Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.Oncol Lett. 2018 Dec;16(6):6998-7007. doi: 10.3892/ol.2018.9534. Epub 2018 Oct 1.
• [62] Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.Mol Cell Proteomics. 2012 Oct;11(10):901-15. doi: 10.1074/mcp.M112.020875. Epub 2012 Jul 3.
• [63] CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women.Lung Cancer. 2008 Apr;60(1):40-46. doi: 10.1016/j.lungcan.2007.09.009. Epub 2007 Nov 5.
• [64] Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.
• [65] Dickkopf-related protein 3 promotes cell adhesion and invasion during progression of lung adenocarcinoma.Pathol Int. 2019 Nov;69(11):646-654. doi: 10.1111/pin.12863.
• [66] Deregulation of small non-coding RNAs at the DLK1-DIO3 imprinted locus predicts lung cancer patient outcome.Oncotarget. 2016 Dec 6;7(49):80957-80966. doi: 10.18632/oncotarget.13133.
• [67] Inhibitory effect of PPAR on NR0B1 in tumorigenesis of lung adenocarcinoma.Int J Oncol. 2012 Oct;41(4):1278-84. doi: 10.3892/ijo.2012.1571. Epub 2012 Jul 25.
• [68] Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):220-8. doi: 10.1093/abbs/gmv139. Epub 2016 Feb 1.
• [69] Overexpression of junctional adhesion molecule-A and EphB2 predicts poor survival in lung adenocarcinoma patients.Tumour Biol. 2017 Feb;39(2):1010428317691000. doi: 10.1177/1010428317691000.
• [70] VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.Oncol Rep. 2017 Nov;38(5):2761-2773. doi: 10.3892/or.2017.5969. Epub 2017 Sep 19.
• [71] Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies.Oncotarget. 2017 Dec 15;9(4):4485-4495. doi: 10.18632/oncotarget.23321. eCollection 2018 Jan 12.
• [72] FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.J Cancer Res Clin Oncol. 2019 Jan;145(1):65-76. doi: 10.1007/s00432-018-2761-y. Epub 2018 Oct 24.
• [73] AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.Oncol Rep. 2017 Jun;37(6):3261-3269. doi: 10.3892/or.2017.5594. Epub 2017 Apr 21.
• [74] Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance.Genet Mol Res. 2015 Aug 28;14(3):10185-92. doi: 10.4238/2015.August.28.2.
• [75] EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.
• [76] Identification of urine biomarkers associated with lung adenocarcinoma.Oncotarget. 2017 Jun 13;8(24):38517-38529. doi: 10.18632/oncotarget.15870.
• [77] Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436.
• [78] IB Kinase Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma.Cancer Res. 2018 Jun 1;78(11):2939-2951. doi: 10.1158/0008-5472.CAN-17-1944. Epub 2018 Mar 27.
• [79] IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma.Immunobiology. 2016 Feb;221(2):291-9. doi: 10.1016/j.imbio.2015.10.006. Epub 2015 Oct 29.
• [80] IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.Lung. 2016 Feb;194(1):137-46. doi: 10.1007/s00408-015-9829-0. Epub 2015 Nov 25.
• [81] RNAi screen identifies essential regulators of human brain metastasis-initiating cells.Acta Neuropathol. 2017 Dec;134(6):923-940. doi: 10.1007/s00401-017-1757-z. Epub 2017 Aug 1.
• [82] SH2B1 promotes epithelial-mesenchymal transition through the IRS1/-catenin signaling axis in lung adenocarcinoma.Mol Carcinog. 2018 May;57(5):640-652. doi: 10.1002/mc.22788. Epub 2018 Feb 20.
• [83] MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.Sci Rep. 2015 Jun 19;5:11471. doi: 10.1038/srep11471.
• [84] MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.Mol Oncol. 2017 Jun;11(6):628-639. doi: 10.1002/1878-0261.12055. Epub 2017 May 2.
• [85] ETS-1-mediated transcriptional up-regulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis.J Biol Chem. 2013 Nov 8;288(45):32126-32137. doi: 10.1074/jbc.M113.495218. Epub 2013 Sep 24.
• [86] Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.Cancer Res. 2014 Jun 1;74(11):3157-67. doi: 10.1158/0008-5472.CAN-13-1727.
• [87] Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation.PLoS One. 2011;6(10):e26439. doi: 10.1371/journal.pone.0026439. Epub 2011 Oct 17.
• [88] Identification of MMP-15 as an anti-apoptotic factor in cancer cells.J Biol Chem. 2005 Oct 7;280(40):34123-32. doi: 10.1074/jbc.M508155200. Epub 2005 Aug 9.
• [89] High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Oncotarget. 2015 May 10;6(13):11694-703. doi: 10.18632/oncotarget.3429.
• [90] ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.Oncotarget. 2019 Mar 8;10(20):1874-1886. doi: 10.18632/oncotarget.26740. eCollection 2019 Mar 8.
• [91] Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4.Cancer Commun (Lond). 2018 Aug 13;38(1):53. doi: 10.1186/s40880-018-0320-1.
• [92] The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses.Viruses. 2014 Jun 2;6(6):2268-86. doi: 10.3390/v6062268.
• [93] The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.Mol Cancer. 2018 Feb 19;17(1):24. doi: 10.1186/s12943-018-0784-2.
• [94] Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation.Cell Biochem Biophys. 2010 Apr;56(2-3):59-71. doi: 10.1007/s12013-009-9071-6.
• [95] Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma.J Cell Physiol. 2019 May;234(5):7579-7586. doi: 10.1002/jcp.27520. Epub 2018 Oct 28.
• [96] MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.Exp Ther Med. 2018 Jun;15(6):4822-4828. doi: 10.3892/etm.2018.6020. Epub 2018 Apr 2.
• [97] Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.Virchows Arch. 2006 Jun;448(6):830-7. doi: 10.1007/s00428-006-0199-0. Epub 2006 Apr 12.
• [98] Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.Mol Cell Biochem. 2019 Jun;456(1-2):145-156. doi: 10.1007/s11010-019-03500-3. Epub 2019 Jan 25.
• [99] Clinical significance of atypical protein kinase C (PKC and PKC) and its relationship with yes-associated protein in lung adenocarcinoma.BMC Cancer. 2019 Aug 14;19(1):804. doi: 10.1186/s12885-019-5992-7.
• [100] Rac3 Regulates Cell Invasion, Migration and EMT in Lung Adenocarcinoma through p38 MAPK Pathway.J Cancer. 2017 Aug 2;8(13):2511-2522. doi: 10.7150/jca.18161. eCollection 2017.
• [101] Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma.J Cell Mol Med. 2019 Nov;23(11):7261-7267. doi: 10.1111/jcmm.14532. Epub 2019 Sep 4.
• [102] Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.J Clin Pathol. 2020 Feb;73(2):96-101. doi: 10.1136/jclinpath-2019-206152. Epub 2019 Sep 27.
• [103] Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.J Transl Med. 2019 Sep 27;17(1):324. doi: 10.1186/s12967-019-2068-z.
• [104] K-ras activation generates an inflammatory response in lung tumors.Oncogene. 2006 Mar 30;25(14):2105-12. doi: 10.1038/sj.onc.1209237.
• [105] Effect of CT window settings on size measurements of the solid component in subsolid nodules: evaluation of prediction efficacy of the degree of pathological malignancy in lung adenocarcinoma.Br J Radiol. 2018 Jul;91(1088):20180251. doi: 10.1259/bjr.20180251. Epub 2018 Jun 6.
• [106] P-selectin-mediated platelet activation promotes adhesion of non-small cell lung carcinoma cells on vascular endothelial cells under flow.Mol Med Rep. 2012 Apr;5(4):935-42. doi: 10.3892/mmr.2012.760. Epub 2012 Jan 19.
• [107] Novel molecular targets for the treatment of lung cancer.Curr Opin Oncol. 2020 Jan;32(1):37-43. doi: 10.1097/CCO.0000000000000590.
• [108] Expression levels and cotargets of miRNA?26?p and miRNA?26?p in lung adenocarcinoma tissues: n exploration with RTqPCR, microarray and bioinformatic analyses.Oncol Rep. 2019 Feb;41(2):939-953. doi: 10.3892/or.2018.6901. Epub 2018 Dec 4.
• [109] ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.PLoS One. 2014 Apr 4;9(4):e94065. doi: 10.1371/journal.pone.0094065. eCollection 2014.
• [110] A transcriptional miRNA-gene network associated with lung adenocarcinoma metastasis based on the TCGA database.Oncol Rep. 2016 Apr;35(4):2257-69. doi: 10.3892/or.2016.4560. Epub 2016 Jan 14.
• [111] Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling.Oncotarget. 2018 Sep 28;9(76):34306-34319. doi: 10.18632/oncotarget.26142. eCollection 2018 Sep 28.
• [112] Transgelin overexpression in lung adenocarcinoma is associated with tumor progression.Int J Mol Med. 2014 Aug;34(2):585-91. doi: 10.3892/ijmm.2014.1805. Epub 2014 Jun 16.
• [113] TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT.Int J Biol Sci. 2019 Jun 2;15(7):1419-1428. doi: 10.7150/ijbs.34076. eCollection 2019.
• [114] siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells.Oncol Rep. 2016 Apr;35(4):1933-40. doi: 10.3892/or.2016.4602. Epub 2016 Feb 1.
• [115] A new gold(I) complex-Au(PPh(3))PT is a deubiquitinase inhibitor and inhibits tumor growth.EBioMedicine. 2019 Jan;39:159-172. doi: 10.1016/j.ebiom.2018.11.047. Epub 2018 Dec 5.
• [116] Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells.Med Oncol. 2019 Sep 27;36(11):91. doi: 10.1007/s12032-019-1312-y.
• [117] Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide.Environ Toxicol Pharmacol. 2018 Jan;57:141-150. doi: 10.1016/j.etap.2017.12.011. Epub 2017 Dec 17.
• [118] HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients.Theranostics. 2019 Apr 6;9(7):2084-2099. doi: 10.7150/thno.29463. eCollection 2019.
• [119] A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis.Cell Rep. 2019 Dec 10;29(11):3421-3434.e8. doi: 10.1016/j.celrep.2019.11.018.
• [120] Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.Hum Mol Genet. 2016 Feb 1;25(3):620-9. doi: 10.1093/hmg/ddv494. Epub 2016 Jan 4.
• [121] ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.EMBO Mol Med. 2019 Apr;11(4):e9976. doi: 10.15252/emmm.201809976.
• [122] Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth.Cancer Biol Ther. 2013 Sep;14(9):860-8. doi: 10.4161/cbt.25643. Epub 2013 Jul 17.
• [123] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.Oncogene. 2018 Jul;37(28):3894-3908. doi: 10.1038/s41388-018-0240-1. Epub 2018 Apr 17.
• [124] Adaptive changes in global gene expression profile of lung carcinoma A549 cells acutely exposed to distinct types of AhR ligands. Toxicol Lett. 2018 Aug;292:162-174.
• [125] Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells.Pharmacology. 2020;105(3-4):209-224. doi: 10.1159/000503688. Epub 2019 Oct 18.
• [126] MicroRNA-520c-3p functions as a novel tumor suppressor in lung adenocarcinoma.FEBS J. 2019 Jul;286(14):2737-2752. doi: 10.1111/febs.14835. Epub 2019 Apr 11.
• [127] Comparative proteome analysis of human adenocarcinoma.Med Oncol. 2010 Jun;27(2):346-56. doi: 10.1007/s12032-009-9216-x. Epub 2009 Apr 21.
• [128] ALKBH5-m(6)A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia.Biochem Biophys Res Commun. 2020 Jan 8;521(2):499-506. doi: 10.1016/j.bbrc.2019.10.145. Epub 2019 Oct 31.
• [129] miR-146a suppresses 5-lipoxygenase activating protein (FLAP) expression and Leukotriene B4 production in lung cancer cells.Oncotarget. 2018 Jun 1;9(42):26751-26769. doi: 10.18632/oncotarget.25482. eCollection 2018 Jun 1.
• [130] Reduced angiomotin p130 expression correlates with poor prognosis in lung adenocarcinoma.J Clin Pathol. 2017 Jul;70(7):625-630. doi: 10.1136/jclinpath-2016-204071. Epub 2016 Dec 15.
• [131] HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.Lung Cancer. 2014 Sep;85(3):373-8. doi: 10.1016/j.lungcan.2014.06.007. Epub 2014 Jul 7.
• [132] MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer.Oncol Lett. 2018 Apr;15(4):5893-5902. doi: 10.3892/ol.2018.8048. Epub 2018 Feb 14.
• [133] microRNA-1205 promotes cell growth by targeting APC2 in lung adenocarcinoma.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1125-1133. doi: 10.26355/eurrev_201902_17003.
• [134] Transcriptome-wide association study reveals candidate causal genes for lung cancer.Int J Cancer. 2020 Apr 1;146(7):1862-1878. doi: 10.1002/ijc.32771. Epub 2019 Dec 9.
• [135] Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cells.Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):486-503. doi: 10.1016/j.bbamcr.2018.10.011. Epub 2018 Oct 13.
• [136] ASAP3 is a downstream target of HIF-1 and is critical for progression of lung adenocarcinoma.Onco Targets Ther. 2019 Jul 17;12:5793-5803. doi: 10.2147/OTT.S199603. eCollection 2019.
• [137] Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells.Mol Cancer Res. 2019 Dec;17(12):2343-2355. doi: 10.1158/1541-7786.MCR-19-0245. Epub 2019 Sep 24.
• [138] Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
• [139] Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.
• [140] Large-scale gene expression analysis reveals robust gene signatures for prognosis prediction in lung adenocarcinoma.PeerJ. 2019 Jun 3;7:e6980. doi: 10.7717/peerj.6980. eCollection 2019.
• [141] AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol. 2008 Nov;3(11):1236-44. doi: 10.1097/JTO.0b013e318189f5ec.
• [142] BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma.Nat Commun. 2018 Aug 20;9(1):3327. doi: 10.1038/s41467-018-05790-5.
• [143] Gene coexpression analysis offers important modules and pathway of human lung adenocarcinomas.J Cell Physiol. 2020 Jan;235(1):454-464. doi: 10.1002/jcp.28985. Epub 2019 Jul 1.
• [144] BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1.Theranostics. 2018 Nov 12;8(21):5890-5902. doi: 10.7150/thno.27667. eCollection 2018.
• [145] Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility.J Biomed Sci. 2016 Feb 3;23:23. doi: 10.1186/s12929-016-0240-9.
• [146] BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma.PLoS One. 2016 Aug 31;11(8):e0156701. doi: 10.1371/journal.pone.0156701. eCollection 2016.
• [147] Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.Anticancer Res. 2019 Aug;39(8):4117-4128. doi: 10.21873/anticanres.13570.
• [148] Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China.Thorac Cancer. 2017 Mar;8(2):88-96. doi: 10.1111/1759-7714.12411. Epub 2017 Jan 13.
• [149] Regulatory interactions between long noncoding RNA LINC00968 and miR-9-3p in non-small cell lung cancer: A bioinformatic analysis based on miRNA microarray, GEO and TCGA.Oncol Lett. 2018 Jun;15(6):9487-9497. doi: 10.3892/ol.2018.8476. Epub 2018 Apr 12.
• [150] Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cells.Sci Rep. 2016 Jun 2;6:27152. doi: 10.1038/srep27152.
• [151] CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.Sci Rep. 2017 Apr 21;7:46662. doi: 10.1038/srep46662.
• [152] The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.
• [153] Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69.Cancer Med. 2018 Mar;7(3):788-795. doi: 10.1002/cam4.1288. Epub 2018 Feb 17.
• [154] Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.Cancer Genet. 2019 Apr;233-234:67-74. doi: 10.1016/j.cancergen.2019.04.001. Epub 2019 Apr 9.
• [155] miR?88 regulates cancer progression by targeting multiple targets in lung adenocarcinoma.Oncol Rep. 2019 Jun;41(6):3367-3376. doi: 10.3892/or.2019.7118. Epub 2019 Apr 16.
• [156] Long non-coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation-dependent repression of CDH1 promoter.J Cell Mol Med. 2019 Sep;23(9):6411-6428. doi: 10.1111/jcmm.14533. Epub 2019 Jul 17.
• [157] Tumor endothelial cell-derived cadherin-2 promotes angiogenesis and has prognostic significance for lung adenocarcinoma.Mol Cancer. 2019 Mar 4;18(1):34. doi: 10.1186/s12943-019-0987-1.
• [158] Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer.Nutr Cancer. 2017 Jan;69(1):92-104. doi: 10.1080/01635581.2017.1247886. Epub 2016 Nov 23.
• [159] Therapeutic Effect of pHLIP-mediated CEACAM6 Gene Silencing in Lung Adenocarcinoma.Sci Rep. 2019 Sep 2;9(1):11607. doi: 10.1038/s41598-019-48104-5.
• [160] [Corrigendum] CENPE promotes lung adenocarcinoma proliferation and is directly regulated by FOXM1.Int J Oncol. 2019 Dec;55(6):1397. doi: 10.3892/ijo.2019.4872. Epub 2019 Sep 6.
• [161] A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.Am J Hum Genet. 2009 Nov;85(5):679-91. doi: 10.1016/j.ajhg.2009.09.012. Epub 2009 Oct 15.
• [162] Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577. doi: 10.1073/pnas.1719577115. Epub 2018 Jan 29.
• [163] A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.Breast Cancer Res Treat. 2019 Apr;174(3):605-613. doi: 10.1007/s10549-018-05079-7. Epub 2019 Jan 3.
• [164] CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway.Pathol Res Pract. 2019 May;215(5):988-994. doi: 10.1016/j.prp.2019.02.005. Epub 2019 Feb 16.
• [165] Mining and validating the expression pattern and prognostic value of acetylcholine receptors in non-small cell lung cancer.Medicine (Baltimore). 2019 May;98(20):e15555. doi: 10.1097/MD.0000000000015555.
• [166] Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.Nat Med. 2019 Nov;25(11):1783-1795. doi: 10.1038/s41591-019-0612-2. Epub 2019 Nov 7.
• [167] Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.Histopathology. 2019 Mar;74(4):545-554. doi: 10.1111/his.13775. Epub 2019 Jan 15.
• [168] A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma.PLoS One. 2015 Nov 5;10(11):e0142162. doi: 10.1371/journal.pone.0142162. eCollection 2015.
• [169] COP9 signalosome subunit CSN5, but not CSN6, is upregulated in lung adenocarcinoma and predicts poor prognosis.J Thorac Dis. 2018 Mar;10(3):1596-1606. doi: 10.21037/jtd.2018.02.09.
• [170] Carboxypeptidase M in apoptosis, adipogenesis and cancer.Clin Chim Acta. 2013 Jan 16;415:306-16. doi: 10.1016/j.cca.2012.11.012. Epub 2012 Nov 21.
• [171] GATA3 acetylation at K119 by CBP inhibits cell migration and invasion in lung adenocarcinoma.Biochem Biophys Res Commun. 2018 Mar 4;497(2):633-638. doi: 10.1016/j.bbrc.2018.02.120. Epub 2018 Feb 14.
• [172] TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.Lung Cancer (Auckl). 2019 Aug 15;10:81-86. doi: 10.2147/LCTT.S212406. eCollection 2019.
• [173] Stage-associated differences in the serum N- and O-glycan profiles of patients with non-small cell lung cancer.Clin Proteomics. 2019 May 10;16:20. doi: 10.1186/s12014-019-9240-6. eCollection 2019.
• [174] Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. J Cell Physiol. 2019 Apr;234(4):4454-4459.
• [175] Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma.Clin Exp Metastasis. 2020 Feb;37(1):115-124. doi: 10.1007/s10585-019-09988-9. Epub 2019 Aug 28.
• [176] Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma.J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26.
• [177] The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.Tumour Biol. 2017 Apr;39(4):1010428317698340. doi: 10.1177/1010428317698340.
• [178] Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma.Cell Cycle. 2019 Mar;18(5):568-579. doi: 10.1080/15384101.2019.1578146. Epub 2019 Feb 17.
• [179] Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma.Mol Cancer Res. 2016 May;14(5):448-57. doi: 10.1158/1541-7786.MCR-15-0480. Epub 2016 Feb 19.
• [180] STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/-catenin signaling pathway.Biochem Biophys Res Commun. 2019 Jun 18;514(1):118-126. doi: 10.1016/j.bbrc.2019.04.107. Epub 2019 Apr 23.
• [181] Notch Signaling Components: Diverging Prognostic Indicators in Lung Adenocarcinoma.Medicine (Baltimore). 2016 May;95(20):e3715. doi: 10.1097/MD.0000000000003715.
• [182] Integrative analysis of multi-omics data reveals distinct impacts of DDB1-CUL4 associated factors in human lung adenocarcinomas.Sci Rep. 2017 Mar 23;7(1):333. doi: 10.1038/s41598-017-00512-1.
• [183] MicroRNA-148a inhibits cell proliferation and cell cycle progression in lung adenocarcinoma via directly targeting transcription factor E2F3.Exp Ther Med. 2018 Dec;16(6):5400-5409. doi: 10.3892/etm.2018.6845. Epub 2018 Oct 11.
• [184] Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922.
• [185] Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress.J Biol Chem. 2019 May 3;294(18):7169-7176. doi: 10.1074/jbc.AC119.008036. Epub 2019 Mar 19.
• [186] MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.J Pathol. 2019 Sep;249(1):52-64. doi: 10.1002/path.5280. Epub 2019 May 21.
• [187] Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: a retrospective study.BMJ Open. 2018 Jun 22;8(6):e021385. doi: 10.1136/bmjopen-2017-021385.
• [188] Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8731-8739. doi: 10.26355/eurrev_201812_16638.
• [189] EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.Epigenetics. 2019 Feb;14(2):118-129. doi: 10.1080/15592294.2019.1573066. Epub 2019 Jan 31.
• [190] Proteomic analysis of eIF-5A in lung adenocarcinomas.Proteomics. 2003 Apr;3(4):496-504. doi: 10.1002/pmic.200390063.
• [191] Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.Mol Cancer Ther. 2012 Sep;11(9):2021-32. doi: 10.1158/1535-7163.MCT-12-0030. Epub 2012 Jul 17.
• [192] The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.Dis Model Mech. 2015 Apr;8(4):393-401. doi: 10.1242/dmm.019257. Epub 2015 Feb 20.
• [193] Genome-wide association study of familial lung cancer.Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.
• [194] Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.Cancer Sci. 2019 May;110(5):1573-1586. doi: 10.1111/cas.13984. Epub 2019 Mar 25.
• [195] The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.Clin Cancer Res. 2010 Apr 15;16(8):2275-83. doi: 10.1158/1078-0432.CCR-09-2000. Epub 2010 Apr 6.
• [196] Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma.J Cancer. 2019 Jan 29;10(4):1032-1038. doi: 10.7150/jca.24314. eCollection 2019.
• [197] Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.BMC Cancer. 2019 Jul 29;19(1):741. doi: 10.1186/s12885-019-5943-3.
• [198] ERR is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes.Cancer Manag Res. 2019 Sep 2;11:8111-8123. doi: 10.2147/CMAR.S204732. eCollection 2019.
• [199] ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.Clin Cancer Res. 2013 Jul 1;19(13):3383-95. doi: 10.1158/1078-0432.CCR-13-0341. Epub 2013 May 9.
• [200] A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.
• [201] Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.BMC Pulm Med. 2018 Jan 23;18(1):13. doi: 10.1186/s12890-018-0585-9.
• [202] Down-regulation of protease-activated receptor 4 in lung adenocarcinoma is associated with a more aggressive phenotype.Asian Pac J Cancer Prev. 2013;14(6):3793-8. doi: 10.7314/apjcp.2013.14.6.3793.
• [203] Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor.Oncol Lett. 2018 Feb;15(2):1549-1558. doi: 10.3892/ol.2017.7517. Epub 2017 Dec 5.
• [204] Fbxw7 and Skp2 Regulate Stem Cell Switch between Quiescence and Mitotic Division in Lung Adenocarcinoma.Biomed Res Int. 2019 Aug 25;2019:9648269. doi: 10.1155/2019/9648269. eCollection 2019.
• [205] FGF4 induces epithelial-mesenchymal transition by inducing store-operated calcium entry in lung adenocarcinoma.Oncotarget. 2016 Nov 8;7(45):74015-74030. doi: 10.18632/oncotarget.12187.
• [206] miR-24-3p/FGFR3 Signaling as a Novel Axis Is Involved in Epithelial-Mesenchymal Transition and Regulates Lung Adenocarcinoma Progression.J Immunol Res. 2018 Apr 5;2018:2834109. doi: 10.1155/2018/2834109. eCollection 2018.
• [207] Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter.J Cell Biol. 2018 Apr 2;217(4):1335-1351. doi: 10.1083/jcb.201708064. Epub 2018 Feb 6.
• [208] FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.Am J Respir Cell Mol Biol. 2018 May;58(5):625-635. doi: 10.1165/rcmb.2017-0164OC.
• [209] Knockdown of FOXP1 promotes the development of lung adenocarcinoma.Cancer Biol Ther. 2019;20(4):537-545. doi: 10.1080/15384047.2018.1537999. Epub 2018 Nov 8.
• [210] Low BIK outside-inside-out interactive inflammation immune-induced transcription-dependent apoptosis through FUT3-PMM2-SQSTM1-SFN-ZNF384.Immunol Res. 2016 Apr;64(2):461-9. doi: 10.1007/s12026-015-8701-x.
• [211] Bioinformatics analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes.Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1582-7.
• [212] Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells.Cancer Chemother Pharmacol. 2007 Aug;60(3):449-57. doi: 10.1007/s00280-006-0406-3. Epub 2007 Feb 16.
• [213] Reduced expression of the Connexin26 gene and its aberrant DNA methylation in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine.Mol Carcinog. 2006 Sep;45(9):710-4. doi: 10.1002/mc.20207.
• [214] Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data.Tumour Biol. 2015 Aug;36(8):6391-9. doi: 10.1007/s13277-015-3327-0. Epub 2015 Apr 11.
• [215] GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.PLoS One. 2017 Aug 3;12(8):e0182410. doi: 10.1371/journal.pone.0182410. eCollection 2017.
• [216] GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.J Cancer Res Clin Oncol. 2019 Apr;145(4):861-872. doi: 10.1007/s00432-019-02845-y. Epub 2019 Jan 19.
• [217] Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose.BMC Cancer. 2018 May 11;18(1):559. doi: 10.1186/s12885-018-4443-1.
• [218] Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of -glucuronidase in tumors.Cancer Gene Ther. 2011 Jun;18(6):381-9. doi: 10.1038/cgt.2011.3. Epub 2011 Feb 25.
• [219] Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.Cancer Med. 2019 Oct;8(14):6383-6392. doi: 10.1002/cam4.1855. Epub 2019 Aug 27.
• [220] HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma.Oncol Lett. 2019 Nov;18(5):4936-4946. doi: 10.3892/ol.2019.10812. Epub 2019 Sep 5.
• [221] An Isolated TCR Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8(+) T Cells To Kill and Secrete IFN- in Response to Lung Adenocarcinoma Cell Lines.J Immunol. 2018 Apr 15;200(8):2965-2977. doi: 10.4049/jimmunol.1701054. Epub 2018 Mar 19.
• [222] An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma.Epigenetics. 2019 Oct;14(10):949-960. doi: 10.1080/15592294.2019.1625673. Epub 2019 Jun 3.
• [223] The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction.Oncol Lett. 2018 Jun;15(6):8556-8572. doi: 10.3892/ol.2018.8381. Epub 2018 Mar 29.
• [224] HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma.PLoS One. 2015 Apr 14;10(4):e0124191. doi: 10.1371/journal.pone.0124191. eCollection 2015.
• [225] Integrated analysis reveals candidate genes and transcription factors in lung adenocarcinoma.Mol Med Rep. 2017 Dec;16(6):8371-8379. doi: 10.3892/mmr.2017.7656. Epub 2017 Sep 28.
• [226] Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
• [227] Heat shock cognate 70 regulates the translocation and angiogenic function of nucleolin.Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):e126-34. doi: 10.1161/ATVBAHA.112.247502. Epub 2012 Jun 28.
• [228] Distinct prognostic roles of HSPB1 expression in non-small cell lung cancer.Neoplasma. 2018;65(1):161-166. doi: 10.4149/neo_2018_102.
• [229] TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice.Oncogene. 2013 May 2;32(18):2273-81, 2281e.1-12. doi: 10.1038/onc.2012.253. Epub 2012 Jun 25.
• [230] HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.J Cell Biochem. 2014 Jun;115(6):1112-21. doi: 10.1002/jcb.24751.
• [231] Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.Mod Pathol. 2019 Apr;32(4):511-523. doi: 10.1038/s41379-018-0160-1. Epub 2018 Oct 26.
• [232] Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon- receptor.Biochem Biophys Res Commun. 2016 Sep 23;478(3):1436-41. doi: 10.1016/j.bbrc.2016.08.142. Epub 2016 Aug 25.
• [233] Alterations of the M6p/Igf2 receptor gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats.Mol Carcinog. 2003 Jan;36(1):32-7. doi: 10.1002/mc.10095.
• [234] IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer.Cancers (Basel). 2019 Jan 2;11(1):36. doi: 10.3390/cancers11010036.
• [235] IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).J Thorac Oncol. 2016 Dec;11(12):2183-2192. doi: 10.1016/j.jtho.2016.07.026. Epub 2016 Aug 12.
• [236] Comprehensive genomic and prognostic analysis of the IL?7 family genes in lung cancer.Mol Med Rep. 2019 Jun;19(6):4906-4918. doi: 10.3892/mmr.2019.10164. Epub 2019 Apr 15.
• [237] Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.Nat Med. 2018 Jul;24(7):978-985. doi: 10.1038/s41591-018-0045-3. Epub 2018 Jun 25.
• [238] Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation.Oncogene. 2018 Feb 22;37(8):1095-1106. doi: 10.1038/onc.2017.405. Epub 2017 Nov 6.
• [239] LAP TGF-Beta Subset of CD4(+)CD25(+)CD127(-) Treg Cells is Increased and Overexpresses LAP TGF-Beta in Lung Adenocarcinoma Patients.Biomed Res Int. 2015;2015:430943. doi: 10.1155/2015/430943. Epub 2015 Oct 25.
• [240] Th9 cells promote antitumor immunity via IL-9 and IL-21 and demonstrate atypical cytokine expression in breast cancer.Int Immunopharmacol. 2017 Nov;52:163-167. doi: 10.1016/j.intimp.2017.08.031. Epub 2017 Sep 15.
• [241] Disrupted cooperation between transcription factors across diverse cancer types.BMC Genomics. 2016 Aug 5;17:560. doi: 10.1186/s12864-016-2842-8.
• [242] LOXL1 Is Regulated by Integrin 11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity.Cancers (Basel). 2019 May 22;11(5):705. doi: 10.3390/cancers11050705.
• [243] Elevated integrin 6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics.J Cancer Res Clin Oncol. 2019 Jul;145(7):1681-1693. doi: 10.1007/s00432-019-02907-1. Epub 2019 Jun 7.
• [244] Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches.Int J Mol Med. 2018 Nov;42(5):2650-2664. doi: 10.3892/ijmm.2018.3826. Epub 2018 Aug 14.
• [245] The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.J Clin Invest. 2011 Apr;121(4):1373-85. doi: 10.1172/JCI42579. Epub 2011 Mar 14.
• [246] JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624. Epub 2019 Sep 10.
• [247] PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.BMC Cancer. 2018 Jan 4;18(1):27. doi: 10.1186/s12885-017-3959-0.
• [248] Overexpression of KCNJ4 correlates with cancer progression and unfavorable prognosis in lung adenocarcinoma.J Biochem Mol Toxicol. 2019 Apr;33(4):e22270. doi: 10.1002/jbt.22270. Epub 2018 Dec 4.
• [249] Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.Oncotarget. 2015 Apr 20;6(11):8663-75. doi: 10.18632/oncotarget.3536.
• [250] KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp3 transcription in lung adenocarcinoma cells.Oncol Lett. 2017 May;13(5):3529-3537. doi: 10.3892/ol.2017.5949. Epub 2017 Mar 29.
• [251] Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.Invest New Drugs. 2019 Aug;37(4):731-737. doi: 10.1007/s10637-019-00735-1. Epub 2019 Feb 1.
• [252] PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.Sci Rep. 2019 Feb 12;9(1):1844. doi: 10.1038/s41598-018-38362-0.
• [253] Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma.J Cancer. 2017 Nov 6;8(19):4125-4140. doi: 10.7150/jca.21802. eCollection 2017.
• [254] Keratin 17 Promotes Lung Adenocarcinoma Progression by Enhancing Cell Proliferation and Invasion.Med Sci Monit. 2018 Jul 11;24:4782-4790. doi: 10.12659/MSM.909350.
• [255] Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.Lung Cancer. 2019 Apr;130:194-200. doi: 10.1016/j.lungcan.2019.02.017. Epub 2019 Feb 19.
• [256] CDX-2 Expression in Primary Lung Adenocarcinoma.Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):16-9. doi: 10.1097/PAI.0000000000000250.
• [257] LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.BMC Cancer. 2019 Apr 2;19(1):293. doi: 10.1186/s12885-019-5506-7.
• [258] CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.Cancer Sci. 2019 Jul;110(7):2284-2295. doi: 10.1111/cas.14040. Epub 2019 May 29.
• [259] Circular RNA circCRIM1 inhibits invasion and metastasis in lung adenocarcinoma through the microRNA (miR)-182/miR-93-leukemia inhibitory factor receptor pathway.Cancer Sci. 2019 Sep;110(9):2960-2972. doi: 10.1111/cas.14131. Epub 2019 Aug 14.
• [260] Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer.Clin Respir J. 2018 Feb;12(2):712-720. doi: 10.1111/crj.12584. Epub 2016 Dec 11.
• [261] LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.Oncotarget. 2016 Dec 13;7(50):82876-82888. doi: 10.18632/oncotarget.12657.
• [262] Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer. Int J Oncol. 2017 Jun;50(6):2154-2170.
• [263] MiR-26 down-regulates TNF-/NF-B signalling and IL-6 expression by silencing HMGA1 and MALT1.Nucleic Acids Res. 2016 May 5;44(8):3772-87. doi: 10.1093/nar/gkw205. Epub 2016 Mar 28.
• [264] Downregulation of estrogen receptor inhibits lung adenocarcinoma cell growth.Oncol Rep. 2019 May;41(5):2967-2974. doi: 10.3892/or.2019.7044. Epub 2019 Mar 5.
• [265] Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.Future Med Chem. 2019 May;11(10):1107-1117. doi: 10.4155/fmc-2018-0462.
• [266] Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma.Dis Markers. 2018 Mar 18;2018:8956072. doi: 10.1155/2018/8956072. eCollection 2018.
• [267] Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma.Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2285-95.
• [268] MDM2 promotes epithelial-mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma.Onco Targets Ther. 2019 Mar 27;12:2247-2258. doi: 10.2147/OTT.S185076. eCollection 2019.
• [269] Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.Int J Cancer. 2018 Oct 1;143(7):1696-1705. doi: 10.1002/ijc.31542. Epub 2018 May 7.
• [270] Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma.Cell Death Dis. 2018 Jan 18;9(2):36. doi: 10.1038/s41419-017-0188-z.
• [271] Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.Pathol Res Pract. 2019 May;215(5):885-892. doi: 10.1016/j.prp.2019.01.032. Epub 2019 Jan 29.
• [272] MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.Oncotarget. 2015 Apr 10;6(10):8407-17. doi: 10.18632/oncotarget.3511.
• [273] Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma.Mol Ther Oncolytics. 2019 Apr 6;14:82-93. doi: 10.1016/j.omto.2019.03.012. eCollection 2019 Sep 27.
• [274] FTSJ2, a heat shock-inducible mitochondrial protein, suppresses cell invasion and migration.PLoS One. 2014 Mar 4;9(3):e90818. doi: 10.1371/journal.pone.0090818. eCollection 2014.
• [275] Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients.Sci Rep. 2019 Feb 28;9(1):2996. doi: 10.1038/s41598-018-35840-3.
• [276] ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2.Biochem Biophys Res Commun. 2019 Aug 13;516(1):278-284. doi: 10.1016/j.bbrc.2019.06.115. Epub 2019 Jun 25.
• [277] Relationship between stromal cells and tumor spread through air spaces in lung adenocarcinoma.Thorac Cancer. 2019 Feb;10(2):256-267. doi: 10.1111/1759-7714.12945. Epub 2019 Jan 3.
• [278] Relationship between MTA1 and spread through air space and their joint influence on prognosis of patients with stage I-III lung adenocarcinoma.Lung Cancer. 2018 Oct;124:211-218. doi: 10.1016/j.lungcan.2018.07.040. Epub 2018 Jul 29.
• [279] MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.BMC Cancer. 2017 Apr 12;17(1):263. doi: 10.1186/s12885-017-3272-y.
• [280] Matrix-Metalloprotease Resistant Mucin-16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome.Proteomics Clin Appl. 2019 Jul;13(4):e1800155. doi: 10.1002/prca.201800155. Epub 2019 Mar 12.
• [281] Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.Pathol Oncol Res. 2019 Oct;25(4):1327-1340. doi: 10.1007/s12253-017-0372-6. Epub 2017 Dec 5.
• [282] XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.Oncol Lett. 2018 Jun;15(6):8973-8982. doi: 10.3892/ol.2018.8491. Epub 2018 Apr 13.
• [283] Amylase mRNA transcripts in normal tissues and neoplasms: the implication of different expressions of amylase isogenes.J Cancer Res Clin Oncol. 1994;120(4):213-20. doi: 10.1007/BF01372559.
• [284] Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.Gastroenterology. 2018 Sep;155(3):799-814.e13. doi: 10.1053/j.gastro.2018.05.024. Epub 2018 Jul 30.
• [285] Gene associated with retinoid-interferon-induced mortality-19 suppresses growth of lung adenocarcinoma tumor in vitro and in vivo.Lung Cancer. 2011 Jun;72(3):287-93. doi: 10.1016/j.lungcan.2010.10.001. Epub 2010 Nov 1.
• [286] Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-B-CCL2 signaling in lung cancer.Oncogene. 2019 Jul;38(29):5792-5804. doi: 10.1038/s41388-019-0840-4. Epub 2019 Jun 26.
• [287] Dimethyl fumarate, a two-edged drug: Current status and future directions.Med Res Rev. 2019 Sep;39(5):1923-1952. doi: 10.1002/med.21567. Epub 2019 Feb 12.
• [288] NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.Oncol Res. 2019 Jul 12;27(7):751-761. doi: 10.3727/096504018X15372657298381. Epub 2019 Feb 7.
• [289] Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.Cancer Med. 2018 May;7(5):1955-1966. doi: 10.1002/cam4.1440. Epub 2018 Mar 23.
• [290] First synthesis of merged hybrids phosphorylated azirino[2,1-b]benzo[e][1,3]oxazine derivatives as anticancer agents.Eur J Med Chem. 2020 Jan 1;185:111771. doi: 10.1016/j.ejmech.2019.111771. Epub 2019 Oct 19.
• [291] 131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging.Int J Oncol. 2017 Feb;50(2):649-659. doi: 10.3892/ijo.2016.3808. Epub 2016 Dec 16.
• [292] Genomic aberrations in lung adenocarcinoma in never smokers.PLoS One. 2010 Dec 6;5(12):e15145. doi: 10.1371/journal.pone.0015145.
• [293] Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.Oncotarget. 2014 Sep 30;5(18):8252-69. doi: 10.18632/oncotarget.1633.
• [294] miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4.Biomed Pharmacother. 2017 Feb;86:466-474. doi: 10.1016/j.biopha.2016.12.003. Epub 2016 Dec 23.
• [295] C/EBP-Slug-Lox1 axis promotes metastasis of lung adenocarcinoma via oxLDL uptake.Oncogene. 2020 Jan;39(4):833-848. doi: 10.1038/s41388-019-1015-z. Epub 2019 Sep 27.
• [296] Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy.J Control Release. 2015 Jul 10;209:179-85. doi: 10.1016/j.jconrel.2015.04.039. Epub 2015 Apr 30.
• [297] Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.
• [298] A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.Oncol Lett. 2018 May;15(5):6147-6160. doi: 10.3892/ol.2018.8105. Epub 2018 Feb 22.
• [299] PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.J Drug Target. 2019 Apr;27(4):460-465. doi: 10.1080/1061186X.2018.1550648. Epub 2018 Dec 4.
• [300] Extracellular Vesicles (EVs) from Lung Adenocarcinoma Cells Promote Human Umbilical Vein Endothelial Cell (HUVEC) Angiogenesis through Yes Kinase-associated Protein (YAP) Transport.Int J Biol Sci. 2019 Aug 7;15(10):2110-2118. doi: 10.7150/ijbs.31605. eCollection 2019.
• [301] Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.Mol Cell Biochem. 2018 Aug;445(1-2):123-134. doi: 10.1007/s11010-017-3258-8. Epub 2018 Jan 11.
• [302] Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients.Int J Cancer. 2012 Jul 15;131(2):E1-9. doi: 10.1002/ijc.26432. Epub 2011 Oct 20.
• [303] Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.Theranostics. 2018 Feb 12;8(7):1808-1823. doi: 10.7150/thno.23177. eCollection 2018.
• [304] Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.Oncogene. 2020 Jan;39(5):1152-1164. doi: 10.1038/s41388-019-1031-z. Epub 2019 Sep 30.
• [305] POLQ Overexpression Is Associated with an Increased Somatic Mutation Load and PLK4 Overexpression in Lung Adenocarcinoma.Cancers (Basel). 2019 May 24;11(5):722. doi: 10.3390/cancers11050722.
• [306] PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.Cell Death Dis. 2017 Oct 26;8(10):e3143. doi: 10.1038/cddis.2017.553.
• [307] miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.Cancer Sci. 2017 Mar;108(3):536-542. doi: 10.1111/cas.13148.
• [308] Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma.Med Sci Monit. 2016 May 31;22:1837-42. doi: 10.12659/msm.895642.
• [309] The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.Int J Med Sci. 2019 Aug 14;16(9):1199-1206. doi: 10.7150/ijms.36071. eCollection 2019.
• [310] PKC is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.Oncogene. 2019 Nov;38(48):7311-7328. doi: 10.1038/s41388-019-0950-z. Epub 2019 Aug 16.
• [311] Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.Ann Surg Oncol. 2019 Jun;26(6):1934-1941. doi: 10.1245/s10434-019-07254-6. Epub 2019 Feb 28.
• [312] The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.Anticancer Res. 2017 May;37(5):2541-2547. doi: 10.21873/anticanres.11597.
• [313] KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma.Cancer Genomics Proteomics. 2012 Jan;9(1):51-4.
• [314] PTK7 expression is associated with lymph node metastasis, ALK and EGFR mutations in lung adenocarcinomas.Histol Histopathol. 2020 May;35(5):489-495. doi: 10.14670/HH-18-183. Epub 2019 Nov 8.
• [315] Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer.PLoS One. 2013 Aug 16;8(8):e71093. doi: 10.1371/journal.pone.0071093. eCollection 2013.
• [316] MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.J Cell Mol Med. 2017 Nov;21(11):2852-2862. doi: 10.1111/jcmm.13198. Epub 2017 Jun 27.
• [317] Implication of a protein-tyrosine-phosphatase in human lung cancer.Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):677-85.
• [318] Different signaling and functionality of Rac1 and Rac1b in the progression of lung adenocarcinoma.Biol Chem. 2020 Mar 26;401(4):517-531. doi: 10.1515/hsz-2019-0329.
• [319] Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells.Ophthalmic Res. 2010;43(3):139-44. doi: 10.1159/000253486. Epub 2009 Oct 30.
• [320] REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.J Cancer Res Clin Oncol. 2019 Sep;145(9):2273-2283. doi: 10.1007/s00432-019-02988-y. Epub 2019 Aug 19.
• [321] RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.Mol Oncol. 2014 Mar;8(2):196-206. doi: 10.1016/j.molonc.2013.11.001. Epub 2013 Nov 12.
• [322] RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.
• [323] RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation.Cell Death Differ. 2017 Oct;24(10):1761-1771. doi: 10.1038/cdd.2017.81. Epub 2017 Jun 2.
• [324] RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.BMC Cancer. 2019 Jul 8;19(1):670. doi: 10.1186/s12885-019-5880-1.
• [325] miR-218 suppresses epithelial-to-mesenchymal transition by targeting Robo1 and Ecop in lung adenocarcinoma cells.Future Oncol. 2017 Dec;13(28):2571-2582. doi: 10.2217/fon-2017-0398. Epub 2017 Sep 22.
• [326] Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.
• [327] Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3 and osteopontin.Mol Cell Biochem. 2016 Jul;418(1-2):21-9. doi: 10.1007/s11010-016-2727-9. Epub 2016 May 28.
• [328] 37LRP induces invasion in hypoxic lung adenocarcinoma cancer cells A549 through the JNK/ERK/c-Jun signaling cascade.Tumour Biol. 2017 Jun;39(6):1010428317701655. doi: 10.1177/1010428317701655.
• [329] R-spondin family members as novel biomarkers and prognostic factors in lung cancer.Oncol Lett. 2019 Oct;18(4):4008-4015. doi: 10.3892/ol.2019.10778. Epub 2019 Aug 22.
• [330] Anti-tumor efficacy and pre-clinical immunogenicity of IFN2a-NGR.Regul Toxicol Pharmacol. 2011 Jun;60(1):73-8. doi: 10.1016/j.yrtph.2011.02.007. Epub 2011 Feb 19.
• [331] Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.J Pathol. 2015 Dec;237(4):520-31. doi: 10.1002/path.4597. Epub 2015 Sep 28.
• [332] TGF-/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression: IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION.J Biol Chem. 2016 Dec 30;291(53):27343-27353. doi: 10.1074/jbc.M116.740084. Epub 2016 Nov 17.
• [333] Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.Am J Respir Cell Mol Biol. 2019 Jun;60(6):659-666. doi: 10.1165/rcmb.2018-0118OC.
• [334] Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.J Thorac Oncol. 2017 Jun;12(6):943-953. doi: 10.1016/j.jtho.2017.03.010. Epub 2017 Mar 21.
• [335] Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.Oncogene. 2017 Nov 16;36(46):6432-6445. doi: 10.1038/onc.2017.253. Epub 2017 Jul 24.
• [336] An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.Cancer Discov. 2019 Nov;9(11):1590-1605. doi: 10.1158/2159-8290.CD-18-1237. Epub 2019 Jul 26.
• [337] Expression of Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated adenocarcinoma patients.QJM. 2016 Apr;109(4):237-44. doi: 10.1093/qjmed/hcv207. Epub 2015 Nov 11.
• [338] Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung.Am J Pathol. 2001 Nov;159(5):1941-8. doi: 10.1016/S0002-9440(10)63041-6.
• [339] The TWIST1-centered competing endogenous RNA network promotes proliferation, invasion, and migration of lung adenocarcinoma.Oncogenesis. 2019 Oct 23;8(11):62. doi: 10.1038/s41389-019-0167-6.
• [340] High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncol Lett. 2017 Nov;14(5):5727-5734.
• [341] Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.Biomaterials. 2018 Nov;183:77-92. doi: 10.1016/j.biomaterials.2018.08.035. Epub 2018 Aug 19.
• [342] Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.Oncotarget. 2016 Oct 25;7(43):69450-69465. doi: 10.18632/oncotarget.11913.
• [343] Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.Sci Transl Med. 2018 Nov 14;10(467):eaat5933. doi: 10.1126/scitranslmed.aat5933.
• [344] Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.Cancer Med. 2019 Nov;8(15):6717-6729. doi: 10.1002/cam4.2493. Epub 2019 Sep 10.
• [345] Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.Thorac Cancer. 2019 May;10(5):1285-1288. doi: 10.1111/1759-7714.13070. Epub 2019 Apr 10.
• [346] AGR2-mediated lung adenocarcinoma metastasis novel mechanism network through repression with interferon coupling cytoskeleton to steroid metabolism-dependent humoral immune response.Cell Immunol. 2014 Jul;290(1):102-6. doi: 10.1016/j.cellimm.2014.05.008. Epub 2014 Jun 11.
• [347] Inflammation-mediated SOD-2 upregulation contributes to epithelial-mesenchymal transition and migration of tumor cells in aflatoxin G(1)-induced lung adenocarcinoma.Sci Rep. 2017 Aug 11;7(1):7953. doi: 10.1038/s41598-017-08537-2.
• [348] CtBP1 interacts with SOX2 to promote the growth, migration and invasion of lung adenocarcinoma.Oncol Rep. 2019 Jul;42(1):67-78. doi: 10.3892/or.2019.7142. Epub 2019 May 2.
• [349] FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5.EBioMedicine. 2019 Jun;44:150-161. doi: 10.1016/j.ebiom.2019.05.046. Epub 2019 May 27.
• [350] Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 promotes lung adenocarcinoma by directly interacting with specificity protein 1.Cancer Sci. 2018 May;109(5):1346-1356. doi: 10.1111/cas.13587. Epub 2018 Apr 22.
• [351] Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.J Hematol Oncol. 2016 Aug 5;9(1):66. doi: 10.1186/s13045-016-0296-8.
• [352] mPR mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.Mol Carcinog. 2020 Feb;59(2):179-192. doi: 10.1002/mc.23139. Epub 2019 Nov 28.
• [353] Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.Oncogene. 2017 Apr 27;36(17):2457-2471. doi: 10.1038/onc.2016.404. Epub 2016 Nov 7.
• [354] Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.PLoS One. 2012;7(10):e46539. doi: 10.1371/journal.pone.0046539. Epub 2012 Oct 10.
• [355] Expression profile and prognostic values of STAT family members in non-small cell lung cancer.Am J Transl Res. 2019 Aug 15;11(8):4866-4880. eCollection 2019.
• [356] The oncogenetic role of stanniocalcin 1 in lung adenocarcinoma: a promising serum candidate biomarker for tracking lung adenocarcinoma progression.Tumour Biol. 2016 Apr;37(4):5633-44. doi: 10.1007/s13277-015-4431-x. Epub 2015 Nov 17.
• [357] Withdrawal Notice: STK33-Dependent Transcriptional Regulation of SFTA3 Induces Cisplatin-Resistance in Lung Adenocarcinoma.Anticancer Agents Med Chem. 2019 May 6. doi: 10.2174/1871520619666190507100912. Online ahead of print.
• [358] Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer.Cancer Biomark. 2017;19(1):35-43. doi: 10.3233/CBM-160239.
• [359] SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.
• [360] Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.FEBS J. 2018 Nov;285(22):4229-4245. doi: 10.1111/febs.14665. Epub 2018 Oct 8.
• [361] Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas.FEBS Lett. 1999 Nov 26;462(1-2):129-34. doi: 10.1016/s0014-5793(99)01493-3.
• [362] TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21-IL-4 pathway in lung adenocarcinoma.Stem Cell Res Ther. 2018 Apr 3;9(1):89. doi: 10.1186/s13287-018-0820-6.
• [363] The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.J Cancer Res Ther. 2018 Dec;14(Supplement):S1201-S1208. doi: 10.4103/jcrt.JCRT_1404_16.
• [364] The prognostic value of Tiam1 correlates with its roles in epithelial-mesenchymal transition progression and angiogenesis in lung adenocarcinoma.Cancer Manag Res. 2019 Feb 21;11:1741-1752. doi: 10.2147/CMAR.S195093. eCollection 2019.
• [365] APRIL promotes non-small cell lung cancer growth and metastasis by targeting ERK1/2 signaling.Oncotarget. 2017 Nov 27;8(65):109289-109300. doi: 10.18632/oncotarget.22672. eCollection 2017 Dec 12.
• [366] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [367] Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma.Cancers (Basel). 2019 Apr 30;11(5):601. doi: 10.3390/cancers11050601.
• [368] Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.PLoS One. 2017 Mar 29;12(3):e0174515. doi: 10.1371/journal.pone.0174515. eCollection 2017.
• [369] TCTP promotes epithelial-mesenchymal transition in lung adenocarcinoma.Onco Targets Ther. 2019 Feb 27;12:1641-1653. doi: 10.2147/OTT.S184555. eCollection 2019.
• [370] Genome-wide analyses of long noncoding RNA expression profiles in lung adenocarcinoma.Sci Rep. 2017 Nov 10;7(1):15331. doi: 10.1038/s41598-017-15712-y.
• [371] TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.Life Sci. 2019 May 1;224:23-32. doi: 10.1016/j.lfs.2019.03.041. Epub 2019 Mar 19.
• [372] CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.Oncogene. 2015 Jul;34(27):3527-35. doi: 10.1038/onc.2014.280. Epub 2014 Sep 1.
• [373] TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p.Nat Commun. 2017 Oct 16;8(1):947. doi: 10.1038/s41467-017-00983-w.
• [374] Expression of the transient receptor potential channel c3 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.Ann Surg Oncol. 2011 Nov;18(12):3377-83. doi: 10.1245/s10434-011-1798-9. Epub 2011 May 21.
• [375] TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer.Mol Biol Rep. 2010 Jul;37(6):2829-38. doi: 10.1007/s11033-009-9835-5. Epub 2009 Sep 29.
• [376] ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.J Cancer Res Clin Oncol. 2019 Jun;145(6):1427-1436. doi: 10.1007/s00432-019-02906-2. Epub 2019 Mar 28.
• [377] The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis.Cell Death Differ. 2020 Jun;27(6):1747-1764. doi: 10.1038/s41418-019-0458-7. Epub 2019 Nov 20.
• [378] Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.Oncogene. 2018 Oct;37(40):5387-5402. doi: 10.1038/s41388-018-0342-9. Epub 2018 Jun 7.
• [379] Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo.Oncol Rep. 2010 Nov;24(5):1179-84. doi: 10.3892/or_00000970.
• [380] VDAC1 Mediated Anticancer Activity of Gallic Acid in Human Lung Adenocarcinoma A549 Cells.Anticancer Agents Med Chem. 2018;18(2):255-262. doi: 10.2174/1871520617666170912115441.
• [381] Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.J Cancer Res Ther. 2016 Apr-Jun;12(2):640-4. doi: 10.4103/0973-1482.150413.
• [382] Induction of fibroblast growth factor-9 and interleukin-1alpha gene expression by motorcycle exhaust particulate extracts and benzo(a)pyrene in human lung adenocarcinoma cells. Toxicol Sci. 2005 Oct;87(2):483-96. doi: 10.1093/toxsci/kfi251. Epub 2005 Jul 7.
• [383] Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.
• [384] Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.Cancer Med. 2018 Nov;7(11):5716-5726. doi: 10.1002/cam4.1834. Epub 2018 Oct 23.
• [385] Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion.Biochem Biophys Res Commun. 2016 Oct 14;479(2):146-151. doi: 10.1016/j.bbrc.2016.07.084. Epub 2016 Jul 25.
• [386] Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.Respir Res. 2017 Apr 11;18(1):56. doi: 10.1186/s12931-017-0545-6.
• [387] MicroRNA?06?p reverses gefitinib resistance in nonsmall cell lung cancer by targeting Yesassociated protein 1.Mol Med Rep. 2019 Feb;19(2):1331-1339. doi: 10.3892/mmr.2018.9710. Epub 2018 Nov 29.
• [388] MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2.Pathol Res Pract. 2019 May;215(5):861-872. doi: 10.1016/j.prp.2019.01.029. Epub 2019 Jan 28.
• [389] ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.Cancer Res. 2008 Oct 15;68(20):8547-54. doi: 10.1158/0008-5472.CAN-08-1235.
• [390] MicroRNA-425 promotes the development of lung adenocarcinoma via targeting A disintegrin and metalloproteinases 9 (ADAM9).Onco Targets Ther. 2018 Jul 16;11:4065-4073. doi: 10.2147/OTT.S160871. eCollection 2018.
• [391] Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases.Mol Genet Genomic Med. 2019 Feb;7(2):e00528. doi: 10.1002/mgg3.528. Epub 2018 Dec 16.
• [392] APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.Cell Death Dis. 2018 Oct 31;9(11):1111. doi: 10.1038/s41419-018-1162-0.
• [393] Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.J Immunother Cancer. 2019 Feb 6;7(1):32. doi: 10.1186/s40425-019-0504-5.
• [394] ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.BMB Rep. 2019 Jul;52(7):457-462. doi: 10.5483/BMBRep.2019.52.7.042.
• [395] BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line.Cancer Sci. 2007 Jul;98(7):1070-7. doi: 10.1111/j.1349-7006.2007.00491.x. Epub 2007 Apr 24.
• [396] Overexpressed BSG related to the progression of lung adenocarcinoma with high-throughput data-mining, immunohistochemistry, in vitro validation and in silico investigation.Am J Transl Res. 2019 Aug 15;11(8):4835-4850. eCollection 2019.
• [397] Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.J Thorac Oncol. 2019 Nov;14(11):2003-2008. doi: 10.1016/j.jtho.2019.07.022. Epub 2019 Aug 2.
• [398] Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.J Exp Med. 1993 May 1;177(5):1231-7. doi: 10.1084/jem.177.5.1231.
• [399] ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells.Biol Pharm Bull. 2019;42(2):247-254. doi: 10.1248/bpb.b18-00670.
• [400] Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.
• [401] CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.Cell Physiol Biochem. 2017;43(2):465-480. doi: 10.1159/000480473. Epub 2017 Sep 1.
• [402] Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.Cancer Res. 1996 Mar 15;56(6):1315-23.
• [403] Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors.J Comput Biol. 2005 Jun;12(5):534-44. doi: 10.1089/cmb.2005.12.534.
• [404] Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenaseinhibitory fluoropyrimidine in EGFRmutated lung adenocarcinoma: retrospective and in vitro studies.Int J Oncol. 2015 Mar;46(3):989-98. doi: 10.3892/ijo.2015.2815. Epub 2015 Jan 7.
• [405] Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.Cancer Res. 2003 Jul 15;63(14):4136-43.
• [406] Long non-coding RNA-HAGLR suppressed tumor growth of lung adenocarcinoma through epigenetically silencing E2F1.Exp Cell Res. 2019 Sep 1;382(1):111461. doi: 10.1016/j.yexcr.2019.06.006. Epub 2019 Jun 10.
• [407] Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach.Exp Biol Med (Maywood). 2017 Apr;242(7):709-717. doi: 10.1177/1535370216677353. Epub 2016 Nov 14.
• [408] Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.
• [409] High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence.Jpn J Clin Oncol. 2017 Jun 1;47(6):543-550. doi: 10.1093/jjco/hyx031.
• [410] Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4300-4305. doi: 10.1073/pnas.1617709114. Epub 2017 Apr 11.
• [411] A subpopulation of airway epithelial cells that express hepatocyte nuclear factor 4 - its implication in the development of non-terminal respiratory unit-type lung adenocarcinoma.Histol Histopathol. 2019 Nov;34(11):1217-1227. doi: 10.14670/HH-18-098. Epub 2019 Mar 8.
• [412] Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase.Gene. 2016 Feb 1;576(2 Pt 2):791-7. doi: 10.1016/j.gene.2015.11.009. Epub 2015 Nov 12.
• [413] Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.
• [414] Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.Cancer Invest. 2018 Mar 16;36(3):185-189. doi: 10.1080/07357907.2018.1445262. Epub 2018 Mar 14.
• [415] Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression.Mol Cancer. 2017 Jan 21;16(1):17. doi: 10.1186/s12943-017-0581-3.
• [416] Author Correction: Down-regulated GATA-1 up-regulates interferon regulatory factor 3 in lung adenocarcinoma.Sci Rep. 2018 Mar 6;8(1):4299. doi: 10.1038/s41598-018-22517-0.
• [417] Prognostic Significance of (18)F-FDG PET/CT Metabolic Parameters and Tumor Galectin-1 Expression in Patients With Surgically Resected Lung Adenocarcinoma.Clin Lung Cancer. 2019 Nov;20(6):420-428. doi: 10.1016/j.cllc.2019.04.002. Epub 2019 May 17.
• [418] Mutational activation of the MAP3K8 protooncogene in lung cancer.Genes Chromosomes Cancer. 2004 Oct;41(2):99-108. doi: 10.1002/gcc.20069.
• [419] SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.BMB Rep. 2018 Dec;51(12):648-653. doi: 10.5483/BMBRep.2018.51.12.205.
• [420] Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.JCI Insight. 2018 Aug 9;3(15):e120941. doi: 10.1172/jci.insight.120941. eCollection 2018 Aug 9.
• [421] miR-125a-5p upregulation suppresses the proliferation and induces the cell apoptosis of lung adenocarcinoma by targeting NEDD9.Oncol Rep. 2017 Sep;38(3):1790-1796. doi: 10.3892/or.2017.5812. Epub 2017 Jul 13.
• [422] N-acetylcysteine conjugate of phenethyl isothiocyanate enhances apoptosis in growth-stimulated human lung cells.Cancer Res. 2005 Sep 15;65(18):8538-47. doi: 10.1158/0008-5472.CAN-05-0236.
• [423] JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.Mol Cancer Ther. 2017 Oct;16(10):2234-2245. doi: 10.1158/1535-7163.MCT-17-0148. Epub 2017 Jul 20.
• [424] Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.J Pathol. 2008 Jul;215(3):290-9. doi: 10.1002/path.2361.
• [425] Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells.FASEB J. 2009 Oct;23(10):3553-63. doi: 10.1096/fj.09-133264. Epub 2009 Jul 1.
• [426] LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway.Mol Cancer Res. 2019 Jun;17(6):1326-1337. doi: 10.1158/1541-7786.MCR-18-0971. Epub 2019 Feb 13.
• [427] A TGF-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.Oncogene. 2017 Jan 19;36(3):373-386. doi: 10.1038/onc.2016.205. Epub 2016 Jun 6.
• [428] Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.Int J Biol Sci. 2018 Jan 11;14(1):47-56. doi: 10.7150/ijbs.22209. eCollection 2018.
• [429] Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.Lung Cancer. 2007 Dec;58(3):376-83. doi: 10.1016/j.lungcan.2007.07.004. Epub 2007 Aug 21.
• [430] Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.J Thorac Oncol. 2018 Jul;13(7):958-967. doi: 10.1016/j.jtho.2018.03.032. Epub 2018 Apr 21.
• [431] Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data.J Mol Diagn. 2004 May;6(2):90-5. doi: 10.1016/S1525-1578(10)60495-3.
• [432] High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.Tumour Biol. 2017 Jul;39(7):1010428317720212. doi: 10.1177/1010428317720212.
• [433] Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma.J Proteome Res. 2009 Dec;8(12):5610-8. doi: 10.1021/pr900705r.
• [434] Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.PLoS Genet. 2019 Oct 7;15(10):e1008439. doi: 10.1371/journal.pgen.1008439. eCollection 2019 Oct.
• [435] Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas.Oncol Rep. 2010 Aug;24(2):321-8. doi: 10.3892/or_00000862.
• [436] Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.Oncogene. 2018 Jan 4;37(1):52-62. doi: 10.1038/onc.2017.304. Epub 2017 Sep 4.
• [437] Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival.PLoS One. 2008 Feb 20;3(2):e1651. doi: 10.1371/journal.pone.0001651.
• [438] MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.Lung Cancer. 2017 May;107:73-83. doi: 10.1016/j.lungcan.2016.06.004. Epub 2016 Jun 14.
• [439] Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene.Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6.
• [440] Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.Oncotarget. 2015 Mar 20;6(8):6191-202. doi: 10.18632/oncotarget.3356.
• [441] Geographic Variation in EGFR Mutation Frequency inLung Adenocarcinoma May Be Explained by Interethnic Genetic Variation.J Thorac Oncol. 2018 Mar;13(3):454-458. doi: 10.1016/j.jtho.2017.11.128. Epub 2017 Dec 13.
• [442] The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH.Sci Rep. 2015 Dec 11;5:17826. doi: 10.1038/srep17826.
• [443] Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.PeerJ. 2017 May 10;5:e3216. doi: 10.7717/peerj.3216. eCollection 2017.
• [444] Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.Eur J Surg Oncol. 2019 May;45(5):870-876. doi: 10.1016/j.ejso.2019.02.006. Epub 2019 Feb 16.
• [445] Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.J Proteome Res. 2017 Sep 1;16(9):3266-3276. doi: 10.1021/acs.jproteome.7b00245. Epub 2017 Aug 8.
• [446] Low glucose transporter SLC2A5-inhibited human normal adjacent lung adenocarcinoma cytoplasmic pro-B cell development mechanism network.Mol Cell Biochem. 2015 Jan;399(1-2):71-6. doi: 10.1007/s11010-014-2233-x. Epub 2014 Oct 18.
• [447] Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma. Ann Thorac Surg. 2015 May;99(5):1755-9.
• [448] ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in A549 cells.FEBS Lett. 2007 Jul 10;581(17):3139-44. doi: 10.1016/j.febslet.2007.05.078. Epub 2007 Jun 6.
• [449] A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.Cancer Res. 2000 Sep 1;60(17):4830-7.
• [450] Choline transporters in human lung adenocarcinoma: expression and functional implications.Acta Biochim Biophys Sin (Shanghai). 2007 Sep;39(9):668-74. doi: 10.1111/j.1745-7270.2007.00323.x.
• [451] Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas.Cancer. 2003 Feb 1;97(3):703-13. doi: 10.1002/cncr.11087.
• [452] UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians.Cancer Epidemiol. 2013 Oct;37(5):625-8. doi: 10.1016/j.canep.2013.06.004. Epub 2013 Jul 11.
• [453] Overexpression and proliferation dependence of acyl-CoA thioesterase 11 and 13 in lung adenocarcinoma.Oncol Lett. 2017 Sep;14(3):3647-3656. doi: 10.3892/ol.2017.6594. Epub 2017 Jul 18.
• [454] Prognostic significance of ACP5 expression in patients with lung adenocarcinoma.Clin Respir J. 2018 Mar;12(3):1100-1105. doi: 10.1111/crj.12637. Epub 2017 Jun 18.
• [455] Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma.J Cell Physiol. 2019 Dec;234(12):22311-22320. doi: 10.1002/jcp.28797. Epub 2019 May 9.
• [456] Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.Cell Death Dis. 2019 Nov 7;10(11):854. doi: 10.1038/s41419-019-2082-3.
• [457] Prognostic and therapeutic potential of Adenylate kinase 2 in lung adenocarcinoma.Sci Rep. 2019 Nov 28;9(1):17757. doi: 10.1038/s41598-019-53594-4.
• [458] Diagnostic value of serum dihydrodiol dehydrogenase 2 levels in patients with non-small-cell lung cancer.Int J Biol Markers. 2018 Jun 1:1724600818776832. doi: 10.1177/1724600818776832. Online ahead of print.
• [459] Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma.Cancer Epidemiol. 2013 Oct;37(5):653-9. doi: 10.1016/j.canep.2013.04.010. Epub 2013 Jun 7.
• [460] Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma.Anticancer Drugs. 2020 Jan;31(1):44-54. doi: 10.1097/CAD.0000000000000831.
• [461] FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.Oncotarget. 2014 May 15;5(9):2475-86. doi: 10.18632/oncotarget.1723.
• [462] A folylpoly--glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.Lung Cancer. 2016 Dec;102:15-20. doi: 10.1016/j.lungcan.2016.10.006. Epub 2016 Oct 19.
• [463] GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma.BMC Cancer. 2018 May 29;18(1):600. doi: 10.1186/s12885-018-4524-1.
• [464] Down-regulation of the expression of the FIH-1 and ARD-1 genes at the transcriptional level by nickel and cobalt in the human lung adenocarcinoma A549 cell line. Int J Environ Res Public Health. 2005 Apr;2(1):10-3. doi: 10.3390/ijerph2005010010.
• [465] Carboxylated short single-walled carbon nanotubes but not plain and multi-walled short carbon nanotubes show in vitro genotoxicity.Toxicol Sci. 2015 Mar;144(1):114-27. doi: 10.1093/toxsci/kfu260. Epub 2014 Dec 10.
• [466] Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis.Biomed Pharmacother. 2020 Jan;121:109562. doi: 10.1016/j.biopha.2019.109562. Epub 2019 Nov 7.
• [467] NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan.Lung Cancer. 2009 Apr;64(1):9-12. doi: 10.1016/j.lungcan.2008.07.001. Epub 2008 Aug 15.
• [468] In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.
• [469] Comparative secretome analyses using a hollow fiber culture system with label-free quantitative proteomics indicates the influence of PARK7 on cell proliferation and migration/invasion in lung adenocarcinoma.J Proteome Res. 2012 Nov 2;11(11):5167-85. doi: 10.1021/pr300362g. Epub 2012 Oct 4.
• [470] Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.Pathobiology. 2012;79(2):84-93. doi: 10.1159/000334340. Epub 2012 Jan 27.
• [471] Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma.Biomed Pharmacother. 2019 May;113:108779. doi: 10.1016/j.biopha.2019.108779. Epub 2019 Mar 16.
• [472] Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.Clin Cancer Res. 2002 Jul;8(7):2298-305.
• [473] Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: different cytogenetic changes are correlated with genders and smoking habits.Lung Cancer. 2007 Sep;57(3):292-301. doi: 10.1016/j.lungcan.2007.04.007. Epub 2007 Jun 5.
• [474] Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence.EMBO Mol Med. 2019 Jun;11(6):e9856. doi: 10.15252/emmm.201809856.
• [475] Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis.Oncogene. 2019 Apr;38(16):3061-3076. doi: 10.1038/s41388-018-0645-x. Epub 2019 Jan 7.
• [476] PRAS40 promotes NF-B transcriptional activity through association with p65.Oncogenesis. 2017 Sep 25;6(9):e381. doi: 10.1038/oncsis.2017.80.
• [477] ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.Br J Cancer. 2011 Feb 15;104(4):700-6. doi: 10.1038/sj.bjc.6606012. Epub 2011 Feb 1.
• [478] FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.Oncotarget. 2015 Feb 20;6(5):3409-19. doi: 10.18632/oncotarget.2636.
• [479] Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma.Sci Rep. 2017 Sep 19;7(1):11893. doi: 10.1038/s41598-017-12131-x.
• [480] Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.
• [481] Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis.CNS Neurosci Ther. 2017 Dec;23(12):947-960. doi: 10.1111/cns.12764. Epub 2017 Sep 29.
• [482] Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5(p)15.33 TERT-CLPTM1Ll Region.J Thorac Oncol. 2019 Aug;14(8):1360-1369. doi: 10.1016/j.jtho.2019.04.008. Epub 2019 Apr 19.
• [483] Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.J Clin Invest. 2019 Jan 2;129(1):215-222. doi: 10.1172/JCI99699. Epub 2018 Nov 26.
• [484] Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.Clin Lung Cancer. 2011 Jul;12(4):237-44. doi: 10.1016/j.cllc.2011.03.025. Epub 2011 Apr 24.
• [485] ERP44 inhibits human lung cancer cell migration mainly via IP3R2.Aging (Albany NY). 2016 Jun;8(6):1276-86. doi: 10.18632/aging.100984.
• [486] Epithelial Splicing Regulatory Protein 1 Inhibits the Invasion and Metastasis of Lung Adenocarcinoma.Am J Pathol. 2018 Aug;188(8):1882-1894. doi: 10.1016/j.ajpath.2018.04.012. Epub 2018 May 24.
• [487] Altered expression of the ERM proteins in lung adenocarcinoma.Lab Invest. 2000 Nov;80(11):1643-50. doi: 10.1038/labinvest.3780174.
• [488] Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.Cancer Biomark. 2019;26(3):367-373. doi: 10.3233/CBM-190520.
• [489] Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.Epigenetics. 2018;13(3):214-227. doi: 10.1080/15592294.2016.1229730. Epub 2018 Apr 18.
• [490] A retinoid responsive cytokine gene, MK, is preferentially expressed in the proximal tubules of the kidney and human tumor cell lines.Am J Pathol. 1993 Feb;142(2):425-31.
• [491] Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.Clin Cancer Res. 2017 Sep 1;23(17):5003-5014. doi: 10.1158/1078-0432.CCR-16-2688. Epub 2017 May 10.
• [492] FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression.Clin Cancer Res. 2018 Feb 15;24(4):916-926. doi: 10.1158/1078-0432.CCR-17-1347. Epub 2017 Dec 7.
• [493] Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma.J Cell Mol Med. 2018 Apr;22(4):2177-2189. doi: 10.1111/jcmm.13493. Epub 2018 Jan 29.
• [494] Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.Mod Pathol. 2018 May;31(5):809-815. doi: 10.1038/modpathol.2017.190. Epub 2018 Jan 12.
• [495] Carboxamide analog ITR-284 evokes apoptosis and inhibits migration ability in human lung adenocarcinoma A549 cells.Oncol Rep. 2017 Mar;37(3):1786-1792. doi: 10.3892/or.2017.5374. Epub 2017 Jan 16.
• [496] TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma.Oncol Lett. 2019 Oct;18(4):4144-4152. doi: 10.3892/ol.2019.10748. Epub 2019 Aug 16.
• [497] HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.
• [498] Acetylated HOXB9 at lysine 27 is of differential diagnostic value in patients with pancreatic ductal adenocarcinoma.Front Med. 2020 Feb;14(1):91-100. doi: 10.1007/s11684-019-0696-6. Epub 2019 Aug 2.
• [499] HOXC10 Promotes the Metastasis of Human Lung Adenocarcinoma and Indicates Poor Survival Outcome.Front Physiol. 2017 Aug 2;8:557. doi: 10.3389/fphys.2017.00557. eCollection 2017.
• [500] Insulin-like growth factor binding protein-4 gene silencing in lung adenocarcinomas.Pathol Int. 2011 Jan;61(1):19-27. doi: 10.1111/j.1440-1827.2010.02612.x. Epub 2010 Nov 3.
• [501] The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.Anticancer Res. 2016 Sep;36(9):4841-6. doi: 10.21873/anticanres.11046.
• [502] The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma.PLoS One. 2013 Apr 23;8(4):e61664. doi: 10.1371/journal.pone.0061664. Print 2013.
• [503] An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma.Oncogene. 2017 Jan 5;36(1):110-121. doi: 10.1038/onc.2016.181. Epub 2016 May 23.
• [504] Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.Neoplasia. 2018 Aug;20(8):838-847. doi: 10.1016/j.neo.2018.06.007. Epub 2018 Jul 13.
• [505] Krppel-like factor 17 inhibits urokinase plasminogen activator gene expression to suppress cell invasion through the Src/p38/ MAPK signaling pathway in human lung adenocarcionma.Oncotarget. 2017 Jun 13;8(24):38743-38754. doi: 10.18632/oncotarget.17020.
• [506] LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung.Virchows Arch. 2006 Feb;448(2):142-50. doi: 10.1007/s00428-005-0063-7. Epub 2005 Sep 21.
• [507] Neuroglobin and myoglobin in non-small cell lung cancer: expression, regulation and prognosis.Lung Cancer. 2011 Dec;74(3):411-8. doi: 10.1016/j.lungcan.2011.05.001. Epub 2011 Jun 2.
• [508] Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.Am J Clin Pathol. 2004 May;121(5):644-53. doi: 10.1309/U4WG-E9EB-FJN6-CM8R.
• [509] HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells.Free Radic Biol Med. 2010 Jun 15;48(12):1626-35. doi: 10.1016/j.freeradbiomed.2010.03.008. Epub 2010 Mar 24.
• [510] OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3/snail/E-cadherin signaling.Oncotarget. 2016 Mar 1;7(9):10402-13. doi: 10.18632/oncotarget.7224.
• [511] Prognostic significance of combining immunohistochemical markers for cancer-associated fibroblasts in lung adenocarcinoma tissue.Virchows Arch. 2019 Aug;475(2):181-189. doi: 10.1007/s00428-019-02587-9. Epub 2019 May 27.
• [512] Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer.Cancer Res. 2005 Aug 15;65(16):7102-10. doi: 10.1158/0008-5472.CAN-04-1877.
• [513] Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.Cancer Sci. 2017 Mar;108(3):528-535. doi: 10.1111/cas.13142.
• [514] The role of Necl-5 in the invasive activity of lung adenocarcinoma.Exp Mol Pathol. 2013 Apr;94(2):330-5. doi: 10.1016/j.yexmp.2012.12.003. Epub 2012 Dec 28.
• [515] Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential.Clin Exp Metastasis. 1999 May;17(3):213-9. doi: 10.1023/a:1006617016451.
• [516] RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report.Cancer Genet. 2019 Feb;231-232:41-45. doi: 10.1016/j.cancergen.2019.01.001. Epub 2019 Jan 9.
• [517] Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma.Oncotarget. 2016 May 24;7(21):31122-36. doi: 10.18632/oncotarget.8860.
• [518] Inhibition of rhotekin exhibits antitumor effects in lung cancer cells.Oncol Rep. 2016 May;35(5):2529-34. doi: 10.3892/or.2016.4634. Epub 2016 Feb 24.
• [519] Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma.Mol Cancer Res. 2019 Apr;17(4):1002-1012. doi: 10.1158/1541-7786.MCR-18-0316. Epub 2019 Jan 11.
• [520] SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma.Oncotarget. 2016 Jul 12;7(28):44417-44429. doi: 10.18632/oncotarget.10088.
• [521] Identification of Methylation-Driven, Differentially Expressed STXBP6 as a Novel Biomarker in Lung Adenocarcinoma.Sci Rep. 2017 Feb 15;7:42573. doi: 10.1038/srep42573.
• [522] Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks.Cancer Med. 2017 Feb;6(2):483-493. doi: 10.1002/cam4.995. Epub 2017 Jan 6.
• [523] AHNAK Loss in Mice Promotes Type II Pneumocyte Hyperplasia and Lung Tumor Development.Mol Cancer Res. 2018 Aug;16(8):1287-1298. doi: 10.1158/1541-7786.MCR-17-0726. Epub 2018 May 3.
• [524] DAL-1 attenuates epithelial to mesenchymal transition and metastasis by suppressing HSPA5 expression in non-small cell lung cancer.Oncol Rep. 2017 Nov;38(5):3103-3113. doi: 10.3892/or.2017.6000. Epub 2017 Sep 26.
• [525] Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer.PLoS One. 2016 Mar 17;11(3):e0151516. doi: 10.1371/journal.pone.0151516. eCollection 2016.
• [526] Screening for transcription factors and their regulatory small molecules involved in regulating the functions of CL1-5 cancer cells under the effects of macrophage-conditioned medium.Oncol Rep. 2014 Mar;31(3):1323-33. doi: 10.3892/or.2013.2937. Epub 2013 Dec 20.
• [527] Expression of OPN3 in lung adenocarcinoma promotes epithelial-mesenchymal transition and tumor metastasis.Thorac Cancer. 2020 Feb;11(2):286-294. doi: 10.1111/1759-7714.13254. Epub 2019 Dec 5.
• [528] Plasma selenoprotein P concentration and lung cancer risk: results from a case-control study nested within the Shanghai Men's Health Study.Carcinogenesis. 2018 Dec 13;39(11):1352-1358. doi: 10.1093/carcin/bgy103.
• [529] Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.PLoS One. 2013 Aug 16;8(8):e71816. doi: 10.1371/journal.pone.0071816. eCollection 2013.
• [530] The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma.J Thorac Oncol. 2006 Feb;1(2):160-7.
• [531] Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.Biomark Med. 2017 Sep;11(9):721-731. doi: 10.2217/bmm-2017-0150. Epub 2017 Jun 29.
• [532] Expression of the Arp11 gene suppresses the tumorigenicity of PC-14 human lung adenocarcinoma cells.Biochem Biophys Res Commun. 2003 Dec 26;312(4):889-96. doi: 10.1016/j.bbrc.2003.10.200.
• [533] Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity.Chembiochem. 2014 Mar 21;15(5):701-12. doi: 10.1002/cbic.201300625.
• [534] Comparative proteomics and global genome-wide expression data implicate role of ARMC8 in lung cancer.Asian Pac J Cancer Prev. 2015;16(9):3691-6. doi: 10.7314/apjcp.2015.16.9.3691.
• [535] shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis.Lung Cancer. 2012 Jul;77(1):24-30. doi: 10.1016/j.lungcan.2012.02.015. Epub 2012 Mar 13.
• [536] Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.Clin Lung Cancer. 2018 Jul;19(4):e431-e438. doi: 10.1016/j.cllc.2018.02.007. Epub 2018 Feb 19.
• [537] Diagnostic and prognostic value of the BEX family in lung adenocarcinoma.Oncol Lett. 2019 Nov;18(5):5523-5533. doi: 10.3892/ol.2019.10905. Epub 2019 Sep 20.
• [538] BHLHB3: a candidate tumor suppressor in lung cancer.Oncogene. 2008 Jun 12;27(26):3761-4. doi: 10.1038/sj.onc.1211038. Epub 2008 Jan 28.
• [539] BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and IsAssociated with a Poor Prognosis.J Thorac Oncol. 2018 Jan;13(1):73-84. doi: 10.1016/j.jtho.2017.10.006. Epub 2017 Oct 31.
• [540] Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.Anticancer Res. 2019 Feb;39(2):627-633. doi: 10.21873/anticanres.13156.
• [541] HP1 Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A.Cancer Res. 2018 Jul 15;78(14):3834-3848. doi: 10.1158/0008-5472.CAN-17-3571. Epub 2018 May 15.
• [542] High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.Br J Cancer. 2013 Sep 3;109(5):1100-8. doi: 10.1038/bjc.2013.440. Epub 2013 Aug 6.
• [543] CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.BMC Cancer. 2019 Jun 13;19(1):576. doi: 10.1186/s12885-019-5793-z.
• [544] Reduced CENPU expression inhibits lung adenocarcinoma cell proliferation and migration through PI3K/AKT signaling.Biosci Biotechnol Biochem. 2019 Jun;83(6):1077-1084. doi: 10.1080/09168451.2019.1588094. Epub 2019 Mar 8.
• [545] ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?.Lung Cancer. 2016 Jan;91:67-9. doi: 10.1016/j.lungcan.2015.11.010. Epub 2015 Nov 10.
• [546] The axis IL-10/claudin-10 is implicated in the modulation of aggressiveness of melanoma cells by B-1 lymphocytes.PLoS One. 2017 Nov 16;12(11):e0187333. doi: 10.1371/journal.pone.0187333. eCollection 2017.
• [547] Proteome analysis for downstream targets of oncogenic KRAS--the potential participation of CLIC4 in carcinogenesis in the lung.PLoS One. 2014 Feb 4;9(2):e87193. doi: 10.1371/journal.pone.0087193. eCollection 2014.
• [548] CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.Cancer Res. 2013 Jan 15;73(2):571-82. doi: 10.1158/0008-5472.CAN-12-0263. Epub 2012 Nov 30.
• [549] TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas.Oncogene. 2017 Jun 29;36(26):3740-3748. doi: 10.1038/onc.2016.524. Epub 2017 Feb 13.
• [550] Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.Oncogene. 2006 Apr 27;25(18):2628-35. doi: 10.1038/sj.onc.1209289.
• [551] Early Steps of Jaagsiekte Sheep Retrovirus-Mediated Cell Transformation Involve the Interaction between Env and the RALBP1 Cellular Protein.J Virol. 2015 Aug;89(16):8462-73. doi: 10.1128/JVI.00590-15. Epub 2015 Jun 3.
• [552] Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.Oncotarget. 2016 Nov 8;7(45):73664-73680. doi: 10.18632/oncotarget.12046.
• [553] FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma.Thorac Cancer. 2019 Apr;10(4):909-917. doi: 10.1111/1759-7714.13027. Epub 2019 Mar 5.
• [554] miR-133 involves in lung adenocarcinoma cell metastasis by targeting FLOT2.Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):224-230. doi: 10.1080/21691401.2017.1324467. Epub 2017 May 14.
• [555] GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4 expression, and KRAS mutations.Histopathology. 2018 Jul;73(1):38-48. doi: 10.1111/his.13500. Epub 2018 Apr 17.
• [556] High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.Breast Cancer Res Treat. 2014 Nov;148(2):423-36. doi: 10.1007/s10549-014-3172-7. Epub 2014 Oct 28.
• [557] GPX2 suppression of H(2)O(2) stress regulates cervical cancer metastasis and apoptosis via activation of the -catenin-WNT pathway.Onco Targets Ther. 2019 Aug 19;12:6639-6651. doi: 10.2147/OTT.S208781. eCollection 2019.
• [558] Effects of selenium supplementation on expression of glutathione peroxidase isoforms in cultured human lung adenocarcinoma cell lines. Lung Cancer. 2007 Jan;55(1):35-42.
• [559] Hypermethylation of the G protein-coupled receptor kinase 6 (GRK6) promoter inhibits binding of C/EBP, and GRK6 knockdown promotes cell migration and invasion in lung adenocarcinoma cells.FEBS Open Bio. 2019 Mar 19;9(4):605-617. doi: 10.1002/2211-5463.12606. eCollection 2019 Apr.
• [560] Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells.Tumour Biol. 2017 Mar;39(3):1010428317694321. doi: 10.1177/1010428317694321.
• [561] HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.Lung Cancer. 2018 Aug;122:151-159. doi: 10.1016/j.lungcan.2018.05.021. Epub 2018 May 22.
• [562] Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma.Sci Rep. 2016 Oct 26;6:35807. doi: 10.1038/srep35807.
• [563] Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway.Oncol Lett. 2018 Aug;16(2):1634-1640. doi: 10.3892/ol.2018.8849. Epub 2018 May 31.
• [564] KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma.Tissue Cell. 2019 Dec;61:44-50. doi: 10.1016/j.tice.2019.09.001. Epub 2019 Sep 3.
• [565] KLF15 suppresses cell growth and predicts prognosis in lung adenocarcinoma.Biomed Pharmacother. 2018 Oct;106:672-677. doi: 10.1016/j.biopha.2018.07.006. Epub 2018 Jul 11.
• [566] Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1.
• [567] miR-1236-3p suppresses the migration and invasion by targeting KLF8 in lung adenocarcinoma A549cells.Biochem Biophys Res Commun. 2017 Oct 21;492(3):461-467. doi: 10.1016/j.bbrc.2017.08.074. Epub 2017 Aug 24.
• [568] The drs tumor suppressor regulates glucose metabolism via lactate dehydrogenase-B.Mol Carcinog. 2016 Jan;55(1):52-63. doi: 10.1002/mc.22258. Epub 2015 Jan 24.
• [569] MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8411-8421. doi: 10.26355/eurrev_201910_19152.
• [570] Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules.J Thorac Oncol. 2018 Nov;13(11):1776-1783. doi: 10.1016/j.jtho.2018.07.097. Epub 2018 Aug 16.
• [571] Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas.Int J Cancer. 1996 Apr 10;66(2):274-9. doi: 10.1002/(SICI)1097-0215(19960410)66:2<274::AID-IJC23>3.0.CO;2-B.
• [572] Prognostic significance of minichromosome maintenance mRNA expression in human lung adenocarcinoma.Oncol Rep. 2019 Dec;42(6):2279-2292. doi: 10.3892/or.2019.7330. Epub 2019 Sep 23.
• [573] Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.Endocr Relat Cancer. 2006 Mar;13(1):113-34. doi: 10.1677/erc.1.01118.
• [574] In vivo and in vitro effects of hyperplasia suppressor gene on the proliferation and apoptosis of lung adenocarcinoma A549 cells.Biosci Rep. 2018 Oct 2;38(5):BSR20180391. doi: 10.1042/BSR20180391. Print 2018 Oct 31.
• [575] MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment.Mol Cancer. 2010 Mar 17;9:62. doi: 10.1186/1476-4598-9-62.
• [576] Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy.Cell Biol Int. 2010 Jan 25;34(2):185-8. doi: 10.1042/CBI20090148.
• [577] Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas.Int J Mol Med. 2005 Oct;16(4):771-4.
• [578] Long non-coding RNA MUC5B-AS1 promotes metastasis through mutually regulating MUC5B expression in lung adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):450. doi: 10.1038/s41419-018-0472-6.
• [579] MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis.EMBO J. 2012 Jan 18;31(2):481-93. doi: 10.1038/emboj.2011.416. Epub 2011 Nov 15.
• [580] A new polymorphism (Ser362Thr) of the L-myc gene is not associated with lung adenocarcinoma risk and prognosis.Eur J Cancer Prev. 2004 Feb;13(1):87-9. doi: 10.1097/00008469-200402000-00014.
• [581] Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.Mol Med Rep. 2015 May;11(5):3523-32. doi: 10.3892/mmr.2014.3141. Epub 2014 Dec 30.
• [582] Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.Oncotarget. 2016 Oct 18;7(42):68360-68370. doi: 10.18632/oncotarget.11721.
• [583] Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma.J Thorac Oncol. 2007 Sep;2(9):796-801. doi: 10.1097/JTO.0b013e318145af5e.
• [584] Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma.Mol Cancer. 2007 Oct 29;6:70. doi: 10.1186/1476-4598-6-70.
• [585] Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):359-73. doi: 10.1016/j.taap.2015.08.008. Epub 2015 Aug 20.
• [586] Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema.Lung Cancer. 2011 Oct;74(1):12-24. doi: 10.1016/j.lungcan.2011.02.006. Epub 2011 Mar 11.
• [587] MiR-1-3p Inhibits Lung Adenocarcinoma Cell Tumorigenesis via Targeting Protein Regulator of Cytokinesis 1.Front Oncol. 2019 Mar 1;9:120. doi: 10.3389/fonc.2019.00120. eCollection 2019.
• [588] Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma.Int J Cancer. 2019 Apr 1;144(7):1723-1734. doi: 10.1002/ijc.31865. Epub 2018 Dec 12.
• [589] Tobacco smoke activates human papillomavirus 16 p97 promoter and cooperates with high-risk E6/E7 for oxidative DNA damage in lung cells.PLoS One. 2015 Apr 1;10(4):e0123029. doi: 10.1371/journal.pone.0123029. eCollection 2015.
• [590] Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway.Cell Prolif. 2019 May;52(3):e12610. doi: 10.1111/cpr.12610. Epub 2019 Apr 22.
• [591] A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma.Cancer Biol Ther. 2019;20(8):1127-1135. doi: 10.1080/15384047.2019.1598762. Epub 2019 Apr 12.
• [592] RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma.Oncogene. 2017 Aug 31;36(35):5083. doi: 10.1038/onc.2017.191. Epub 2017 Jun 12.
• [593] Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB.Oncotarget. 2018 Jul 31;9(59):31559. doi: 10.18632/oncotarget.25943. eCollection 2018 Jul 31.
• [594] Prolonged survival of patients with colorectal cancer is associated with a higher regucalcin gene expression: Overexpression of regucalcin suppresses the growth of human colorectal carcinoma cells invitro.Int J Oncol. 2018 Sep;53(3):1313-1322. doi: 10.3892/ijo.2018.4458. Epub 2018 Jun 28.
• [595] Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1).J Biol Chem. 2016 Jul 22;291(30):15641-52. doi: 10.1074/jbc.M116.714196. Epub 2016 May 18.
• [596] Decreased expression of RPS15A suppresses proliferation of lung cancer cells.Tumour Biol. 2015 Sep;36(9):6733-40. doi: 10.1007/s13277-015-3371-9. Epub 2015 Apr 3.
• [597] Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma.Mol Cancer Res. 2018 Nov;16(11):1737-1749. doi: 10.1158/1541-7786.MCR-18-0392. Epub 2018 Jul 12.
• [598] Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer.Hum Mol Genet. 2016 Apr 15;25(8):1457-67. doi: 10.1093/hmg/ddw014. Epub 2016 Jan 19.
• [599] The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.PLoS One. 2015 Nov 18;10(11):e0143376. doi: 10.1371/journal.pone.0143376. eCollection 2015.
• [600] Effects of Slit3 silencing on the invasive ability of lung carcinoma A549 cells.Oncol Rep. 2015 Aug;34(2):952-60. doi: 10.3892/or.2015.4031. Epub 2015 Jun 5.
• [601] Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.Cancer Res. 2017 Apr 1;77(7):1719-1729. doi: 10.1158/0008-5472.CAN-16-2159. Epub 2017 Feb 15.
• [602] Inactivation of SMARCA2 by promoter hypermethylation drives lung cancer development.Gene. 2019 Mar 1;687:193-199. doi: 10.1016/j.gene.2018.11.032. Epub 2018 Nov 14.
• [603] The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.J Cell Physiol. 2019 Jul;234(7):10918-10925. doi: 10.1002/jcp.27917. Epub 2018 Dec 13.
• [604] LncRNA LINC00857 regulates lung adenocarcinoma progression, apoptosis and glycolysis by targeting miR-1179/SPAG5 axis.Hum Cell. 2020 Jan;33(1):195-204. doi: 10.1007/s13577-019-00296-8. Epub 2019 Oct 30.
• [605] Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with Lung Adenocarcinoma.PLoS One. 2019 Jul 19;14(7):e0219467. doi: 10.1371/journal.pone.0219467. eCollection 2019.
• [606] Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.Cancer Res. 2014 Feb 15;74(4):1105-15. doi: 10.1158/0008-5472.CAN-13-1481. Epub 2013 Dec 26.
• [607] LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.Int J Mol Sci. 2019 Apr 16;20(8):1874. doi: 10.3390/ijms20081874.
• [608] TRB3 interacts with ERK and JNK and contributes to the proliferation, apoptosis, and migration of lung adenocarcinoma cells.J Cell Physiol. 2020 Jan;235(1):538-547. doi: 10.1002/jcp.28993. Epub 2019 Jun 29.
• [609] Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.
• [610] Methyl-CpG Binding Domain Protein 2 Inhibits the Malignant Characteristic of Lung Adenocarcinoma through the Epigenetic Modulation of 10 to 11 Translocation 1 and miR-200s.Am J Pathol. 2019 May;189(5):1065-1076. doi: 10.1016/j.ajpath.2019.01.010. Epub 2019 Feb 5.
• [611] Strong invitro and vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives.Eur J Med Chem. 2019 Dec 15;184:111751. doi: 10.1016/j.ejmech.2019.111751. Epub 2019 Oct 2.
• [612] Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth.Cell Death Dis. 2016 Dec 22;7(12):e2528. doi: 10.1038/cddis.2016.432.
• [613] Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.Cancer Sci. 2020 Feb;111(2):637-646. doi: 10.1111/cas.14226. Epub 2020 Jan 17.
• [614] Deficiency of Functional Iron-Sulfur Domains in ABCE1 Inhibits the Proliferation and Migration of Lung Adenocarcinomas By Regulating the Biogenesis of Beta-Actin In Vitro.Cell Physiol Biochem. 2017;44(2):554-566. doi: 10.1159/000485090. Epub 2017 Nov 17.
• [615] Human alpha beta hydrolase domain containing protein 11 and its yeast homolog are lipid hydrolases.Biochem Biophys Res Commun. 2017 Jun 10;487(4):875-880. doi: 10.1016/j.bbrc.2017.04.145. Epub 2017 Apr 29.
• [616] Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17.
• [617] Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis.Mol Cancer Ther. 2018 Nov;17(11):2427-2438. doi: 10.1158/1535-7163.MCT-17-1198. Epub 2018 Sep 6.
• [618] Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma.EBioMedicine. 2018 Jan;27:167-175. doi: 10.1016/j.ebiom.2017.12.005. Epub 2017 Dec 6.
• [619] Function of low ADARB1 expression in lung adenocarcinoma.PLoS One. 2019 Sep 6;14(9):e0222298. doi: 10.1371/journal.pone.0222298. eCollection 2019.
• [620] miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.Biochem Biophys Res Commun. 2014 Mar 28;446(1):179-86. doi: 10.1016/j.bbrc.2014.02.073. Epub 2014 Feb 28.
• [621] Promoter methylation profiles between human lung adenocarcinoma multidrug resistant A549/cisplatin (A549/DDP) cells and its progenitor A549 cells.Biol Pharm Bull. 2013;36(8):1310-6. doi: 10.1248/bpb.b13-00153.
• [622] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.
• [623] Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma.Mol Carcinog. 2009 Dec;48(12):1116-22. doi: 10.1002/mc.20563.
• [624] Long noncoding RNA ZFPM2-AS1 is involved in lung adenocarcinoma via miR-511-3p/AFF4 pathway.J Cell Biochem. 2020 Mar;121(3):2534-2542. doi: 10.1002/jcb.29476. Epub 2019 Nov 6.
• [625] Overexpression of human Argonaute2 inhibits cell and tumor growth.Biochim Biophys Acta. 2013 Mar;1830(3):2553-61. doi: 10.1016/j.bbagen.2012.11.013.
• [626] A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma.Sci Rep. 2019 Aug 23;9(1):12329. doi: 10.1038/s41598-019-48243-9.
• [627] Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1 to drive lung adenocarcinoma metastasis.J Hematol Oncol. 2019 Jan 29;12(1):12. doi: 10.1186/s13045-019-0698-5.
• [628] Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.Mol Cancer Res. 2018 Jul;16(7):1161-1171. doi: 10.1158/1541-7786.MCR-18-0042. Epub 2018 May 2.
• [629] 15-Lipoxygenase-2/15(S)-hydroxyeicosatetraenoic acid regulates cell proliferation and metastasis via the STAT3 pathway in lung adenocarcinoma.Prostaglandins Other Lipid Mediat. 2018 Sep;138:31-40. doi: 10.1016/j.prostaglandins.2018.07.003. Epub 2018 Aug 12.
• [630] Identification of a panel of mitotic spindle-related genes as a signature predicting survival in lung adenocarcinoma.J Cell Physiol. 2020 May;235(5):4361-4375. doi: 10.1002/jcp.29312. Epub 2019 Oct 21.
• [631] APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.EBioMedicine. 2019 Jun;44:138-149. doi: 10.1016/j.ebiom.2019.05.028. Epub 2019 May 16.
• [632] Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.Mult Scler Relat Disord. 2020 Jan;37:101447. doi: 10.1016/j.msard.2019.101447. Epub 2019 Oct 14.
• [633] Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma.Interact Cardiovasc Thorac Surg. 2017 Dec 1;25(6):856-861. doi: 10.1093/icvts/ivx202.
• [634] miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM.Cancer Res. 2014 Jun 1;74(11):3031-42. doi: 10.1158/0008-5472.CAN-13-2193. Epub 2014 Apr 7.
• [635] Rho Guanine Nucleotide Exchange Factor 5 Increases Lung Cancer Cell Tumorigenesis via MMP-2 and Cyclin D1 Upregulation.Mol Cancer Ther. 2015 Jul;14(7):1671-9. doi: 10.1158/1535-7163.MCT-14-0724. Epub 2015 Mar 16.
• [636] -PIX controls intracellular viscoelasticity to regulate lung cancer cell migration.J Cell Mol Med. 2015 May;19(5):934-47. doi: 10.1111/jcmm.12441. Epub 2015 Feb 16.
• [637] Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma.Neoplasma. 2019 May 23;66(3):487-493. doi: 10.4149/neo_2018_181029N805. Epub 2019 Mar 7.
• [638] Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.Cell Rep. 2017 Sep 19;20(12):2846-2859. doi: 10.1016/j.celrep.2017.08.087.
• [639] Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State.Front Cell Dev Biol. 2019 Oct 15;7:238. doi: 10.3389/fcell.2019.00238. eCollection 2019.
• [640] An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.J Thorac Oncol. 2018 Nov;13(11):1676-1691. doi: 10.1016/j.jtho.2018.07.096. Epub 2018 Aug 16.
• [641] In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.Cancer Discov. 2020 Feb;10(2):270-287. doi: 10.1158/2159-8290.CD-19-0780. Epub 2019 Nov 19.
• [642] ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells.J Cell Sci. 2010 Apr 1;123(Pt 7):1171-80. doi: 10.1242/jcs.062034.
• [643] Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma.Int J Biol Markers. 2017 Jul 24;32(3):e325-e332. doi: 10.5301/ijbm.5000275.
• [644] Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib.Sci Rep. 2017 Dec 19;7(1):17814. doi: 10.1038/s41598-017-18165-5.
• [645] Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.PLoS One. 2012;7(10):e48532. doi: 10.1371/journal.pone.0048532. Epub 2012 Oct 31.
• [646] ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma.Cancer Res. 2019 Oct 15;79(20):5159-5166. doi: 10.1158/0008-5472.CAN-19-0647. Epub 2019 Sep 3.
• [647] MicroRNA profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma.J Cell Biochem. 2015 Mar;116(3):458-66. doi: 10.1002/jcb.24999.
• [648] B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells.J Clin Med. 2019 Nov 9;8(11):1928. doi: 10.3390/jcm8111928.
• [649] Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis.Cancer Biol Ther. 2010 May 15;9(10):832-40. doi: 10.4161/cbt.9.10.11589. Epub 2010 May 23.
• [650] The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis.PLoS One. 2012;7(9):e38046. doi: 10.1371/journal.pone.0038046. Epub 2012 Sep 26.
• [651] BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma.Int J Cancer. 2017 Nov 15;141(10):2050-2061. doi: 10.1002/ijc.30906. Epub 2017 Aug 7.
• [652] The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.Metallomics. 2015 Mar;7(3):553-66. doi: 10.1039/c5mt00037h.
• [653] Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis.Sci Rep. 2019 Oct 10;9(1):14624. doi: 10.1038/s41598-019-50874-x.
• [654] Up-regulation of C5orf34 promotes lung adenocarcinoma migration and is correlated with worse prognosis.Gene. 2019 May 15;696:47-53. doi: 10.1016/j.gene.2019.02.019. Epub 2019 Feb 13.
• [655] Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D-mediated tube formation in endothelial cells.Oncotarget. 2017 Aug 7;8(48):83913-83924. doi: 10.18632/oncotarget.19996. eCollection 2017 Oct 13.
• [656] Differentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis.Cancer Med. 2018 Apr;7(4):1081-1092. doi: 10.1002/cam4.1363. Epub 2018 Mar 9.
• [657] The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR.J Thorac Dis. 2017 Aug;9(8):2397-2403. doi: 10.21037/jtd.2017.07.02.
• [658] CASTOR1 suppresses the progression of lung adenocarcinoma and predicts poor prognosis.J Cell Biochem. 2018 Dec;119(12):10186-10194. doi: 10.1002/jcb.27360. Epub 2018 Aug 21.
• [659] A systematic analysis reveals gene expression alteration of serum deprivation response (SDPR) gene is significantly associated with the survival of patients with cancer.Oncol Rep. 2019 Sep;42(3):1161-1172. doi: 10.3892/or.2019.7212. Epub 2019 Jun 26.
• [660] ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.Oncogene. 2019 Jun;38(26):5142-5157. doi: 10.1038/s41388-019-0785-7. Epub 2019 Mar 20.
• [661] Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.Cancer Res. 2018 Sep 1;78(17):4984-4996. doi: 10.1158/0008-5472.CAN-17-3858. Epub 2018 Jun 26.
• [662] Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer Sci. 2013 Jul;104(7):896-903. doi: 10.1111/cas.12175. Epub 2013 May 12.
• [663] The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells.J Hematol Oncol. 2018 May 31;11(1):74. doi: 10.1186/s13045-018-0557-9.
• [664] High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.Thorac Cancer. 2018 Jul;9(7):775-784. doi: 10.1111/1759-7714.12643. Epub 2018 May 2.
• [665] The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.Cancer Immunol Res. 2019 Nov;7(11):1775-1788. doi: 10.1158/2326-6066.CIR-19-0168. Epub 2019 Sep 4.
• [666] Design, synthesis and cytotoxicity studies of novel pyrazolo[1, 5-a]pyridine derivatives.Eur J Med Chem. 2017 Jan 27;126:277-285. doi: 10.1016/j.ejmech.2016.11.037. Epub 2016 Nov 17.
• [667] Effects of tetraspanin CD151 inhibition on A549 human lung adenocarcinoma cells.Mol Med Rep. 2015 Feb;11(2):1258-65. doi: 10.3892/mmr.2014.2774. Epub 2014 Oct 27.
• [668] A systematic analysis of immune genes and overall survival in cancer patients.BMC Cancer. 2019 Dec 16;19(1):1225. doi: 10.1186/s12885-019-6414-6.
• [669] EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.Biochim Biophys Acta. 2015 Jul;1852(7):1540-9. doi: 10.1016/j.bbadis.2015.04.020. Epub 2015 Apr 23.
• [670] CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle.Pathol Res Pract. 2019 Nov;215(11):152559. doi: 10.1016/j.prp.2019.152559. Epub 2019 Aug 1.
• [671] Homophilic complex formation of CDCP1 via the extracellular CUB2 domain facilitates SFK activation and promotes cancer cell migration.Oncol Rep. 2019 Oct;42(4):1507-1516. doi: 10.3892/or.2019.7271. Epub 2019 Aug 8.
• [672] The strong propensity of Cadherin-23 for aggregation inhibits cell migration.Mol Oncol. 2019 May;13(5):1092-1109. doi: 10.1002/1878-0261.12469. Epub 2019 Mar 19.
• [673] CDK10 is not a target for aberrant DNA methylation in breast cancer.Anticancer Res. 2009 Oct;29(10):3939-44.
• [674] Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.Mol Cancer Res. 2014 Jun;12(6):912-23. doi: 10.1158/1541-7786.MCR-13-0620-T. Epub 2014 Mar 11.
• [675] Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma.Br J Cancer. 2015 Dec 22;113(12):1735-43. doi: 10.1038/bjc.2015.378. Epub 2015 Nov 10.
• [676] Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.Clin Cancer Res. 2018 Sep 1;24(17):4089-4097. doi: 10.1158/1078-0432.CCR-18-0483. Epub 2018 Jul 17.
• [677] Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.Br J Cancer. 2012 Nov 6;107(10):1745-53. doi: 10.1038/bjc.2012.422. Epub 2012 Oct 25.
• [678] Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.Pathol Res Pract. 2019 Feb;215(2):292-301. doi: 10.1016/j.prp.2018.11.016. Epub 2018 Nov 24.
• [679] CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.Thorac Cancer. 2018 May;9(5):652-655. doi: 10.1111/1759-7714.12617. Epub 2018 Mar 8.
• [680] CFHR1 is a potentially downregulated gene in lung adenocarcinoma.Mol Med Rep. 2019 Oct;20(4):3642-3648. doi: 10.3892/mmr.2019.10644. Epub 2019 Sep 3.
• [681] Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.Oncotarget. 2015 Oct 13;6(31):31181-90. doi: 10.18632/oncotarget.5070.
• [682] Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).J Cancer Res Clin Oncol. 2019 Sep;145(9):2285-2292. doi: 10.1007/s00432-019-02989-x. Epub 2019 Aug 1.
• [683] CHRNA3 polymorphism modifies lung adenocarcinoma risk in the Chinese Han population.Int J Mol Sci. 2014 Mar 28;15(4):5446-57. doi: 10.3390/ijms15045446.
• [684] Up-regulation of CKAP2L expression promotes lung adenocarcinoma invasion and is associated with poor prognosis.Onco Targets Ther. 2019 Feb 12;12:1171-1180. doi: 10.2147/OTT.S182242. eCollection 2019.
• [685] Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells.Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):769-780. doi: 10.1016/j.bbamcr.2018.03.001. Epub 2018 Mar 7.
• [686] Caffeic acid phenethyl ester down-regulates claudin-2 expression at the transcriptional and post-translational levels and enhances chemosensitivity to doxorubicin in lung adenocarcinoma A549 cells. J Nutr Biochem. 2018 Jun;56:205-214. doi: 10.1016/j.jnutbio.2018.02.016. Epub 2018 Mar 2.
• [687] Identification and association study with lung cancer for novel insertion polymorphisms of human endogenous retrovirus.Carcinogenesis. 2013 Nov;34(11):2531-8. doi: 10.1093/carcin/bgt253. Epub 2013 Jul 19.
• [688] Methylation of CLEC14A is associated with its expression and lung adenocarcinoma progression.J Cell Physiol. 2019 Mar;234(3):2954-2962. doi: 10.1002/jcp.27112. Epub 2018 Sep 7.
• [689] Calsyntenin-1, clusterin and neutrophil gelatinase-associated lipocalin are candidate serological biomarkers for lung adenocarcinoma.Oncotarget. 2017 Nov 14;8(64):107964-107976. doi: 10.18632/oncotarget.22438. eCollection 2017 Dec 8.
• [690] COL5A1 may contribute the metastasis of lung adenocarcinoma.Gene. 2018 Jul 30;665:57-66. doi: 10.1016/j.gene.2018.04.066. Epub 2018 Apr 24.
• [691] COPB2 promotes cell proliferation and tumorigenesis through up-regulating YAP1 expression in lung adenocarcinoma cells.Biomed Pharmacother. 2018 Jul;103:373-380. doi: 10.1016/j.biopha.2018.04.006. Epub 2018 Apr 24.
• [692] Downregulation of cytochrome c oxidase subunit 7A1 expression is important in enhancing cell proliferation in adenocarcinoma cells.Biochem Biophys Res Commun. 2017 Jan 22;482(4):713-719. doi: 10.1016/j.bbrc.2016.11.100. Epub 2016 Nov 17.
• [693] Interleukin-1 provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma.Oncoimmunology. 2019 Apr 11;8(7):1593802. doi: 10.1080/2162402X.2019.1593802. eCollection 2019.
• [694] Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.Carcinogenesis. 2014 Jun;35(6):1248-57. doi: 10.1093/carcin/bgt494. Epub 2014 Jan 7.
• [695] CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer.Oncol Lett. 2019 Sep;18(3):2835-2844. doi: 10.3892/ol.2019.10659. Epub 2019 Jul 24.
• [696] Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer.Oncol Lett. 2018 Feb;15(2):2661-2668. doi: 10.3892/ol.2017.7591. Epub 2017 Dec 12.
• [697] Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma.Cancers (Basel). 2019 Nov 7;11(11):1750. doi: 10.3390/cancers11111750.
• [698] High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients.Cancer Cell Int. 2019 Nov 29;19:318. doi: 10.1186/s12935-019-1041-5. eCollection 2019.
• [699] Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas.Stem Cells. 2015 Dec;33(12):3423-36. doi: 10.1002/stem.2188. Epub 2015 Sep 26.
• [700] The Expression Pattern of p120-Catenin is Associated With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):64-70. doi: 10.1097/PAI.0000000000000381.
• [701] -Catenin promotes tumorigenesis and metastasis of lung adenocarcinoma.Oncol Rep. 2018 Feb;39(2):809-817. doi: 10.3892/or.2017.6140. Epub 2017 Dec 8.
• [702] Localization of the invadopodia-related proteins actinin-1 and cortactin to matrix-contact-side cytoplasm of cancer cells in surgically resected lung adenocarcinomas.Pathobiology. 2011;78(1):10-23. doi: 10.1159/000322734. Epub 2011 Apr 5.
• [703] CUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma.Oncotarget. 2015 Aug 21;6(24):20685-96. doi: 10.18632/oncotarget.3930.
• [704] NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B.J Cell Mol Med. 2019 Oct;23(10):6965-6977. doi: 10.1111/jcmm.14581. Epub 2019 Aug 26.
• [705] Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17.Cell Oncol (Dordr). 2020 Apr;43(2):311-320. doi: 10.1007/s13402-019-00491-7. Epub 2019 Dec 12.
• [706] Cytoglobin has bimodal: tumour suppressor and oncogene functions in lung cancer cell lines.Hum Mol Genet. 2013 Aug 15;22(16):3207-17. doi: 10.1093/hmg/ddt174. Epub 2013 Apr 15.
• [707] Design of Block Copolymer Micellar Aggregates for Co-Delivery of Enzyme and Anticancer Prodrug.Chem Asian J. 2017 Jan 17;12(2):176-180. doi: 10.1002/asia.201601198. Epub 2016 Dec 14.
• [708] miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2.Mol Ther Nucleic Acids. 2019 Dec 6;18:627-637. doi: 10.1016/j.omtn.2019.09.025. Epub 2019 Oct 3.
• [709] 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12961-6. eCollection 2015.
• [710] Selective Cu(I) complex with phosphine-peptide (SarGly) conjugate contra breast cancer: Synthesis, spectroscopic characterization and insight into cytotoxic action.J Inorg Biochem. 2018 Sep;186:162-175. doi: 10.1016/j.jinorgbio.2018.06.009. Epub 2018 Jun 18.
• [711] EGFR and Ras regulate DDX59 during lung cancer development.Gene. 2018 Feb 5;642:95-102. doi: 10.1016/j.gene.2017.11.029. Epub 2017 Nov 10.
• [712] Long Noncoding RNA LINC00472 Inhibits Proliferation and Promotes Apoptosis of Lung Adenocarcinoma Cells via Regulating miR-24-3p/ DEDD.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818790490. doi: 10.1177/1533033818790490.
• [713] The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma.EMBO Mol Med. 2019 Dec;11(12):e10849. doi: 10.15252/emmm.201910849. Epub 2019 Oct 21.
• [714] DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3.Am J Transl Res. 2019 Aug 15;11(8):4881-4894. eCollection 2019.
• [715] DIAPH3 promotes the tumorigenesis of lung adenocarcinoma.Exp Cell Res. 2019 Dec 1;385(1):111662. doi: 10.1016/j.yexcr.2019.111662. Epub 2019 Oct 3.
• [716] DKK4-knockdown enhances chemosensitivity of A549/DTX cells to docetaxel.Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):899-906. doi: 10.1093/abbs/gmx086.
• [717] DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.Oncotarget. 2016 Jul 19;7(29):45144-45157. doi: 10.18632/oncotarget.9266.
• [718] DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell.Cancer Lett. 2019 Jul 1;453:45-56. doi: 10.1016/j.canlet.2019.03.045. Epub 2019 Mar 27.
• [719] Effects of Dynamin-related Protein 1 Regulated Mitochondrial Dynamic Changes on Invasion and Metastasis of Lung Cancer Cells.J Cancer. 2019 Jul 8;10(17):4045-4053. doi: 10.7150/jca.29756. eCollection 2019.
• [720] TGF-/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis.Genes Dev. 2015 Feb 1;29(3):250-61. doi: 10.1101/gad.248963.114.
• [721] DRG1 is a potential oncogene in lung adenocarcinoma and promotes tumor progression via spindle checkpoint signaling regulation.Oncotarget. 2016 Nov 8;7(45):72795-72806. doi: 10.18632/oncotarget.11973.
• [722] Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival.Br J Cancer. 2010 Dec 7;103(12):1870-4. doi: 10.1038/sj.bjc.6605976. Epub 2010 Nov 23.
• [723] Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.Aging (Albany NY). 2018 May 11;10(5):973-987. doi: 10.18632/aging.101441.
• [724] SNHG6 functions as a competing endogenous RNA to regulate E2F7 expression by sponging miR-26a-5p in lung adenocarcinoma.Biomed Pharmacother. 2018 Nov;107:1434-1446. doi: 10.1016/j.biopha.2018.08.099. Epub 2018 Sep 1.
• [725] Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.PLoS One. 2013 Nov 18;8(11):e79542. doi: 10.1371/journal.pone.0079542. eCollection 2013.
• [726] Beclin 1 promotes apoptosis and decreases invasion by upregulating the expression of ECRG4 in A549 human lung adenocarcinoma cells.Mol Med Rep. 2016 Jul;14(1):355-60. doi: 10.3892/mmr.2016.5219. Epub 2016 May 6.
• [727] Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma.Sci Rep. 2017 Aug 17;7(1):8649. doi: 10.1038/s41598-017-08851-9.
• [728] Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F.Oncogene. 2020 Jan;39(3):617-636. doi: 10.1038/s41388-019-1009-x. Epub 2019 Sep 16.
• [729] Overexpression of miR-519d in lung adenocarcinoma inhibits cell proliferation and invasion via the association of eIF4H.Tumour Biol. 2017 Mar;39(3):1010428317694566. doi: 10.1177/1010428317694566.
• [730] Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.Nat Commun. 2019 Nov 28;10(1):5438. doi: 10.1038/s41467-019-13295-y.
• [731] ELK1-induced upregulation of lncRNA HOXA10-AS promotes lung adenocarcinoma progression by increasing Wnt/-catenin signaling.Biochem Biophys Res Commun. 2018 Jun 27;501(3):612-618. doi: 10.1016/j.bbrc.2018.04.224.
• [732] Image analysis of the nuclear characteristics of emerin protein and the correlation with nuclear grooves and intranuclear cytoplasmic inclusions in lung adenocarcinoma.Oncol Rep. 2019 Jan;41(1):133-142. doi: 10.3892/or.2018.6848. Epub 2018 Nov 2.
• [733] ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways.J Cancer. 2019 Jul 5;10(17):3975-3984. doi: 10.7150/jca.30021. eCollection 2019.
• [734] Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma.Int J Oncol. 2019 May;54(5):1747-1758. doi: 10.3892/ijo.2019.4732. Epub 2019 Feb 27.
• [735] Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.Gene. 2019 Apr 5;691:70-76. doi: 10.1016/j.gene.2018.12.028. Epub 2018 Dec 22.
• [736] Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.Lung Cancer. 2017 Dec;114:79-89. doi: 10.1016/j.lungcan.2017.10.012. Epub 2017 Oct 31.
• [737] Suppression subtractive hybridization identified differentially expressed genes in lung adenocarcinoma: ERGIC3 as a novel lung cancer-related gene.BMC Cancer. 2013 Feb 1;13:44. doi: 10.1186/1471-2407-13-44.
• [738] Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers.Oncol Rep. 2018 Mar;39(3):929-938. doi: 10.3892/or.2018.6197. Epub 2018 Jan 8.
• [739] Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.Lung Cancer. 2017 Jul;109:21-27. doi: 10.1016/j.lungcan.2017.04.009. Epub 2017 Apr 21.
• [740] DNA methylation profiling identifies the HOXA11 gene as an early diagnostic and prognostic molecular marker in human lung adenocarcinoma.Oncotarget. 2017 May 16;8(20):33100-33109. doi: 10.18632/oncotarget.16528.
• [741] High FA2H and UGT8 transcript levels predict hydroxylated hexosylceramide accumulation in lung adenocarcinoma.J Lipid Res. 2019 Oct;60(10):1776-1786. doi: 10.1194/jlr.M093955. Epub 2019 Aug 13.
• [742] LFG-500, a novel synthetic flavonoid, suppresses epithelial-mesenchymal transition in human lung adenocarcinoma cells by inhibiting NLRP3 in inflammatory microenvironment.Cancer Lett. 2017 Aug 1;400:137-148. doi: 10.1016/j.canlet.2017.04.035. Epub 2017 Apr 29.
• [743] FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma.Onco Targets Ther. 2019 Apr 17;12:2829-2842. doi: 10.2147/OTT.S190934. eCollection 2019.
• [744] A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.Nat Genet. 2012 Jul 15;44(8):900-3. doi: 10.1038/ng.2353.
• [745] Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.PLoS One. 2013 Jun 10;8(6):e67054. doi: 10.1371/journal.pone.0067054. Print 2013.
• [746] Identification of transcription factors that may reprogram lung adenocarcinoma.Artif Intell Med. 2017 Nov;83:52-57. doi: 10.1016/j.artmed.2017.03.010. Epub 2017 Apr 1.
• [747] FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.Cell Death Dis. 2019 Jun 19;10(7):486. doi: 10.1038/s41419-019-1732-9.
• [748] Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.J Thorac Oncol. 2016 Feb;11(2):203-12. doi: 10.1016/j.jtho.2015.10.005. Epub 2015 Dec 19.
• [749] Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.J Natl Cancer Inst. 2011 Sep 7;103(17):1323-37. doi: 10.1093/jnci/djr290. Epub 2011 Aug 10.
• [750] Kindlin-2 links mechano-environment to proline synthesis and tumor growth.Nat Commun. 2019 Feb 19;10(1):845. doi: 10.1038/s41467-019-08772-3.
• [751] FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma.J Mol Med (Berl). 2019 Dec;97(12):1657-1668. doi: 10.1007/s00109-019-01848-z. Epub 2019 Nov 28.
• [752] Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819827317. doi: 10.1177/1533033819827317.
• [753] Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.J Pathol. 2019 Oct;249(2):193-205. doi: 10.1002/path.5290. Epub 2019 Jun 24.
• [754] Loss of FGL1 induces epithelialmesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma.Int J Oncol. 2019 Sep;55(3):697-707. doi: 10.3892/ijo.2019.4838. Epub 2019 Jul 15.
• [755] Overexpression of fibronectin type III domain containing 3B is correlated with epithelial-mesenchymal transition and predicts poor prognosis in lung adenocarcinoma.Exp Ther Med. 2019 May;17(5):3317-3326. doi: 10.3892/etm.2019.7370. Epub 2019 Mar 12.
• [756] LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response.Cancer Res. 2019 Jun 15;79(12):3050-3062. doi: 10.1158/0008-5472.CAN-18-2034. Epub 2019 Feb 22.
• [757] Tumor suppression function of FoxD3 in lung cancer.Ir J Med Sci. 2016 Aug;185(3):547-553. doi: 10.1007/s11845-015-1297-2. Epub 2015 Apr 17.
• [758] Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.Nat Commun. 2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.
• [759] Clinical value of microRNA-198-5p downregulation in lung adenocarcinoma and its potential pathways.Oncol Lett. 2019 Sep;18(3):2939-2954. doi: 10.3892/ol.2019.10610. Epub 2019 Jul 12.
• [760] Fucosyltransferase 2 induced epithelial-mesenchymal transition via TGF-/Smad signaling pathway in lung adenocarcinaoma.Exp Cell Res. 2018 Sep 15;370(2):613-622. doi: 10.1016/j.yexcr.2018.07.026. Epub 2018 Jul 18.
• [761] Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.Int J Cancer. 2019 Feb 15;144(4):788-801. doi: 10.1002/ijc.31975. Epub 2018 Dec 4.
• [762] GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.Oncotarget. 2015 Dec 8;6(39):41916-28. doi: 10.18632/oncotarget.6019.
• [763] Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma.BMC Cancer. 2019 Jul 11;19(1):680. doi: 10.1186/s12885-019-5885-9.
• [764] Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.Mol Cancer. 2019 Jun 20;18(1):108. doi: 10.1186/s12943-019-1027-x.
• [765] GBX2, as a tumor promoter in lung adenocarcinoma, enhances cells viability, invasion and migration by regulating the AKT/ERK signaling pathway.J Gene Med. 2020 Feb;22(2):e3147. doi: 10.1002/jgm.3147. Epub 2019 Dec 20.
• [766] GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.Lung Cancer. 2018 Jan;115:5-11. doi: 10.1016/j.lungcan.2017.10.011. Epub 2017 Oct 27.
• [767] Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.J Thorac Oncol. 2019 Apr;14(4):656-671. doi: 10.1016/j.jtho.2018.12.004. Epub 2018 Dec 19.
• [768] LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Jun 28;38(1):280. doi: 10.1186/s13046-019-1276-y.
• [769] Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.J Exp Clin Cancer Res. 2019 Feb 21;38(1):96. doi: 10.1186/s13046-019-1057-7.
• [770] Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer.Cell Biol Toxicol. 2016 Oct;32(5):419-35. doi: 10.1007/s10565-016-9343-z. Epub 2016 Jun 15.
• [771] Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.
• [772] DNA hypomethylation-related overexpression of SFN, GORASP2 and ZYG11A is a novel prognostic biomarker for early stage lung adenocarcinoma.Oncotarget. 2019 Feb 26;10(17):1625-1636. doi: 10.18632/oncotarget.26676. eCollection 2019 Feb 26.
• [773] miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.Cell Prolif. 2016 Oct;49(5):636-43. doi: 10.1111/cpr.12288. Epub 2016 Aug 24.
• [774] Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation.Cancer Manag Res. 2019 Jun 7;11:5333-5341. doi: 10.2147/CMAR.S204358. eCollection 2019.
• [775] Up-regulation of long non-coding RNA SPRY4-IT1 promotes tumor cell migration and invasion in lung adenocarcinoma.Oncotarget. 2017 Apr 7;8(31):51058-51065. doi: 10.18632/oncotarget.16918. eCollection 2017 Aug 1.
• [776] Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.Int J Cancer. 2017 Oct 15;141(8):1589-1599. doi: 10.1002/ijc.30851. Epub 2017 Jul 17.
• [777] Solution structure and functional investigation of human guanylate kinase reveals allosteric networking and a crucial role for the enzyme in cancer.J Biol Chem. 2019 Aug 2;294(31):11920-11933. doi: 10.1074/jbc.RA119.009251. Epub 2019 Jun 14.
• [778] Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2305-11. eCollection 2014.
• [779] HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.Theranostics. 2019 Apr 13;9(9):2460-2474. doi: 10.7150/thno.31097. eCollection 2019.
• [780] Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial-Mesenchymal Transition.Am J Respir Crit Care Med. 2016 Apr 15;193(8):869-80. doi: 10.1164/rccm.201412-2226OC.
• [781] A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.BMC Genomics. 2013;14 Suppl 6(Suppl 6):S5. doi: 10.1186/1471-2164-14-S6-S5. Epub 2013 Oct 25.
• [782] YAP mediates the positive regulation of hnRNPK on the lung adenocarcinoma H1299 cell growth.Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):677-687. doi: 10.1093/abbs/gmz053.
• [783] HOPX is methylated and exerts tumour-suppressive function through Ras-induced senescence in human lung cancer.J Pathol. 2015 Feb;235(3):397-407. doi: 10.1002/path.4469. Epub 2014 Dec 18.
• [784] HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress.Cancer Res. 2018 Nov 1;78(21):6196-6208. doi: 10.1158/0008-5472.CAN-18-1377. Epub 2018 Sep 5.
• [785] Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10.J Cell Physiol. 2019 Jul;234(7):11805-11821. doi: 10.1002/jcp.27886. Epub 2019 Feb 4.
• [786] Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.Int J Oncol. 2018 Oct;53(4):1557-1579. doi: 10.3892/ijo.2018.4508. Epub 2018 Jul 30.
• [787] HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells.Anticancer Res. 2008 Jul-Aug;28(4B):2121-7.
• [788] HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.Oncogene. 2018 Jun;37(26):3575-3588. doi: 10.1038/s41388-018-0229-9. Epub 2018 Mar 26.
• [789] HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1.Am J Cancer Res. 2017 Sep 1;7(9):1820-1834. eCollection 2017.
• [790] Regulation of miRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls Cancer Stem-like Features.Cancer Res. 2019 May 15;79(10):2549-2563. doi: 10.1158/0008-5472.CAN-18-2376. Epub 2019 Mar 15.
• [791] Transcription deregulation at the 15q25 locus in association with lung adenocarcinoma risk.Clin Cancer Res. 2009 Mar 1;15(5):1837-42. doi: 10.1158/1078-0432.CCR-08-2107. Epub 2009 Feb 17.
• [792] Inhibitor of DNA-Binding Protein 4 Suppresses Cancer Metastasis through the Regulation of Epithelial Mesenchymal Transition in Lung Adenocarcinoma.Cancers (Basel). 2019 Dec 14;11(12):2021. doi: 10.3390/cancers11122021.
• [793] Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [(18) F]FDG.Cancer Med. 2019 Sep;8(11):5341-5351. doi: 10.1002/cam4.2421. Epub 2019 Jul 29.
• [794] Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.Onco Targets Ther. 2019 Oct 3;12:8139-8149. doi: 10.2147/OTT.S220698. eCollection 2019.
• [795] Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma.Pathol Res Pract. 2019 Jul;215(7):152444. doi: 10.1016/j.prp.2019.152444. Epub 2019 May 6.
• [796] Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma.Thorac Cancer. 2017 Jul;8(4):337-343. doi: 10.1111/1759-7714.12451. Epub 2017 May 23.
• [797] VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.Oncogene. 2019 May;38(21):4169-4181. doi: 10.1038/s41388-019-0715-8. Epub 2019 Jan 30.
• [798] Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer.Tumour Biol. 2017 Apr;39(4):1010428317695928. doi: 10.1177/1010428317695928.
• [799] Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.PLoS One. 2017 Jul 20;12(7):e0181598. doi: 10.1371/journal.pone.0181598. eCollection 2017.
• [800] Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma.Thorac Cancer. 2019 Nov;10(11):2142-2151. doi: 10.1111/1759-7714.13200. Epub 2019 Oct 3.
• [801] Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.J Natl Cancer Inst. 2019 Jul 1;111(7):664-674. doi: 10.1093/jnci/djy166.
• [802] Effect of FAM196B in human lung adenocarcinoma.J Cancer. 2018 Jun 14;9(14):2451-2459. doi: 10.7150/jca.24907. eCollection 2018.
• [803] Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.PLoS One. 2011;6(9):e25301. doi: 10.1371/journal.pone.0025301. Epub 2011 Sep 22.
• [804] Interferon regulatory factor 4 (IRF4) is overexpressed in human nonsmall cell lung cancer (NSCLC) and activates the Notch signaling pathway.Mol Med Rep. 2017 Nov;16(5):6034-6040. doi: 10.3892/mmr.2017.7319. Epub 2017 Aug 22.
• [805] Genome-wide identification of transcription factors that are critical to non-small cell lung cancer.Cancer Lett. 2018 Oct 10;434:132-143. doi: 10.1016/j.canlet.2018.07.020. Epub 2018 Jul 18.
• [806] Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.Int J Mol Med. 2013 Jan;31(1):33-42. doi: 10.3892/ijmm.2012.1171. Epub 2012 Nov 1.
• [807] Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.Epigenetics. 2015;10(10):903-12. doi: 10.1080/15592294.2015.1078049. Epub 2015 Aug 7.
• [808] Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed and functions as an oncogene in several tumor types.Biochem Pharmacol. 2017 Aug 1;137:1-9. doi: 10.1016/j.bcp.2017.03.023. Epub 2017 Apr 2.
• [809] PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6.Nucleic Acids Res. 2016 Dec 15;44(22):10662-10675. doi: 10.1093/nar/gkw808. Epub 2016 Sep 8.
• [810] Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget. 2016 Jun 14;7(24):36101-36114. doi: 10.18632/oncotarget.9137.
• [811] ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.J Cancer Res Clin Oncol. 2015 Feb;141(2):221-7. doi: 10.1007/s00432-014-1807-z. Epub 2014 Aug 26.
• [812] Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.Lung Cancer. 2018 Apr;118:27-29. doi: 10.1016/j.lungcan.2017.08.019. Epub 2017 Sep 4.
• [813] Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.Cancer Res. 2018 Sep 1;78(17):5124-5134. doi: 10.1158/0008-5472.CAN-18-1022. Epub 2018 Jul 9.
• [814] Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.IUBMB Life. 2019 Jul;71(7):942-955. doi: 10.1002/iub.2030. Epub 2019 Feb 28.
• [815] Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis.Cancer Med. 2018 Sep;7(9):4678-4689. doi: 10.1002/cam4.1710. Epub 2018 Aug 13.
• [816] High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma.Biochem Biophys Res Commun. 2018 Feb 26;497(1):65-72. doi: 10.1016/j.bbrc.2018.02.020. Epub 2018 Feb 7.
• [817] Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.Cancer Biomark. 2019;24(3):371-382. doi: 10.3233/CBM-181512.
• [818] Krppel-like Transcription Factor KLF10 Suppresses TGF-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism.Cancer Res. 2017 May 1;77(9):2387-2400. doi: 10.1158/0008-5472.CAN-16-2589. Epub 2017 Mar 1.
• [819] High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients.Genes (Basel). 2019 Jan 10;10(1):36. doi: 10.3390/genes10010036.
• [820] A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma.Front Oncol. 2019 Dec 3;9:1281. doi: 10.3389/fonc.2019.01281. eCollection 2019.
• [821] Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma.Mol Ther Nucleic Acids. 2019 Dec 6;18:166-182. doi: 10.1016/j.omtn.2019.08.005. Epub 2019 Aug 14.
• [822] Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer.Cancers (Basel). 2019 Jan 9;11(1):63. doi: 10.3390/cancers11010063.
• [823] Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.Virchows Arch. 2017 Sep;471(3):375-382. doi: 10.1007/s00428-017-2202-3. Epub 2017 Jul 19.
• [824] miR-17-92/p38 Dysregulation Enhances Wnt Signaling and Selects Lgr6+ Cancer Stem-like Cells during Lung Adenocarcinoma Progression.Cancer Res. 2016 Jul 1;76(13):4012-22. doi: 10.1158/0008-5472.CAN-15-3302. Epub 2016 May 4.
• [825] LHX3 is an early stage and radiosensitivity prognostic biomarker in lung adenocarcinoma.Oncol Rep. 2017 Sep;38(3):1482-1490. doi: 10.3892/or.2017.5833. Epub 2017 Jul 18.
• [826] A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma.Oncogene. 2019 Mar;38(10):1611-1624. doi: 10.1038/s41388-018-0548-x. Epub 2018 Oct 23.
• [827] Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis.J Hum Genet. 2018 Oct;63(10):1015-1028. doi: 10.1038/s10038-018-0497-9. Epub 2018 Aug 6.
• [828] LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.J Exp Clin Cancer Res. 2019 Feb 21;38(1):95. doi: 10.1186/s13046-019-1092-4.
• [829] Lipin-1 determines lung cancer cell survival and chemotherapy sensitivity by regulation of endoplasmic reticulum homeostasis and autophagy.Cancer Med. 2018 Jun;7(6):2541-2554. doi: 10.1002/cam4.1483. Epub 2018 Apr 16.
• [830] Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.BMC Cancer. 2019 Jan 8;19(1):35. doi: 10.1186/s12885-018-5241-5.
• [831] Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.Genome Med. 2018 Jul 20;10(1):55. doi: 10.1186/s13073-018-0562-1.
• [832] Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma.J Am Chem Soc. 2019 Nov 20;141(46):18492-18499. doi: 10.1021/jacs.9b08777. Epub 2019 Nov 11.
• [833] Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma.Cancers (Basel). 2019 Jun 3;11(6):768. doi: 10.3390/cancers11060768.
• [834] Water-soluble variant of human Lynx1 induces cell cycle arrest and apoptosis in lung cancer cells via modulation of 7 nicotinic acetylcholine receptors.PLoS One. 2019 May 31;14(5):e0217339. doi: 10.1371/journal.pone.0217339. eCollection 2019.
• [835] Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.Oncotarget. 2016 Dec 20;7(51):85235-85243. doi: 10.18632/oncotarget.13252.
• [836] LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis.Eur J Pharmacol. 2019 Sep 15;859:172465. doi: 10.1016/j.ejphar.2019.172465. Epub 2019 Jun 15.
• [837] An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.J Pathol. 2014 Oct;234(2):277-88. doi: 10.1002/path.4354. Epub 2014 Aug 18.
• [838] Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor 2 expression.Mol Cell Biol. 2011 Nov;31(21):4270-85. doi: 10.1128/MCB.05562-11. Epub 2011 Sep 6.
• [839] MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.J Clin Invest. 2019 Mar 1;129(3):1015-1029. doi: 10.1172/JCI97712. Epub 2019 Jan 28.
• [840] MARCH9 Suppresses Lung Adenocarcinoma Progression by Downregulating ICAM-1.Cell Physiol Biochem. 2018;50(1):92-107. doi: 10.1159/000493961. Epub 2018 Oct 2.
• [841] Mammalian mediator 19 mediates H1299 lung adenocarcinoma cell clone conformation, growth, and metastasis.Asian Pac J Cancer Prev. 2012;13(8):3695-700. doi: 10.7314/apjcp.2012.13.8.3695.
• [842] Loss of imprinting of PEG1/MEST in lung cancer cell lines.Oncol Rep. 2004 Dec;12(6):1273-8.
• [843] The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.Mol Cell. 2016 May 5;62(3):335-345. doi: 10.1016/j.molcel.2016.03.021. Epub 2016 Apr 21.
• [844] MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer.Cancer Res. 2019 Dec 15;79(24):6215-6226. doi: 10.1158/0008-5472.CAN-19-1982. Epub 2019 Oct 3.
• [845] MID1-PP2A complex functions as new insights in human lung adenocarcinoma.J Cancer Res Clin Oncol. 2018 May;144(5):855-864. doi: 10.1007/s00432-018-2601-0. Epub 2018 Feb 15.
• [846] MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer.Oncotarget. 2016 Feb 23;7(8):9118-34. doi: 10.18632/oncotarget.7001.
• [847] Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma.Front Oncol. 2019 Aug 6;9:556. doi: 10.3389/fonc.2019.00556. eCollection 2019.
• [848] MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway.Cell Death Dis. 2019 Feb 15;10(3):148. doi: 10.1038/s41419-019-1324-8.
• [849] p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.Cancer Sci. 2018 Dec;109(12):3783-3793. doi: 10.1111/cas.13818. Epub 2018 Oct 26.
• [850] Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.Cancer Sci. 2017 Jul;108(7):1394-1404. doi: 10.1111/cas.13271. Epub 2017 Jun 10.
• [851] Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.Oncol Rep. 2011 May;25(5):1243-51. doi: 10.3892/or.2011.1184. Epub 2011 Feb 14.
• [852] MTBP promotes migration and invasion by regulation of ZEB2-mediated epithelial-mesenchymal transition in lung cancer cells.Onco Targets Ther. 2018 Oct 10;11:6741-6756. doi: 10.2147/OTT.S167963. eCollection 2018.
• [853] Prognostic roles of mitochondrial transcription termination factors in non-small cell lung cancer.Oncol Lett. 2019 Oct;18(4):3453-3462. doi: 10.3892/ol.2019.10680. Epub 2019 Jul 29.
• [854] Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma.Clin Exp Metastasis. 2018 Feb;35(1-2):15-23. doi: 10.1007/s10585-017-9869-3. Epub 2017 Dec 7.
• [855] Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.PLoS One. 2019 Apr 11;14(4):e0215237. doi: 10.1371/journal.pone.0215237. eCollection 2019.
• [856] IL-25 promotes cisplatin resistance of lung cancer cells by activating NF-B signaling pathway to increase of major vault protein.Cancer Med. 2019 Jul;8(7):3491-3501. doi: 10.1002/cam4.2213. Epub 2019 May 1.
• [857] LncRNA LOXL1-AS1 regulates the tumorigenesis and development of lung adenocarcinoma through sponging miR-423-5p and targeting MYBL2.Cancer Med. 2020 Jan;9(2):689-699. doi: 10.1002/cam4.2641. Epub 2019 Nov 23.
• [858] Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.Endocr Pathol. 2020 Mar;31(1):39-45. doi: 10.1007/s12022-019-09600-6.
• [859] Identification of an eight-gene prognostic signature for lung adenocarcinoma.Cancer Manag Res. 2018 Sep 10;10:3383-3392. doi: 10.2147/CMAR.S173941. eCollection 2018.
• [860] NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma.J Cell Mol Med. 2017 Apr;21(4):665-676. doi: 10.1111/jcmm.13010. Epub 2016 Nov 15.
• [861] Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.
• [862] Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma.Oncol Lett. 2018 Sep;16(3):3992-4000. doi: 10.3892/ol.2018.9113. Epub 2018 Jul 10.
• [863] Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma.BMC Cancer. 2015 May 2;15:346. doi: 10.1186/s12885-015-1349-z.
• [864] Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
• [865] Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.Mol Cancer Res. 2013 Apr;11(4):329-38. doi: 10.1158/1541-7786.MCR-12-0456. Epub 2013 Jan 30.
• [866] NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma.Elife. 2017 Jul 24;6:e26733. doi: 10.7554/eLife.26733.
• [867] Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling.Oncogene. 2020 Jan;39(2):385-398. doi: 10.1038/s41388-019-0994-0. Epub 2019 Sep 2.
• [868] NFIX downregulation independently predicts poor prognosis in lung adenocarcinoma, but not in squamous cell carcinoma.Future Oncol. 2018 Dec;14(30):3135-3144. doi: 10.2217/fon-2018-0164. Epub 2018 Nov 12.
• [869] NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis.Nature. 2017 Nov 30;551(7682):639-643. doi: 10.1038/nature24637. Epub 2017 Nov 22.
• [870] MiR-142-3p suppresses the proliferation, migration and invasion through inhibition of NR2F6 in lung adenocarcinoma.Hum Cell. 2019 Oct;32(4):437-446. doi: 10.1007/s13577-019-00258-0. Epub 2019 Jun 5.
• [871] Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis.PLoS One. 2016 Apr 4;11(4):e0152918. doi: 10.1371/journal.pone.0152918. eCollection 2016.
• [872] NUP58 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the GSK-3/Snail signaling pathway.Am J Transl Res. 2019 Jan 15;11(1):393-405. eCollection 2019.
• [873] Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma.Ann Surg Oncol. 2014 Dec;21 Suppl 4:S490-6. doi: 10.1245/s10434-013-3452-1. Epub 2014 Jan 14.
• [874] High expression of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) is associated with poor prognosis in lung adenocarcinoma.Pathol Int. 2018 Nov;68(11):596-604. doi: 10.1111/pin.12724. Epub 2018 Oct 15.
• [875] Increase in resistance to anticancer drugs involves occludin in spheroid culture model of lung adenocarcinoma A549 cells.Sci Rep. 2018 Oct 11;8(1):15157. doi: 10.1038/s41598-018-33566-w.
• [876] Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation.PLoS One. 2013 Sep 13;8(9):e72889. doi: 10.1371/journal.pone.0072889. eCollection 2013.
• [877] Serum -1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.Comb Chem High Throughput Screen. 2018;21(10):755-759. doi: 10.2174/1386207322666190119163024.
• [878] The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis.Nat Commun. 2019 Jul 2;10(1):2914. doi: 10.1038/s41467-019-10824-7.
• [879] Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.Front Oncol. 2019 Sep 11;9:862. doi: 10.3389/fonc.2019.00862. eCollection 2019.
• [880] Ovol2 gene inhibits the Epithelial-to-Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1.Gene. 2017 Feb 5;600:1-8. doi: 10.1016/j.gene.2016.11.034. Epub 2016 Nov 21.
• [881] High-resolution detection of recurrent aberrations in lung adenocarcinomas by array comparative genomic hybridization and expression analysis of selective genes by quantitative PCR.Int J Oncol. 2014 Jun;44(6):2068-76. doi: 10.3892/ijo.2014.2384. Epub 2014 Apr 11.
• [882] Overexpression of PAFAH1B1 is associated with tumor metastasis and poor survival in non-small cell lung cancer.Lung Cancer. 2012 Sep;77(3):585-92. doi: 10.1016/j.lungcan.2012.05.105. Epub 2012 Jun 29.
• [883] Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3 pathway in lung adenocarcinoma.Hum Pathol. 2019 Apr;86:233-242. doi: 10.1016/j.humpath.2018.11.017. Epub 2018 Nov 26.
• [884] Modulation of Mutant Kras(G12D) -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function.Mol Cancer Res. 2019 Feb;17(2):594-603. doi: 10.1158/1541-7786.MCR-18-0739. Epub 2018 Nov 8.
• [885] Absolute quantification of DNA methylation using microfluidic chip-based digital PCR.Biosens Bioelectron. 2017 Oct 15;96:339-344. doi: 10.1016/j.bios.2017.05.021. Epub 2017 May 12.
• [886] PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma.Oncogenesis. 2019 Mar 14;8(3):22. doi: 10.1038/s41389-019-0132-4.
• [887] Expression of programmed cell death 5 protein inhibits progression of lung carcinoma in vitro and in vivo via the mitochondrial apoptotic pathway.Mol Med Rep. 2014 Oct;10(4):2059-64. doi: 10.3892/mmr.2014.2454. Epub 2014 Aug 5.
• [888] HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells.Anticancer Agents Med Chem. 2018;18(14):2062-2067. doi: 10.2174/1871520619666181203110835.
• [889] MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.J Exp Clin Cancer Res. 2018 Aug 17;37(1):195. doi: 10.1186/s13046-018-0871-7.
• [890] miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.Cancer Gene Ther. 2015 Apr;22(3):108-14. doi: 10.1038/cgt.2014.73. Epub 2015 Feb 27.
• [891] Pellino-1 promotes lung carcinogenesis via the stabilization of Slug and Snail through K63-mediated polyubiquitination.Cell Death Differ. 2017 Mar;24(3):469-480. doi: 10.1038/cdd.2016.143. Epub 2016 Dec 23.
• [892] PERP gene therapy attenuates lung cancer xenograft via inducing apoptosis and suppressing VEGF.Cancer Biol Ther. 2011 Dec 15;12(12):1114-9. doi: 10.4161/cbt.12.12.18435. Epub 2011 Dec 15.
• [893] The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1.Onco Targets Ther. 2018 Nov 22;11:8275-8292. doi: 10.2147/OTT.S183191. eCollection 2018.
• [894] PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.Cancer Med. 2019 May;8(5):2429-2441. doi: 10.1002/cam4.2115. Epub 2019 Apr 1.
• [895] Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis.Oncotarget. 2017 Sep 18;8(62):104831-104854. doi: 10.18632/oncotarget.21022. eCollection 2017 Dec 1.
• [896] High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.Oncotarget. 2017 Aug 1;8(35):59000-59007. doi: 10.18632/oncotarget.19777. eCollection 2017 Aug 29.
• [897] Identification of the targets of hematoporphyrin derivative in lung adenocarcinoma using integrated network analysis.Biol Res. 2019 Feb 4;52(1):4. doi: 10.1186/s40659-019-0213-z.
• [898] TGF- regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression.Mol Carcinog. 2015 Jun;54 Suppl 1:E162-71. doi: 10.1002/mc.22243. Epub 2014 Nov 5.
• [899] PINK1 Expression Is Associated with Poor Prognosis in Lung Adenocarcinoma.Tohoku J Exp Med. 2018 Jun;245(2):115-121. doi: 10.1620/tjem.245.115.
• [900] High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis.Pathol Res Pract. 2018 Dec;214(12):2046-2053. doi: 10.1016/j.prp.2018.09.025. Epub 2018 Sep 29.
• [901] PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/-catenin signaling pathway.Cancer Cell Int. 2019 Apr 11;19:96. doi: 10.1186/s12935-019-0800-7. eCollection 2019.
• [902] Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma.Cancer Med. 2018 Jan;7(1):157-166. doi: 10.1002/cam4.1248. Epub 2017 Nov 23.
• [903] High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial-mesenchymal Transition.Sci Rep. 2019 Feb 4;9(1):1324. doi: 10.1038/s41598-018-37285-0.
• [904] Transcription factor PREP1 induces EMT and metastasis by controlling the TGF--SMAD3 pathway in non-small cell lung adenocarcinoma.Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3775-84. doi: 10.1073/pnas.1407074111. Epub 2014 Aug 25.
• [905] Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells.Sci Rep. 2019 Oct 18;9(1):14954. doi: 10.1038/s41598-019-51004-3.
• [906] Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC.Gene. 2016 Dec 5;594(1):23-29. doi: 10.1016/j.gene.2016.08.043. Epub 2016 Aug 28.
• [907] Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases.Histopathology. 2017 Jan;70(2):232-241. doi: 10.1111/his.13048. Epub 2016 Sep 27.
• [908] Phospholipid Phosphatase 4 promotes proliferation and tumorigenesis, and activates Ca(2+)-permeable Cationic Channel in lung carcinoma cells.Mol Cancer. 2017 Aug 29;16(1):147. doi: 10.1186/s12943-017-0717-5.
• [909] TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways.Carcinogenesis. 2013 Aug;34(8):1764-72. doi: 10.1093/carcin/bgt132. Epub 2013 Apr 24.
• [910] Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes invitro.Oncol Rep. 2018 Nov;40(5):2477-2486. doi: 10.3892/or.2018.6659. Epub 2018 Aug 17.
• [911] Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer.Lab Invest. 2013 Apr;93(4):408-21. doi: 10.1038/labinvest.2013.2. Epub 2013 Jan 28.
• [912] Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.PLoS One. 2012;7(3):e33287. doi: 10.1371/journal.pone.0033287. Epub 2012 Mar 15.
• [913] PRDM16 functions as a suppressor of lung adenocarcinoma metastasis.J Exp Clin Cancer Res. 2019 Jan 25;38(1):35. doi: 10.1186/s13046-019-1042-1.
• [914] Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.Carcinogenesis. 2007 Sep;28(9):1971-7. doi: 10.1093/carcin/bgm156. Epub 2007 Aug 11.
• [915] Downregulation of peroxiredoxin-1 by -elemene enhances the radiosensitivity of lung adenocarcinoma xenografts.Oncol Rep. 2015 Mar;33(3):1427-33. doi: 10.3892/or.2015.3732. Epub 2015 Jan 19.
• [916] DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3.Tumour Biol. 2016 Jul;37(7):9781-8. doi: 10.1007/s13277-016-4811-x. Epub 2016 Jan 25.
• [917] PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.Biomed Pharmacother. 2014 May;68(4):463-70. doi: 10.1016/j.biopha.2014.03.006. Epub 2014 Mar 18.
• [918] Proscillaridin A Promotes Oxidative Stress and ER Stress, Inhibits STAT3 Activation, and Induces Apoptosis in A549 Lung Adenocarcinoma Cells.Oxid Med Cell Longev. 2018 Jan 11;2018:3853409. doi: 10.1155/2018/3853409. eCollection 2018.
• [919] PSMA7 inhibits the tumorigenicity of A549 human lung adenocarcinoma cells.Mol Cell Biochem. 2012 Jul;366(1-2):131-7. doi: 10.1007/s11010-012-1290-2. Epub 2012 May 15.
• [920] Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.JCI Insight. 2019 Feb 21;4(4):e125693. doi: 10.1172/jci.insight.125693. eCollection 2019 Feb 21.
• [921] Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.Oncol Rep. 2015 Sep;34(3):1137-45. doi: 10.3892/or.2015.4082. Epub 2015 Jun 25.
• [922] Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.Nat Commun. 2019 Dec 16;10(1):5735. doi: 10.1038/s41467-019-13732-y.
• [923] The anoikis effector Bit1 displays tumor suppressive function in lung cancer cells.PLoS One. 2014 Jul 8;9(7):e101564. doi: 10.1371/journal.pone.0101564. eCollection 2014.
• [924] Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.J Clin Pathol. 2011 Jan;64(1):16-24. doi: 10.1136/jcp.2010.075853. Epub 2010 Nov 2.
• [925] Rab27b Is a Potential Indicator for Lymph Node Metastasis and Unfavorable Prognosis in Lung Adenocarcinoma.Dis Markers. 2018 Dec 2;2018:7293962. doi: 10.1155/2018/7293962. eCollection 2018.
• [926] CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be?.Cancer Discov. 2011 Dec;1(7):560-1. doi: 10.1158/2159-8290.CD-11-0295.
• [927] Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879. doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13.
• [928] A gene mutation in RNA-binding protein 10 is associated with lung adenocarcinoma progression and poor prognosis.Oncol Lett. 2018 Nov;16(5):6283-6292. doi: 10.3892/ol.2018.9496. Epub 2018 Sep 24.
• [929] Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial-Mesenchymal Transition.Clin Cancer Res. 2017 Sep 15;23(18):5598-5610. doi: 10.1158/1078-0432.CCR-16-2909. Epub 2017 Jun 12.
• [930] LINC01419 promotes cell proliferation and metastasis in lung adenocarcinoma via sponging miR-519b-3p to up-regulate RCCD1.Biochem Biophys Res Commun. 2019 Nov 26;520(1):107-114. doi: 10.1016/j.bbrc.2019.09.090. Epub 2019 Sep 30.
• [931] RDM1 plays an oncogenic role in human lung adenocarcinoma cells.Sci Rep. 2018 Aug 1;8(1):11525. doi: 10.1038/s41598-018-30071-y.
• [932] REG I gene expression is linked with the poor prognosis of lung adenocarcinoma and squamous cell carcinoma patients via discrete mechanisms.Oncol Rep. 2013 Dec;30(6):2625-31. doi: 10.3892/or.2013.2739. Epub 2013 Sep 19.
• [933] Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma.Oncol Rep. 2018 Dec;40(6):3392-3404. doi: 10.3892/or.2018.6736. Epub 2018 Sep 26.
• [934] RFC3 induces epithelialmesenchymal transition in lung adenocarcinoma cells through the Wnt/catenin pathway and possesses prognostic value in lung adenocarcinoma.Int J Mol Med. 2019 Dec;44(6):2276-2288. doi: 10.3892/ijmm.2019.4386. Epub 2019 Oct 29.
• [935] Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.Oncol Lett. 2018 Sep;16(3):2873-2880. doi: 10.3892/ol.2018.9000. Epub 2018 Jun 20.
• [936] Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro.Biochem Biophys Res Commun. 2010 May 28;396(2):501-7. doi: 10.1016/j.bbrc.2010.04.127. Epub 2010 Apr 24.
• [937] Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis.Med Sci Monit. 2017 May 23;23:2453-2464. doi: 10.12659/msm.901460.
• [938] Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway.Biochimie. 2012 Feb;94(2):345-53. doi: 10.1016/j.biochi.2011.07.025. Epub 2011 Jul 28.
• [939] The human Bcl-2 family member Bcl-rambo and voltage-dependent anion channels manifest a genetic interaction in Drosophila and cooperatively promote the activation of effector caspases in human cultured cells.Exp Cell Res. 2019 Aug 15;381(2):223-234. doi: 10.1016/j.yexcr.2019.05.015. Epub 2019 May 15.
• [940] Association of PD-1 polymorphisms with the risk and prognosis of lung adenocarcinoma in the northeastern Chinese Han population.BMC Med Genet. 2019 Nov 12;20(1):177. doi: 10.1186/s12881-019-0914-8.
• [941] Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.Cell Signal. 2018 Mar;43:21-31. doi: 10.1016/j.cellsig.2017.11.006. Epub 2017 Dec 2.
• [942] Downregulation of ribosomal protein S6 inhibits the growth of non-small cell lung cancer by inducing cell cycle arrest, rather than apoptosis.Cancer Lett. 2014 Nov 28;354(2):378-89. doi: 10.1016/j.canlet.2014.08.045. Epub 2014 Sep 6.
• [943] Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol. 2007 Apr;14(4):1397-404. doi: 10.1245/s10434-006-9089-6. Epub 2006 Dec 29.
• [944] RUFY3 Predicts Poor Prognosis and Promotes Metastasis through Epithelial-mesenchymal Transition in Lung Adenocarcinoma.J Cancer. 2019 Oct 17;10(25):6278-6285. doi: 10.7150/jca.35072. eCollection 2019.
• [945] RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis.Biochem Biophys Res Commun. 2018 Apr 15;498(4):932-939. doi: 10.1016/j.bbrc.2018.03.084. Epub 2018 Mar 15.
• [946] Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.PLoS One. 2015 Nov 6;10(11):e0142642. doi: 10.1371/journal.pone.0142642. eCollection 2015.
• [947] S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.Oncotarget. 2017 Apr 11;8(15):24804-24814. doi: 10.18632/oncotarget.15063.
• [948] Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.Oncotarget. 2017 Jul 11;8(28):45710-45724. doi: 10.18632/oncotarget.17391.
• [949] Identification of genes associated with matrix metalloproteinases in invasive lung adenocarcinoma.Oncol Lett. 2018 Jul;16(1):123-130. doi: 10.3892/ol.2018.8683. Epub 2018 May 10.
• [950] SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation.Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):229-33. doi: 10.1016/j.bbrc.2014.10.153. Epub 2014 Nov 6.
• [951] SASS6 overexpression is associated with mitotic chromosomal abnormalities and a poor prognosis in patients with colorectal cancer.Oncol Rep. 2015 Aug;34(2):727-38. doi: 10.3892/or.2015.4014. Epub 2015 May 28.
• [952] Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS.Clin Respir J. 2018 Jun;12(6):2036-2045. doi: 10.1111/crj.12771. Epub 2018 Feb 21.
• [953] MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma.Oncotarget. 2016 Jan 5;7(1):386-401. doi: 10.18632/oncotarget.6299.
• [954] SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.Cancer Res Treat. 2016 Jan;48(1):398-402. doi: 10.4143/crt.2014.254. Epub 2015 Feb 17.
• [955] Semaphorin 5A suppresses the proliferation and migration of lung adenocarcinoma cells.Int J Oncol. 2020 Jan;56(1):165-177. doi: 10.3892/ijo.2019.4932. Epub 2019 Dec 2.
• [956] Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.JCI Insight. 2018 Dec 20;3(24):e123093. doi: 10.1172/jci.insight.123093.
• [957] Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas.Oncotarget. 2017 Oct 3;8(53):90706-90718. doi: 10.18632/oncotarget.21456. eCollection 2017 Oct 31.
• [958] miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-I.Life Sci. 2019 Aug 15;231:116539. doi: 10.1016/j.lfs.2019.06.014. Epub 2019 Jun 6.
• [959] Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma.PLoS One. 2018 Nov 12;13(11):e0207204. doi: 10.1371/journal.pone.0207204. eCollection 2018.
• [960] Stratifin Inhibits SCF(FBW7) Formation and Blocks Ubiquitination of Oncoproteins during the Course of Lung Adenocarcinogenesis.Clin Cancer Res. 2019 May 1;25(9):2809-2820. doi: 10.1158/1078-0432.CCR-18-3631. Epub 2019 Feb 6.
• [961] Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.Mol Med. 2014 Apr 8;20(1):164-78. doi: 10.2119/molmed.2013.00149.
• [962] Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinoma.Biotech Histochem. 2018;93(5):364-372. doi: 10.1080/10520295.2018.1444790. Epub 2018 Jun 29.
• [963] Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59-specific shRNA.Clin Sci (Lond). 2019 Nov 15;133(21):2159-2169. doi: 10.1042/CS20190395.
• [964] Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors.Lung Cancer. 2018 Dec;126:174-181. doi: 10.1016/j.lungcan.2018.11.010. Epub 2018 Nov 10.
• [965] CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.
• [966] Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma.Genes Dev. 2013 Jul 15;27(14):1557-67. doi: 10.1101/gad.222745.113.
• [967] Expression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinoma.Sci Rep. 2018 Sep 5;8(1):13221. doi: 10.1038/s41598-018-31592-2.
• [968] Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.J Exp Clin Cancer Res. 2019 Dec 4;38(1):481. doi: 10.1186/s13046-019-1486-3.
• [969] MiR-218-5p Suppresses the Killing Effect of Natural Killer Cell to Lung Adenocarcinoma by Targeting SHMT1.Yonsei Med J. 2019 Jun;60(6):500-508. doi: 10.3349/ymj.2019.60.6.500.
• [970] SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis.Mol Oncol. 2019 May;13(5):1235-1248. doi: 10.1002/1878-0261.12482. Epub 2019 Apr 17.
• [971] The expression profile and clinic significance of the SIX family in non-small cell lung cancer.J Hematol Oncol. 2016 Nov 8;9(1):119. doi: 10.1186/s13045-016-0339-1.
• [972] Multi-omics facilitated variable selection in Cox-regression model for cancer prognosis prediction.Methods. 2017 Jul 15;124:100-107. doi: 10.1016/j.ymeth.2017.06.010. Epub 2017 Jun 13.
• [973] Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment.Anticancer Drugs. 2021 Jun 1;32(6):657-663. doi: 10.1097/CAD.0000000000000720.
• [974] When the guardian sleeps: Reactivation of the p53 pathway in cancer.Mutat Res Rev Mutat Res. 2017 Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003. Epub 2017 Feb 17.
• [975] SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.Oncologist. 2019 Jan;24(1):9-13. doi: 10.1634/theoncologist.2018-0016. Epub 2018 Nov 9.
• [976] A functional variant in miR-155 regulation region contributes to lung cancer risk and survival.Oncotarget. 2015 Dec 15;6(40):42781-92. doi: 10.18632/oncotarget.5840.
• [977] MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.J Biol Chem. 2016 Jan 22;291(4):1877-1889. doi: 10.1074/jbc.M115.667568. Epub 2015 Nov 5.
• [978] Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.Clin Nucl Med. 2020 Jan;45(1):e63-e64. doi: 10.1097/RLU.0000000000002781.
• [979] Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.Sci Rep. 2015 May 18;5:9755. doi: 10.1038/srep09755.
• [980] Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial-mesenchymal transition in lung adenocarcinoma.Cell Death Dis. 2018 Apr 1;9(4):429. doi: 10.1038/s41419-018-0457-5.
• [981] Influence of miR-7a and miR-24-3p on the SOX18 transcript in lung adenocarcinoma.Oncol Rep. 2018 Jan;39(1):201-208. doi: 10.3892/or.2017.6077. Epub 2017 Nov 6.
• [982] A Novel Long Non-Coding RNA, SOX21-AS1, Indicates a Poor Prognosis and Promotes Lung Adenocarcinoma Proliferation.Cell Physiol Biochem. 2017;42(5):1857-1869. doi: 10.1159/000479543. Epub 2017 Jul 27.
• [983] SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients.Respir Res. 2018 Dec 4;19(1):241. doi: 10.1186/s12931-018-0952-3.
• [984] SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21(CIPI) , cyclin D1 and -catenin.FEBS Open Bio. 2020 Jan;10(1):135-146. doi: 10.1002/2211-5463.12762. Epub 2019 Dec 12.
• [985] Decreased expression of SOX7 is correlated with poor prognosis in lung adenocarcinoma patients.Pathol Oncol Res. 2012 Oct;18(4):1039-45. doi: 10.1007/s12253-012-9542-8. Epub 2012 Jul 10.
• [986] SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.Biomed Pharmacother. 2018 Apr;100:233-239. doi: 10.1016/j.biopha.2018.02.015. Epub 2018 Feb 16.
• [987] SPOP regulates the DNA damage response and lung adenocarcinoma cell response to radiation.Am J Cancer Res. 2019 Jul 1;9(7):1469-1483. eCollection 2019.
• [988] SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle.Am J Physiol Lung Cell Mol Physiol. 2003 Oct;285(4):L889-98. doi: 10.1152/ajplung.00065.2003. Epub 2003 Jun 27.
• [989] miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.Eur J Cancer. 2014 Mar;50(5):1013-24. doi: 10.1016/j.ejca.2013.12.024. Epub 2014 Jan 20.
• [990] STIP1 Regulates Proliferation and Migration of Lung Adenocarcinoma Through JAK2/STAT3 Signaling Pathway.Cancer Manag Res. 2019 Nov 29;11:10061-10072. doi: 10.2147/CMAR.S233758. eCollection 2019.
• [991] STK24 expression is modulated by DNA copy number/methylation in lung adenocarcinoma and predicts poor survival.Future Oncol. 2018 Sep;14(22):2253-2263. doi: 10.2217/fon-2018-0126. Epub 2018 Mar 20.
• [992] SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-B.Thorac Cancer. 2019 Jan;10(1):33-40. doi: 10.1111/1759-7714.12895. Epub 2018 Nov 4.
• [993] SUN1 silencing inhibits cell growth through G0/G1 phase arrest in lung adenocarcinoma.Onco Targets Ther. 2017 Jun 2;10:2825-2833. doi: 10.2147/OTT.S79727. eCollection 2017.
• [994] The transcriptional repression activity of STAF65 is facilitated by promoter tethering and nuclear import of class IIa histone deacetylases.Biochim Biophys Acta. 2014 Jul;1839(7):579-91. doi: 10.1016/j.bbagrm.2014.05.007. Epub 2014 May 19.
• [995] Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma.Clin Epigenetics. 2018 Oct 22;10(1):129. doi: 10.1186/s13148-018-0562-4.
• [996] Identification SYT13 as a novel biomarker in lung adenocarcinoma.J Cell Biochem. 2020 Feb;121(2):963-973. doi: 10.1002/jcb.29224. Epub 2019 Oct 17.
• [997] TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1.Cell Biol Int. 2019 Dec;43(12):1416-1424. doi: 10.1002/cbin.11189. Epub 2019 Jul 11.
• [998] Prognostic significance of TCF21 mRNA expression in patients with lung adenocarcinoma.Sci Rep. 2017 May 17;7(1):2027. doi: 10.1038/s41598-017-02290-2.
• [999] Expression of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from DNA damage.Oncotarget. 2017 Nov 27;9(11):9618-9631. doi: 10.18632/oncotarget.22709. eCollection 2018 Feb 9.
• [1000] TEAD4 exerts pro-metastatic effects and is negatively regulated by miR6839-3p in lung adenocarcinoma progression.J Cell Mol Med. 2018 Jul;22(7):3560-3571. doi: 10.1111/jcmm.13634. Epub 2018 Apr 18.
• [1001] Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma.Oncotarget. 2017 Jun 16;8(31):51703-51718. doi: 10.18632/oncotarget.18512. eCollection 2017 Aug 1.
• [1002] Mitochondrial transcription factor A regulated ionizing radiation-induced mitochondrial biogenesis in human lung adenocarcinoma A549 cells.J Radiat Res. 2013 Nov 1;54(6):998-1004. doi: 10.1093/jrr/rrt046. Epub 2013 May 3.
• [1003] TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.Mol Cancer. 2014 Apr 26;13:89. doi: 10.1186/1476-4598-13-89.
• [1004] Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.Cancer Lett. 2017 Aug 28;402:190-202. doi: 10.1016/j.canlet.2017.06.002. Epub 2017 Jun 10.
• [1005] NetSig: network-based discovery from cancer genomes.Nat Methods. 2018 Jan;15(1):61-66. doi: 10.1038/nmeth.4514. Epub 2017 Dec 4.
• [1006] A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma.Oncogenesis. 2019 Nov 4;8(11):65. doi: 10.1038/s41389-019-0173-8.
• [1007] THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma.Onco Targets Ther. 2019 Jul 12;12:5651-5660. doi: 10.2147/OTT.S208908. eCollection 2019.
• [1008] Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases.PLoS One. 2016 Aug 11;11(8):e0161007. doi: 10.1371/journal.pone.0161007. eCollection 2016.
• [1009] High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma.Hum Pathol. 2018 Jul;77:54-62. doi: 10.1016/j.humpath.2017.12.029. Epub 2018 Apr 7.
• [1010] Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice.Biochem Biophys Res Commun. 2015 Aug 7;463(4):1230-6. doi: 10.1016/j.bbrc.2015.06.090. Epub 2015 Jun 15.
• [1011] TM4SF4 overexpression in radiation-resistant lung carcinoma cells activates IGF1R via elevation of IGF1.Oncotarget. 2014 Oct 30;5(20):9823-37. doi: 10.18632/oncotarget.2450.
• [1012] Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.Lung Cancer. 2015 Jun;88(3):352-4. doi: 10.1016/j.lungcan.2015.03.014. Epub 2015 Mar 21.
• [1013] Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome.Am J Clin Pathol. 2019 Jul 5;152(2):207-216. doi: 10.1093/ajcp/aqz035.
• [1014] Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma.J Transl Med. 2018 Dec 27;16(1):372. doi: 10.1186/s12967-018-1732-z.
• [1015] TRAF4 overexpression is a common characteristic of human carcinomas.Oncogene. 2007 Jan 4;26(1):142-7. doi: 10.1038/sj.onc.1209762. Epub 2006 Jun 26.
• [1016] TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration.Cerebellum. 2019 Apr;18(2):245-254. doi: 10.1007/s12311-018-0987-5.
• [1017] TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma.Am J Cancer Res. 2019 Sep 1;9(9):2019-2027. eCollection 2019.
• [1018] Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses.J Cancer. 2019 Jan 29;10(4):843-852. doi: 10.7150/jca.27856. eCollection 2019.
• [1019] TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549cell line via downregulation of 14-3-3.Biochem Biophys Res Commun. 2017 Nov 4;493(1):568-572. doi: 10.1016/j.bbrc.2017.08.151. Epub 2017 Sep 1.
• [1020] Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma.Oncotarget. 2017 Jan 10;8(2):2890-2905. doi: 10.18632/oncotarget.13761.
• [1021] Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.Biochem Biophys Res Commun. 2018 May 15;499(3):416-424. doi: 10.1016/j.bbrc.2018.03.129. Epub 2018 Mar 30.
• [1022] Trophinin-associated protein expression is an independent prognostic biomarker in lung adenocarcinoma.J Thorac Dis. 2019 May;11(5):2043-2050. doi: 10.21037/jtd.2019.04.86.
• [1023] Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.Int Immunopharmacol. 2020 Jan;78:106077. doi: 10.1016/j.intimp.2019.106077. Epub 2019 Dec 5.
• [1024] Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.J Cancer Res Clin Oncol. 2019 Apr;145(4):1027-1035. doi: 10.1007/s00432-019-02861-y. Epub 2019 Feb 27.
• [1025] Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.Cancer Res. 2008 Mar 15;68(6):1707-14. doi: 10.1158/0008-5472.CAN-07-6325.
• [1026] Overexpression of APC11 predicts worse survival in lung adenocarcinoma.Onco Targets Ther. 2018 Oct 17;11:7125-7132. doi: 10.2147/OTT.S177252. eCollection 2018.
• [1027] Growth inhibition of KRASand EGFRmutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis.Oncol Rep. 2018 Sep;40(3):1761-1768. doi: 10.3892/or.2018.6536. Epub 2018 Jul 2.
• [1028] Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas.Oncogene. 2004 Feb 5;23(5):1166-76. doi: 10.1038/sj.onc.1207234.
• [1029] Embryo-chondrocyte expressed gene 1, downregulating hypoxia-inducible factor 1alpha, is another marker of lung tumor hypoxia.Acta Pharmacol Sin. 2007 Apr;28(4):549-58. doi: 10.1111/j.1745-7254.2007.00516.x.
• [1030] MicroRNA-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting BPTF.Biochem Cell Biol. 2019 Aug;97(4):415-422. doi: 10.1139/bcb-2018-0301. Epub 2018 Nov 27.
• [1031] Regulation of transforming growth factor beta1 by nitric oxide.Cancer Res. 1999 May 1;59(9):2142-9.
• [1032] Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.Hum Mol Genet. 2017 Jan 15;26(2):454-465. doi: 10.1093/hmg/ddw414.
• [1033] Identification of Las2, a major modifier gene affecting the Pas1 mouse lung tumor susceptibility locus.Cancer Res. 2009 Aug 1;69(15):6290-8. doi: 10.1158/0008-5472.CAN-09-0782. Epub 2009 Jul 21.
• [1034] c-erbB-2/p185-directed therapy in human lung adenocarcinoma.Ann Thorac Surg. 1996 Nov;62(5):1454-9. doi: 10.1016/0003-4975(96)00630-3.
• [1035] Mucin mRNA expression in lung adenocarcinoma cell lines and tissues.Oncology. 1996 Mar-Apr;53(2):118-26. doi: 10.1159/000227547.
• [1036] Aberrant expression of caspase 14 in salivary gland carcinomas.J Oral Pathol Med. 2015 Jul;44(6):444-8. doi: 10.1111/jop.12253. Epub 2014 Sep 25.
• [1037] Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.Neoplasia. 2009 Aug;11(8):763-70. doi: 10.1593/neo.09470.
• [1038] Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells.Chin Med J (Engl). 2007 May 20;120(10):905-9.
• [1039] MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A.Oncol Lett. 2017 Sep;14(3):3573-3579. doi: 10.3892/ol.2017.6603. Epub 2017 Jul 18.
• [1040] CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung.Dis Markers. 2014;2014:619273. doi: 10.1155/2014/619273. Epub 2014 Dec 7.
• [1041] CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.Mol Oncol. 2016 Feb;10(2):317-29. doi: 10.1016/j.molonc.2015.10.015. Epub 2015 Nov 5.
• [1042] Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.Clin Cancer Res. 2009 Jun 1;15(11):3827-33. doi: 10.1158/1078-0432.CCR-08-3027. Epub 2009 May 12.
• [1043] CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.Oncotarget. 2016 May 17;7(20):29199-210. doi: 10.18632/oncotarget.8638.
• [1044] Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.Eur J Cancer. 2015 Sep;51(14):1897-903. doi: 10.1016/j.ejca.2015.07.015. Epub 2015 Jul 30.
• [1045] Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer.Am J Respir Cell Mol Biol. 2013 Sep;49(3):418-25. doi: 10.1165/rcmb.2012-0396OC.
• [1046] Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.Elife. 2018 Nov 26;7:e33718. doi: 10.7554/eLife.33718.
• [1047] Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression.Lab Invest. 2019 Apr;99(4):551-567. doi: 10.1038/s41374-018-0142-4. Epub 2018 Dec 12.
• [1048] Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements.Med Sci Monit. 2019 Jan 23;25:675-690. doi: 10.12659/MSM.913054.
• [1049] ERp29 downregulation enhances lung adenocarcinoma cell chemosensitivity to gemcitabine by upregulating HSP27 phosphorylation.Exp Ther Med. 2019 Jan;17(1):817-823. doi: 10.3892/etm.2018.7040. Epub 2018 Nov 30.
• [1050] FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer.Elife. 2018 Nov 26;7:e38579. doi: 10.7554/eLife.38579.
• [1051] Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma.Oncotarget. 2017 Feb 14;8(7):12211-12224. doi: 10.18632/oncotarget.14661.
• [1052] Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.Br J Cancer. 2004 Jan 26;90(2):436-42. doi: 10.1038/sj.bjc.6601531.
• [1053] GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.Mod Pathol. 2017 Dec;30(12):1720-1727. doi: 10.1038/modpathol.2017.88. Epub 2017 Aug 4.
• [1054] Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.Cancer Control. 2018 Jan-Mar;25(1):1073274818778001. doi: 10.1177/1073274818778001.
• [1055] Quinacrine Inhibits ICAM-1 Transcription by Blocking DNA Binding of the NF-B Subunit p65 and Sensitizes Human Lung Adenocarcinoma A549 Cells to TNF- and the Fas Ligand.Int J Mol Sci. 2017 Dec 2;18(12):2603. doi: 10.3390/ijms18122603.
• [1056] The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis.Carcinogenesis. 2004 Jul;25(7):1157-63. doi: 10.1093/carcin/bgh113. Epub 2004 Feb 12.
• [1057] Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma.Mol Med. 2012 Jul 18;18(1):874-86. doi: 10.2119/molmed.2011.00230.
• [1058] Expression pattern of the scaffold protein IQGAP1 in lung cancer.Oncol Rep. 2005 Mar;13(3):427-31.
• [1059] Increased KIF15 Expression Predicts a Poor Prognosis in Patients with Lung Adenocarcinoma.Cell Physiol Biochem. 2018;51(1):1-10. doi: 10.1159/000495155. Epub 2018 Nov 15.
• [1060] Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein.J Zhejiang Univ Sci B. 2017 Dec.;18(12):1046-1054. doi: 10.1631/jzus.B1700129.
• [1061] Elevated Krppel-like factor 5 expression in spatiotemporal mouse lungs is similar to human congenital cystic adenomatoid malformation of the lungs.J Int Med Res. 2018 Jul;46(7):2856-2865. doi: 10.1177/0300060518774998. Epub 2018 Jun 13.
• [1062] Selective assembly of laminin variants by human carcinoma cells.Lab Invest. 1994 Nov;71(5):719-30.
• [1063] Methylation-specific loop-mediated isothermal amplification for detecting hypermethylated DNA in simplex and multiplex formats.Clin Chem. 2010 Aug;56(8):1287-96. doi: 10.1373/clinchem.2010.143545. Epub 2010 Jun 15.
• [1064] The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development.Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19932-7. doi: 10.1073/pnas.0805003105. Epub 2008 Dec 5.
• [1065] Lipase member H is a novel secreted protein selectively upregulated in human lung adenocarcinomas and bronchioloalveolar carcinomas.Biochem Biophys Res Commun. 2014 Jan 24;443(4):1141-7. doi: 10.1016/j.bbrc.2013.12.106. Epub 2013 Dec 28.
• [1066] Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance status.PLoS One. 2017 Aug 14;12(8):e0183136. doi: 10.1371/journal.pone.0183136. eCollection 2017.
• [1067] Olmsted syndrome with squamous cell carcinoma of extremities and adenocarcinoma of the lung: failure to detect loricrin gene mutation.Eur J Dermatol. 2003 Nov-Dec;13(6):524-8.
• [1068] Lumican is overexpressed in lung adenocarcinoma pleural effusions.PLoS One. 2015 May 11;10(5):e0126458. doi: 10.1371/journal.pone.0126458. eCollection 2015.
• [1069] MACC1 overexpression in carcinomaassociated fibroblasts induces the invasion of lung adenocarcinoma cells via paracrine signaling.Int J Oncol. 2019 Apr;54(4):1367-1375. doi: 10.3892/ijo.2019.4702. Epub 2019 Jan 30.
• [1070] Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer.Biochem Biophys Res Commun. 2008 Jan 11;365(2):221-6. doi: 10.1016/j.bbrc.2007.10.144. Epub 2007 Oct 31.
• [1071] Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas.J Pathol. 2004 Mar;202(3):321-9. doi: 10.1002/path.1524.
• [1072] High glucose promotes tumor cell proliferation and migration in lung adenocarcinoma via the RAGENOXs pathway.Mol Med Rep. 2018 Jun;17(6):8536-8541. doi: 10.3892/mmr.2018.8914. Epub 2018 Apr 23.
• [1073] Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo.Oncogene. 2004 Apr 15;23(17):3089-96. doi: 10.1038/sj.onc.1207433.
• [1074] pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.Int J Nanomedicine. 2018 Oct 26;13:6885-6902. doi: 10.2147/IJN.S180119. eCollection 2018.
• [1075] Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10155-60. doi: 10.1073/pnas.0709618105. Epub 2008 Jul 15.
• [1076] Placenta-specific protein 8 promotes the proliferation of lung adenocarcinoma PC-9 cells and their tolerance to an epidermal growth factor receptor tyrosine kinase inhibitor by activating the ERK signaling pathway.Oncol Lett. 2019 Nov;18(5):5621-5627. doi: 10.3892/ol.2019.10911. Epub 2019 Sep 24.
• [1077] Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma.Clin Cancer Res. 2009 Mar 1;15(5):1527-33. doi: 10.1158/1078-0432.CCR-08-2459. Epub 2009 Feb 17.
• [1078] Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis.Mutat Res. 1997 Jun;386(3):263-77. doi: 10.1016/s1383-5742(97)00008-2.
• [1079] Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk.Cancer. 2010 Feb 15;116(4):896-902. doi: 10.1002/cncr.24850.
• [1080] miR-938 promotes cell proliferation by regulating RBM5 in lung adenocarcinoma cells.Cell Biol Int. 2020 Jan;44(1):295-305. doi: 10.1002/cbin.11233. Epub 2019 Sep 25.
• [1081] Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1.J Biol Chem. 2009 Sep 25;284(39):26331-9. doi: 10.1074/jbc.M109.033514. Epub 2009 Jul 1.
• [1082] Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.Cancer Sci. 2010 Jan;101(1):46-53. doi: 10.1111/j.1349-7006.2009.01351.x. Epub 2009 Sep 9.
• [1083] Overexpression of S100A14 contributes to malignant progression and predicts poor prognosis of lung adenocarcinoma.Thorac Cancer. 2018 Jul;9(7):827-835. doi: 10.1111/1759-7714.12654. Epub 2018 May 7.
• [1084] Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma.Hum Pathol. 2018 Apr;74:148-155. doi: 10.1016/j.humpath.2018.01.001. Epub 2018 Jan 7.
• [1085] Selenophosphate synthetase genes from lung adenocarcinoma cells: Sps1 for recycling L-selenocysteine and Sps2 for selenite assimilation.Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16162-7. doi: 10.1073/pnas.0406313101. Epub 2004 Nov 8.
• [1086] SERINC2-knockdown inhibits proliferation, migration and invasion in lung adenocarcinoma.Oncol Lett. 2018 Nov;16(5):5916-5922. doi: 10.3892/ol.2018.9403. Epub 2018 Sep 5.
• [1087] Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer.Cancer Gene Ther. 2006 Sep;13(9):856-63. doi: 10.1038/sj.cgt.7700953. Epub 2006 May 19.
• [1088] MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G?S transition and apoptosis by targeting p21(WAF1/CIP1).Br J Cancer. 2014 Jul 15;111(2):339-54. doi: 10.1038/bjc.2014.157. Epub 2014 Jun 12.
• [1089] COP9 signalosome subunit 5 regulates cancer metastasis by deubiquitinating SNAIL.Oncotarget. 2018 Apr 17;9(29):20670-20680. doi: 10.18632/oncotarget.25060. eCollection 2018 Apr 17.
• [1090] MiR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma.Oncol Rep. 2016 May;35(5):3115-21. doi: 10.3892/or.2016.4648. Epub 2016 Mar 3.
• [1091] Spermassociated antigen 4 (SPAG4) as a new cancer marker interacts with Nesprin3 to regulate cell migration in lung carcinoma.Oncol Rep. 2018 Aug;40(2):783-792. doi: 10.3892/or.2018.6473. Epub 2018 Jun 4.
• [1092] SULFs in human neoplasia: implication as progression and prognosis factors.J Transl Med. 2011 May 21;9:72. doi: 10.1186/1479-5876-9-72.
• [1093] Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes.Front Oncol. 2018 Oct 30;8:482. doi: 10.3389/fonc.2018.00482. eCollection 2018.
• [1094] Grg1 acts as a lung-specific oncogene in a transgenic mouse model.Cancer Res. 2006 Feb 1;66(3):1294-301. doi: 10.1158/0008-5472.CAN-05-1634.
• [1095] The upregulation of TMPRSS4, partly ascribed to the downregulation of miR?25a?p, promotes the growth of human lung adenocarcinoma via the NFB signaling pathway.Int J Oncol. 2018 Jul;53(1):148-158. doi: 10.3892/ijo.2018.4396. Epub 2018 May 7.
• [1096] Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.Cancer Res. 2008 Sep 15;68(18):7570-8. doi: 10.1158/0008-5472.CAN-08-0632.
• [1097] Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival.Lung Cancer. 2007 Mar;55(3):271-7. doi: 10.1016/j.lungcan.2006.10.023. Epub 2006 Dec 4.
• [1098] Ras mutations in United Kingdom examples of oral malignancies are infrequent.Int J Cancer. 1991 May 30;48(3):409-12. doi: 10.1002/ijc.2910480318.